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Abstract
Ginseng is a widely prescribed herbal drug that has been used for over 2000 years in Asia
for the treatment o f several different disorders o f the body including those o f the cardiovascular
system. Advances in ginseng research have identified the bioactive constituents considered
responsible for eliciting its pharmacological effects known as ‘ginsenosides’. Several published
reports have demonstrated the potential ability o f ginseng and their isolated ginsenosides in the
prevention and treatment o f heart disease. In the study presented here the effects of ginseng on
agonist-induced cardiac hypertrophy in isolated cardiomyocytes (Chapter 2 - 4) as well as an in
vivo model o f heart failure (Chapter 4) were investigated.
In our first study (Chapter 2), the ability o f ginseng to prevent leptin-induced ventricular
cardiac hypertrophy by inhibiting p i 15RhoGEF-RhoA/ROCK-dependent MAPK activation was
investigated. Leptin (50 ng/ml, which is a concentration representative o f plasma levels found in
obese individuals) produced a robust hypertrophic response that was associated with
RhoA/ROCK activation resulting in a significant increase in cofilin-2 phosphorylation and actin
polymerization, the latter evidenced by a reduction in the globular to filamentous actin ratio.
These effects were prevented by North American ginseng (alcoholic extract; 10 pg/ml), hereon
referred to as “ginseng”. The stimulation o f RhoA/ROCK by leptin was associated with
significantly increased pll5R hoG EF gene and protein expression and exchange activity, all of
which were inhibited by ginseng. The attenuation o f leptin-induced activation o f RhoA/ROCK
by ginseng was further associated with diminished p38 MAPK activation and nuclear
translocation.
In a follow-up study (Chapter 3), the ability of ginseng to reverse leptin-induced cardiac
hypertrophy by enhancing Rnd3-pl90RhoGAP-mediated downregulation of RhoA/ROCK

activation, was investigated. Cardiomyocytes incubated with leptin for 48 h displayed
significantly increased cell surface area, which was accompanied by an increase in the
expression o f the fetal gene a-skeletal actin. A decrease in the G/F actin ratio, most likely as a
result o f RhoA/ROCK cofilin-2 phosphorylation was observed in hypertrophied cells treated
with leptin. Treatment with ginseng however reversed these effects. In leptin-treated cells, Rnd3
gene and protein expression were decreased however treatment with ginseng reversed these
effects by leptin. In the left ventricular tissues o f rats subjected to four weeks of sustained
myocardial infarction (MI), Rnd3 protein expression was markedly reduced while p63RhoGEF
and ROCK expressions, which reflect upregulation o f RhoA, were increased. These Mi-induced
effects however were restored by ginseng to expressions as observed in sham.
For our third study (C hapter 4), we investigated the ability o f ginseng to reverse already
established cardiac dysfunction as well as hypertrophy both in vitro and in vivo by inhibition of
calcineurin/NFAT3 activation. The ability o f a pharmacological agent to reverse HF is of
particular importance as the majority o f current treatments are unable to reverse already
established myocardial remodelling and ventricular dysfunction. Accordingly, ginseng was
administered in drinking water ad libitum to rats after 4 weeks of sustained coronary artery
ligation (CAL) when hypertrophy and HF were established or to hypertrophic neonatal
ventricular

myocytes

treated

with

angiotensin

II,

endothelin-1

or

phenylephrine.

Echocardiographie and catheter-based measurements of hemodynamic parameters revealed
complete reversibility o f systolic and diastolic abnormalities as well as increased myocardial
collagen gene expression in CAL-rats after treatment with ginseng. Similarly, ginseng
administration to hypertrophic cardiomyocytes resulted in complete reversal to a normal
phenotype after 24 h as determined by cell surface area and a-skeletal gene expression. The
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effects o f ginseng in vivo were associated with a tendency to attenuate calcineurin activation and
MCIP-1 gene expression. In the cultured cardiomyocytes however, ginseng completely reversed
agonist-induced calcineurin activation and NFAT3 nuclear translocation. Taken together, results
from our studies demonstrate a marked anti-hypertrophic and anti-remodelling ability o f ginseng
in the prevention and treatment of cardiovascular disease.

K eyw ords: cardiac hypertrophy, leptin, pll5R hoG EF, RhoA/ROCK, ginseng, ginsenosides,
heart failure, reversal, calcineurin/NFAT3
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1.1

The Heart
A general overview of the anatomical and physiological characteristics o f the heart has

been provided in the subsequent sections as supporting background information for the material
discussed in this thesis. These concepts include a basic description of the structural (section
1.1.1.1) and cellular (section 1.1.1.2) anatomy followed by the physiological (section 1.1.1.3)
function o f the heart relevant to the content o f the thesis.
1.1.1

Anatomy o f the Heart
1.1.1.1 Structural Anatomy o f the Heart

Weighing at 250 to 300 g and the size o f one’s own fist, the human heart is a powerful
muscular pump that provides oxygenated blood to the whole body. Enclosed and protected in a
double-layered (fibrous/outer and visceral/inner layer) sac known as the pericardium, the heart is
located in the thoracic chamber where it sits anterior to the spinal cord and posterior to the
sternum.
The heart is a four chamber pump consisting of the right and left atria (RA and LA,
respectively) which are located at the apex (top) and the right and left ventricles (RV and LV,
respectively) toward the base (bottom) of the heart. The RA, located superior to the RV, receives
oxygen depleted blood from the tissues via the superior and inferior vena cava (SVC and IVC,
respectively). Deoxygenated blood collected in the RA is ejected through the tricuspid valve
into the RV and subsequently out through the semilunar pulmonary valve. Deoxygenated blood
continues to travel through the pulmonary arteries towards the lungs where oxygen is diffused
into the blood via capillary diffusion. Oxygenated blood returns to the heart via the pulmonary
veins and into the LA where it is directed through the mitral or bicuspid valve into the LV. The
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blood is subsequently ejected through the semilunar aortic valve into the aorta to provide oxygen
to the tissues of the body (reviewed in Cabin, 2002; Klabunde, 2005).
Coordinated and synchronized contraction of the heart is initiated by an intricate
electrical network that consists o f the sino atrial (SA) node located near the superior portion of
the RA close to the SVC, followed by the atrial ventricular (AV) node between the RA and RV.
The electrical network is further branched out at the base of the heart into the bundle o f His
which extends upward throughout the RV and LV. Efficient communication beginning at the SA
node towards the bundle of His branches allows synchronized contraction of the heart to provide
oxygenated blood to the rest o f the body (reviewed in Cabin, 2002; Klabunde, 2005).
1.1.1.2 Cellular Anatomy o f the Heart
The heart is essentially made up o f three layers which include the epicardium,
myocardium and endocardium (reviewed in Cabin, 2002). The epicardium, which is also fused to
the visceral pericardium, is the most exterior layer o f the heart and is predominantly made up of
connective tissue that serves as a protective barrier. Immediately adjacent to the epicardium is
the myocardium or middle layer which is composed o f cardiac muscle responsible for producing
contraction o f the heart. The endocardium is the innermost layer o f the heart consisting mainly of
endothelial cells lining the chambers and has also been shown to contribute to myocardial
contraction (reviewed in Cabin, 2002; Klabunde, 2005).
The myocardium is composed of striated cardiac muscle fibers, which are fundamentally
comprised of heart cells termed cardiomyocytes. Unlike skeletal myocytes which may contain
several nuclei, cardiomyocytes are typically mono or dinucleated. Cardiomyocytes are similar to
skeletal myocytes as they both contain contractile apparati known as myofibrils. Continuous
chains of sarcomeric segments which contain thick and thin actin filaments that slide between
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each other are the functional units that comprise the myofibrils responsible for producing
cardiomyocyte contraction (Solaro, 2010). Most importantly, the cellular and membranous
components o f a cardiomyocyte which are multitudinous, significantly contribute to the
intracellular homeostatic environment. Changes in intracellular ion concentration, pH or
extracellular stimuli can lead to significant changes in the molecular signalling of the
cardiomyocyte which may negatively affect cardiomyocyte contraction as well as the cellular
morphology. The cellular signalling pathways of the cardiomyocyte have been summarized in
detail in section 1.2.2.
1.1.2

Physiology o f the Heart

1.1.2.1 The Cardiac Cycle
The cardiac cycle describes the stages of cardiac relaxation (diastole) in which blood fills
the ventricle and contraction (systole) in which blood is ejected from the heart in a single beat.
The events within a cardiac cycle can be visualized using a pressure sensitive catheter that is
inserted into the LV, which can record pressure changes while the heart is beating. Figure 1.1
demonstrates a standard example o f the changes in pressure and volume of the LV as a function
o f time. In the RV, the pattern o f pressure and volume changes is generally similar to that
observed in the LV (reviewed in Cabin, 2002; Klabunde, 2005).
The cardiac cycle is comprised o f five phases which are (1) atrial contraction, (2)
isovolumetric contraction, (3) ventricular contraction, (4) isovolumetric relaxation and (5)
ventricular filling.

Phase 1 or atrial contraction: in atrial contraction, the atrium becomes

depolarized and begins to contract causing an increase in atrial pressure, which pushes the blood
into the ventricle. Most of the ventricular filling however occurs as a result of passive blood flow
into the ventricle, which is dependent on venous return. At this point in time, the ventricle is
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maximally filled and is represented on Figure 1.1 A as the end-diastolic volume (EDV). Phase 2
or isovolumetric contraction: the end o f phase 1 marks the beginning of isovolumetric
contraction where electrical depolarization o f the ventricle initiates contraction while
maintaining a constant volume. Phase 3 or ventricular contraction: as the ventricular pressure
begins to rapidly rise, it exceeds the pressure in the aorta and contraction occurs as blood is
rapidly ejected from the LV through the aortic valve. Phase 4 or isovolumetric relaxation:
immediately after rapid ejection of the blood from the LV, the ventricle experiences
repolarization and begins to relax. The intraventricular pressure of the LV continues to gradually
decline and consequently forces the aortic valves close. All the while, ventricular volume
remains constant and the residual volume at the end o f this phase is the end-systolic volume
(ESV) (Figure 1.1 A). Phase 5 or ventricular filling: as a result of continuous venous return into
the atrium, the atrial pressure begins to steadily increase and consequently establishes a pressure
gradient between the atrium and ventricle. This consequently favours movement of blood into
the ventricle, thereby restarting the cardiac cycle (reviewed in Cabin 2002; Klabunde 2005).
1.1.2.2

Pressure-Volume Loops

The measurements of pressure and volume during one cardiac cycle can be translated into a
graphical representation known as a pressure-volume (PV) loop (Figure 1.1B), which can
provide an abundant amount of information for assessing cardiac function (Sagawa, 1978; Katz,
1988). The ESV and EDV are indicated on the PV loop of Figure 1.1B at the bottom left and
right, respectively. The difference between EDV and ESV, which can be visualized by a line
drawn across the PV loop or the width of the PV loop, is the stroke volume (SV). In a healthy
individual, more than 60% of the EDV is ejected during systole (reviewed in Klabunde, 2005).
The SV divided by EDV provides an important marker known as the ejection fraction (EF) to
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Figure 1.1. Cardiac cycle and pressure-volume loop. Graphical representations of the changes in pressure and volume of the
LV within a single heart beat. Graph A represents the cardiac cycle. Numbers above indicate the cardiac phases as described in
the text. Graph B represents the changes in pressure as a function o f volume. Image has been recreated and modified from
Klabunde, 2005. EDV: end-diastolic volume; ESV: end-systolic volume; EDPVR: end-diastolic pressure volume relationship;
ESPVR: end-systolic pressure volume relationship; SV: stroke volume.
as

represent cardiac function. In addition to EF, the SV is essential in calculating cardiac output
(CO), which is the amount of blood ejected from the ventricle per minute (mL/min or L/min), or
SV multiplied by heart rate (HR) (reviewed in Klabunde, 2005).
Mathematical measurements such as the PV relationship slopes at the end of systole and
diastole (ESPVR and EDPVR, respectively) from the PV loop may also be obtained. ESPVR is
drawn on the top-left hand side of the PV loop, which indicates the contractile efficiency of the
ventricle, while the EDPVR is drawn on the bottom-right hand side o f the PV loop, representing
ventricular compliance (reviewed in Klabunde, 2005). Pathological changes to the heart, such as
heart failure (HF) which is discussed in detail in section 1.2, result in abnormal pressure and
volume measurements that are translated as shifts o f the PV loop along the pressure and (y) and
volume (jc) axis (Katz, 1988). These aberrations consequently affect the ESPVR and EDPVR
slopes providing valuable information for clinicians in the assessment o f ventricular function.
1.2

Cardiovascular Disease
Cardiovascular disease (CVD) describes a disorder of the heart (cardio) and blood vessels

(vascular) as well as any other organs that may be affected by the circulatory system namely, but
not limited to, the brain, lungs and kidney (Canada, 2010). The specific types of CVD are termed
and categorized by the origin o f the disease (reviewed in Nabel, 2003).
The predominant vascular-specific CVD types include cerebrovascular disease (stroke)
which is an impediment o f blood supply in the vasculature of the brain that can be further
classified as a transient ischemic attack (blockage less than 24 hours) or a cerebrovascular
thrombosis/clot (chronic blockage) and peripheral vascular disease, which is a disease in the
vasculature o f the legs and arms. (Canada, 2010).
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Cardio-originating CVDs includes ischemic heart disease as a result of a myocardial
infarction (MI) or impediment o f the blood supply to the cardiac muscle; congenital heart disease,
which is the result o f an anatomical birth defect o f the heart or genetic mutation; rheumatic heart
disease, which is most common in younger individuals as a result of a bacterial infection of the
heart valves; inflammatory heart disease that specifically includes endocarditis or pericarditis,
which is the inflammation of the inner cardiac muscle and outer lining sac of the heart,
respectively; and HF, which is considered the end stage result of CVDs where the pumping
efficiency o f the heart to supply adequate blood to the rest of the body is impaired.

1.2.1

Heart Failure
1.2.1.1 Definition and Types o f Heart Failure

HF has been described as the ‘state o f any heart disease in which [...] the heart’s output
is decreased or in which the heart is unable to pump blood at a rate adequate for satisfying the
requirements of the tissues with function parameters remaining within normal limits’ (Denolin et
al., 1983). As discussed below HF can be described as either acute or chronic and can also be
classified as either systolic or diastolic (HF with preserved ejection fraction) (Bhatia et al., 2006;
Owan et al., 2006). Classification systems such as the New York Heart Association (NYHA)
(Criteria Committee, New York Heart Association, 1964) as well as the American College of
Cardiology/American Heart Association (ACC/AHA) have been developed to rate the severity o f
HF in patients and to provide appropriate recommendations for therapy (Hunt et al., 2002).
Acute HF, which may manifest after short-term stimuli such as cardiac surgery, acute
sepsis or MI, refers to the rapid onset o f decreased cardiac function/output in the absence o f
compensatory mechanisms that lasts for hours to days. In contrast however, chronic HF is the
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development o f cardiac dysfunction involving adaptive responses at the global and molecular
level over a longer period of time (Dickstein et al., 2008).
Diastolic (DHF) and systolic (SHF) HF are classical types of chronic HF that may
manifest as individual syndromes, however these are often clinically presented together where
distinct molecular and structural remodelling o f the heart have occurred (van Heerebeek et al.,
2006). DHF refers to an impairment of the elasticity or an increased stiffness of the myocardium
resulting in abnormal ventricular filling during diastole while SHF refers to abnormal ventricular
contraction o f the heart (reviewed in Chatterjee and Massey, 2007).
1.2.1.2

Diagnosis and Classification o f Heart Failure

Clinical diagnosis o f HF is determined by echocardiography, which is a technique that
uses ultrasound waves at high frequencies to provide two-dimensional images of the heart (Oh et
al., 1997). An echocardiogram can provide essential information for the analysis of ventricular
function such as EDV and ESV to calculate SV, CO and EF and can additionally provide
morphological recordings to visualize any abnormal changes in chamber dimension.
While there are many methods of classifying HF, such as whether the disorder is
predominantly left or right-sided, or if it pertains to depressed contraction or relaxation of the
heart (SHF and DHF, respectively), the commonly applied system of categorizing is the NYHA
classification. The NYHA scale rates the degree of abnormal function of the heart based on
presenting symptoms and quality o f life, which essentially describes the severity of the disease
(Criteria Committee, New York Heart Association, 1964).

Class I is the least severe which

describes a patient with no limitation or associated symptoms during ordinary activities and up to
Class IV, which is the most severe where the minimalist of physical activity inflicts discomfort
and symptoms manifest even at rest. Class IV patients have a very low predicted survival
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outcome and may require more invasive treatment options such as heart transplantation as the
patients are most often non-responsive to conventional pharmacotherapy (Criteria Committee,
New York Heart Association, 1964).
In comparison, the AHA/ACC classification system of HF is arranged by stages from A
to B which describes the progression o f the disorder. It has an advantage over the NYHA
classification as it includes a pre-HF stage A which describes patients who are absent of the
disease but who demonstrate a high risk factor for the development of HF. Stage B is equivalent
to NYHA class I and includes patients with structural damage with no associated symptoms
present. Stage D is comparable to NYHA class IV and describes the most advanced HF with
severe symptoms that are challenging to manage with conventional therapy (Hunt et al., 2001).
Detection o f HF at the earliest stage is fundamental for success in treatment of the disorder
(reviewed in Jessup and Brozena, 2001).
1.2.1.3 Etiology and Pathophysiology o f Heart Failure
The causes of HF are numerous and habitually coexist with one another. The
predominant factors leading to HF namely include ischemic heart disease, which is the number
one cause o f mortality worldwide (World Health Organization, 2011), followed by cigarette
smoking, hypertension, obesity, diabetes and valvular heart disease (reviewed in McMurray and
Stewart, 2000). Less common causes o f HF are arrhythmias, viral infections, and damages to the
cellular structures o f the heart such as amyloidosis or systemic lupus erythematosus (Canada,
2008).
These initiating stimuli compromises the normal function of the heart, which may be
manifested by an EF o f less than 40%, increased EDV and ESV, increased end-diastolic pressure
(EDP), decreased end-systolic pressure (ESP), an early to late (atrial) ventricular filling velocity
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measured across the mitral valve (E/A ratio) o f greater than 1.5 (Bella et al., 2002) and/or
significant enlargements o f the ventricular chambers.
A decrease in CO from the failing heart signals the body to appropriately adapt to the
compromised circumstance by increasing sympathetic stimulation. For example, in an effort to
counterbalance the decrease in arterial blood pressure, the brain signals the release of
catecholamines to induce systemic vasoconstriction or directly enhances the release of
antidiuretic hormone or vasopressin to promote fluid retention in the kidneys (Clark and Cleland,
2000; Charkoudian and Rabbits, 2009; Floras, 2009). Decreased systemic perfusion to the kidney
upregulates the renin-aldosterone-angiotensin system (RAAS) and consequently results in
vasoconstriction in an effort to increase blood pressure and volume. Long term effects of this
compensatory mechanism however leads to an increase in peripheral resistance and therefore a
greater afterload producing a marked increase in resistance to left ventricular outflow. In addition
to the changes in blood pressure, significant modifications to the heart termed cardiac
remodelling also occur further aggravating the HF syndrome.

1.2.2

Cardiac Remodelling and Hypertrophy

Cardiac remodelling may refer to either the structural changes, such as shape and size, of
the heart (global remodelling) or to the changes in the molecular signalling of the cardiomyocyte
(cellular remodelling) as well as modifications to the extracellular matrix (ECM) of the
myocardium (extracellular remodelling) (reviewed in Fedak et al., 2005). The most characteristic
feature in the cardiac remodelling process is the development of cardiac hypertrophy that is
considered a maladaptive compensatory mechanism which results in decreased pumping
efficiency of the heart.
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1.2.2.1 Types o f Hypertrophy: Physiological vs. Pathological and Concentric vs.
Eccentric
Cardiac hypertrophy is classified as either physiological or pathological (reviewed in
MucMullen and Jennings, 2007; Bernardo et al., 2010). In cases o f physiological hypertrophy,
which mainly occur during fetal growth, pregnancy or as a result o f chronic exercise (athlete’s
heart), there is a proportional increase in chamber sizes. In contrast, pathological hypertrophy is
detrimental because it involves abnormal structural and cellular remodelling that may lead to
necrosis and apoptosis of viable myocardium resulting in cardiac dysfunction and ultimately HF
(reviewed in Bernardo et al., 2010). Evidently, there are significant differences in the diagnostic
markers which classify physiological and pathological hypertrophy as the stimuli and global and
cellular remodelling processes are unique to both classifications of hypertrophy. For example,
the reexpression of fetal genes such as a-skeletal actin (aSA) or atrial natriuretic peptide (ANP)
(Ueno et al., 1999) are present in pathological but are absent in physiological hypertrophy
(reviewed in Bernardo et al., 2010). In addition, activation o f specific cellular signalling
pathways are upregulated in pathological hypertrophy while it has no Contribution in the
physiological hypertrophic process. An example o f this phenomenon is the activation of the
calcineurin/NFAT3 signalling pathway (discussed in section 1.2.3.3) that was upregulated only
in mice subjected to pressure-overload or Mi-induced pathological hypertrophy and not in
exercise training-induced physiological hypertrophy (Wilkins et al., 2004).
Cardiac hypertrophy can additionally be classified as concentric or eccentric hypertrophy
which is based on the structural arrangement o f the cardiomyocytes (reviewed in Jessup and
Brozena, 2003). In concentric hypertrophy, cardiac cells increase along the horizontal axis and
are stacked in parallel therefore resulting in an increase in the mass and width of the ventricular

12

wall and a decrease in the ventricular cavity. Pressure overload stimuli such as strength
training/heavy lifting in athletes (Mihl et ah, 2008) or hypertension and aortic stenosis are
examples of causes o f concentric hypertrophy (reviewed in Bernardo et ah, 2010). Conversely,
eccentric hypertrophy involves an elongation of the cardiomyocyte arranged in series which
produces a thinner ventricular wall and an increase in ventricular cavity size. Eccentric
hypertrophy usually arises from volume overload stimuli which may include endurance training
(Mihl et ah, 2008) or valvular disease (reviewed in Bemado et ah, 2010).
1.2.3

Signalling Pathways in Cardiac Hypertrophy

As many humoral factors are released in the circulation in response to a prohypertrophic
stimuli, there are consequently multiple and complex signalling pathways that may contribute to
the pathogenesis o f cardiac hypertrophy (reviewed in Frey and Olson, 2003).

Accordingly,

select molecular mechanisms which have been studied in this thesis, particularly mitogen
activation of protein kinases (MAPK) and small GTPases protein signalling pathways are
discussed in detail in section 1.2.3.1 and 1.2.3.2, respectively.
1.2.3.1 M itosen-activatim Protein Kinase (MAPK) Pathway: p38 and ERK1/2
One of the cellular signalling pathways that has been shown to be upregulated by several
different classes o f extracellular hypertrophic stimuli is the MAPK pathway (reviewed in Rose et
ah, 2010). Communication between the initial external stimuli and the nucleus o f the
cardiomyocyte is appropriately coordinated and transmitted via the MAPKs to induce an
upregulation of transcriptional factors which lead to hypertrophy.
MAPKs are specific serine/threonine-protein kinases that are activated by upstream
protein kinases, which include a three-step MAPK cascade in response to inflammatory
cytokines, growth factors or G-protein coupled receptors (GPCRs) agonists (reviewed in Rose et
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al., 2010). First in response to the external stimuli are MAP kinase kinase kinases (MAPKKK,
MAP3K, MEKK or MKKK) such as MLK3 (Chadee and Kyriakis, 2004) or MEK2,3 (Xiao et
al., 2001; Shama et al., 2008). MAPKKKs subsequently phosphorylate the MAP kinase kinases
(MAPKK MAP2K, MEK or MKK) on serine or threonine residues, which are second in line of
the three-tier cascade. Activation of MAPKKs phosphorylate threonine and tyrosine residues
( Thr-X-Tyr or T-X-Y motif) (Canagarajah et al., 1997) of their respective MAPKs. The cascade
is complete when activated MAPKs phosphorylate the appropriate nuclear and cellular substrates
downstream of the specific MAPK pathway (reviewed in Rose et al., 2010).
The three major MAPKs that have been implicated in cardiac hypertrophy and HF are the
extracellular signal-regulated kinases (ERK) phosphorylated at the Thr-Glu-Tyr sites, c-Jun Nterminal kinases (JNKs) also known as stress-activated protein kinases (SAPKs) phosphorylated
at Thr-Pro-Tyr m otif and the p38 isoforms (a, (3, y and 8), also a type o f SAPK, which are
phosphorylated at Thr-Gly-Tyr (reviewed in Rose et al., 2010). Although there are unique
characteristics o f each MAPK signalling cascade they are also very much intertwined with each
another.
1.2.3.1.1

ERK1/2 MAPK Signalling in Cardiac Hypertrophy

ERK 1 and 2 (ERK 1/2) were the first to be identified and cloned in the ERK MAPK
signalling cascade in 1991 (Boulton et al., 1991) and are mainly responsive to mitogenic growth
factors that stimulate receptor tyrosine kinases (RTKs) and GPCRs (reviewed in Rose et al.,
2010). ERK 1 and 2 are nearly identical to each other as they proceed via similar signalling
mechanisms and have consequently been referred to as simply ERK 1/2.
The ERK MAPK cascade has been demonstrated to be involved in several other
pathological disorders such as cancer (Roberts and Der, 2007; Wu, 2007), diabetes (Mokhtari et
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al., 2008; Pan et al., 2011) and CVDs (Ruwhof and van der Laarse, 2000; Muslin, 2008) as it has
been shown to affect several different cellular processes regulating cell cycle progression, gap
junctions, cellular adhesions and cytoskeleton dynamics by activation of more than 100
substrates (Yoon and Seger, 2006). External stimuli which activates RTKs or GPCRs such as
platelet-derived growth factor (PDGF) (Reusch et al., 2001; Yamada et al. 2002; Beeser et al.,
2005) or angiotensin II (Angll) (Zou et al., 1996; Hong et al., 2004), respectively, activates Ras
in the cytosol subsequently recruiting the MAP3K, Raf. Activated Raf phosphorylates the
corresponding MAP2K, MEK1/2, which activates the final component of the cascade, ERK1/2.
Phosphorylated or activated ERK1/2 activates downstream substrates that have the ability to
increase the transcription o f prohypertrophic factors (reviewed in Rose et al., 2010; Kolch, 2000)
such as GATA-4 (Liang et al., 2001). In addition, protein tyrosine phosphatase Shp2 and
* S\

increases in intracellular calcium levels ([Ca ]j) have been demonstrated to upregulate protein
kinase C (PKC) activity that is also linked to activation of the Ras/Raf/MEK/ERKl/2 cascade
(Hagiwara et al., 2007).
There are several in vitro and in vivo studies that have demonstrated the role o f the
Ras/Raf/M EKl/ERKl/2 cascade in cardiac hypertrophy (reviewed in Rose et al., 2010). By
compromising expression and activity o f the components of the ERK1/2 MAPK cascade, cardiac
hypertrophy, ventricular dysfunction and cardiac fibrosis were inhibited. For example,
attenuation of hypertrophy was observed by expression o f a dominant negative Raf (Harris et al.,
2004). Elsewhere, in transgenic animal studies where cardiac Ras was constitutively active, such
as in the MLC-2v-H-Ras-V12 (Zheng et al., 2004) and a-MHC-H-Ras-V12 (Mitchell et al., 2006)
mouse mutant models, significant LV hypertrophy and cardiac dysfunction were observed.
Constitutive activation o f MEK1 has similarly been demonstrated to induce cardiac hypertrophy
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(Bueno et al., 2000; Ueyama et al., 2000). However attenuation o f MEK1 via direct inhibition by
a dominant negative expression o f MEK1 in cardiomyocytes prevents the hypertrophic program
(Ueyama et al., 2000). Attenuation o f the ERK1/2 cascade can also be achieved by inhibition of
the upstream components o f R af such as via prevention of PKC activation (Schonwasser et al.,
1998; P anet al., 2005).
Direct upregulation of ERK1/2 in cultured cardiomyocytes by classical hypertrophic
agonists such as Angll, endothelin-1 (ET-1) and phenylephrine (Phe) as well as other growth and
stress factors have likewise been observed (reviewed in Rose et al., 2010). In a clinical aspect,
upregulation o f ERK1/2 activation has been detected in tissues o f HF patients (Takeishi et al.,
2002) and in another study was correspondingly attenuated after mechanical unloading using a
left ventricular assist device (LVAD) (Baba et al., 2003). Interestingly however, in a transgenic
model investigating the role o f ERK1/2 in pressure-overload-induced cardiac hypertrophy of
mutant mice that either lacked ERK1/2 or overexpressed the ERK1/2 inhibiting protein dualspecific phosphatase 6 (DUSP-6), pressure-loaded or neuroendocrine agonist-induced cardiac
hypertrophy was not attenuated (Purcell et al., 2007). Similarly, in the case o f leptin-induced
cardiac hypertrophy, the ERK1/2 inhibitor, PD98509, only partially attenuated leptin-induced
cell surface area and protein synthesis (Rajapurohitam et al., 2003). These results may propose
that although the ERK1/2 MAPK cascade is upregulated in the pathogenesis of cardiac
hypertrophy, it may be secondary to additional pathways that have a more contributive role in the
disorder.
1.2.3.1.2

p38 MAPK Signalling in Cardiac Hypertrophy

The p38 MAPK cascade may refer to any o f the four isoforms (a, P, y and ô) and is
induced by stress-like stimuli such as UV radiation and oxidative stress (reviewed in Rose et al.,
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2010). Although the p38 isoforms share very similar homologies, deletion of the p38 a in mutant
mice is lethal while knockout of the other three isoforms produce viable progeny (Mudgett et al.,
2000; Tamura et al., 2000). Activation of p38 can also be upregulated by inflammatory cytokines
via the gpl30 cytokine membrane receptor and is therefore typically implicated in chronic
inflammatory diseases (Langdon et al., 2003). The p38 signalling cascade generally involves
MEKK1-4, MKK2/3 and ASK 1/2 as MAPKKKs which have the potential to phosphorylate the
MKKs that include MKK4 and MKK3/6 (reviewed Rose et al., 2010). p38 may be additionally
directly activated by factors separate from the MAPK cascade such as via GPCR-agonistinduced TAO1/2/3 activation (Chen et al., 2003; Raman et al., 2007) as well as by the growth
factor TGF-P-induced TAK1 (Kimura et al., 2000). Activation of p38 involves phosphorylation
or translocation into the nucleus where it upregulates several transcription factors such as c-fos
(FBJ murine osteosarcoma viral oncogene) and serum response factor (SRF) contributing to the
development o f hypertrophy (Lee et al., 2008; Ely et al., 2011).
Although the specific role of p38 in the heart has not been fully detailed, several in vitro
and in vivo work have demonstrated its robust role in the hypertrophic program (reviewed in
Rose et al., 2010). It appears as though p38 may be upregulated via its prototypic MAPK
signalling cascade, but similar to the ERK1/2 pathway as previously discussed, additional cross
talk with other associated pathways in hypertrophy exists.

In isolated cardiomyocytes, the

specific inhibitors o f p38, SB203580 (Rajapurohitam et al., 2003) or SB202190 (Kinugawa et al.,
2005) in addition to adenoviruses expressing a dominant negative form of p38 (Wang et al., 1998)
inhibited agonist-induced cardiac hypertrophy. In leptin-induced cardiac hypertrophy, p38
inhibition by SB203580 exhibited a more marked reduction in molecular indices of hypertrophy
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in comparison to the inhibition o f ERK1/2, further indicating the significance o f the p38 MAPK
cascade in cardiac hypertrophy (Rajapurohitam et al., 2003).
In transgenic animal models with a dominant negative form of p38 (Watanabe et ah,
2007), cardiac hypertrophy and ventricular dysfunction were similarly attenuated further
supporting in vitro results that implicated a more robust role o f p38 in comparison to ERK1/2 in
the hypertrophic program. While inhibition o f MKK3 and MKK6 in isolated cardiomyocytes has
been shown to attenuate cardiac hypertrophy (Wang et ah, 1998), results from in vivo studies
demonstrate that dominant negative forms o f MKK3/6 can result in compensatory upregulation
o f other pro-hypertrophic pathways (Braz et ah, 2003). Conversely however, others have
demonstrated that constitutively active cardiac MKK 3 and 6 contributes to the development of
interstitial fibrosis and ventricular dysfunction (Liao et ah, 2001). The in vivo evidence
demonstrating the ability to prevent cardiac hypertrophy by inhibiting p38 activation remains
non-conclusive and consequently is still an area o f active research.
1.2.3.2 Small GTPase Proteins - RhoA/ROCK Pathway
There is evidence o f cross-talk between MAPK signalling cascades and non-MAPK
pathways such as the small guanine triphosphatase (GTPase) binding protein signalling pathways,
which is a unique cascade that eventually leads to the development o f cardiac hypertrophy
(reviewed in Brown et ah, 2006). Small GTPases are small monomeric proteins (20 to 25 kDa)
o f which there are over 100 members that are further divided into 5 main groups: Ras, Rho, Rab,
A rf and Ran (reviewed in Lezoualc’h et ah, 2008). In addition to their difference in molecular
weights, they are uniquely distinct from heterotrimeric GTPases as they do not interact with
GPCRs or with (3/y G-protein subunits. Small GTPases act as molecular switches transitioning
from its inactive to active state when it is bound to GDP and GTP, respectively. Once activated,
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the small G-protein-GTP bound member acts on its effector molecules eliciting the appropriate
cellular responses (reviewed in Brown et al., 2006).
While there is minimal literature on the effects of the Rab, A rf and Ran groups in CVD,
there have been reviews which discuss Ras-mediated hypertrophy (reviewed in Sugden and
Clerk, 2000; Proud, 2004) and particularly the subfamily members, Racl and RhoA, as they
were the first o f the groups to be linked to cardiac hypertrophy. After the first publication by
Ridley and Hall, which described the role o f RhoA and Racl in cytoskeleton actin dynamics in
fibroblasts (Ridley and Hall, 1992), several studies subsequently followed, providing further
insight into the cellular processes affected by RhoA. These include, but are not exclusive to, cell
proliferation and transformation, smooth muscle contraction, ion channel activity and reactive
oxygen species production (reviewed in Brown et al., 2005; Lezoualc’h et al., 2008). For the
purpose o f this thesis, only RhoA activation and its role in cardiac hypertrophy are reviewed.
Several hypertrophic stimuli, namely GPCR-agonists, result in the activation of RhoA.
The most acknowledged effector molecules downstream of RhoA are Rho-associated coiled-coil
protein kinase (ROCK) and mammalian diaphanous (mDia). The regulation and function of
ROCK and its implication in hypertension and HF has also been reviewed extensively elsewhere
(reviewed in Loirand et al., 2006; Noma et al., 2006). In cardiac hypertrophy, activation of RhoA
results in the activation o f ROCK, which phosphorylates the secondary effector enzyme, lim
kinase (LIMK). Activation of LIMK will subsequently phosphorylate the ubiquitous actin
depolymerizing agent, cofilin-2, resulting in a decrease in the globular (G) to filamentous (F)
actin.
In cultured neonatal ventricular cardiomyocytes, RhoA activation is upregulated by
classic agonists of the heterotrimeric G protein Gaq such as Angll, ET-1, phenylephrine and
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prostaglandin F2a (reviewed in Brown et al., 2006; Lezoualc’h et al., 2008). Activation of RhoA
may also result from stretch stimuli (Torsoni et al., 2005), activation o f G 12/13 (Maruyama et al,.
2002) and by a non-classical agonist, leptin, acting on the leptin receptor (Ob-Rb), which has
been studied extensively in our laboratory (Rajapurohitam et al., 2003; Rajapurohitam et al.,
2004; Purdham et al., 2008; Zeidan et al., 2006; Zeidan et al., 2008; Moey et al., 2011; Zeidan et
al., 2011).
RhoA/ROCK activation appears to be a critical pathway in the hypertrophic program as
studies have shown that by inhibiting RhoA/ROCK activation with C3 exoenzyme or Y-27632,
inhibitors o f RhoA and ROCK, respectively, phenylephrine- (Yanazume et al., 2002), ET-1(Kuwahara et al., 1999; Porchia et al., 2008; Hunter et al., 2009), Angll- (Yamakawa et al., 2000;
Guilluy et al., 2010), LPA- (Hilal-Dandan et al., 2004) and leptin- (Zeidan et al., 2008; Zeidan et
al., 2006) induced cardiac hypertrophy was significantly attenuated. Interaction between the
RhoA/ROCK and other associated pathways such as the MAPK cascades has also been observed
in the hypertrophic phenotype (Zeidan et al., 2006; Zeidan et al., 2008; Moey et al., 2011; Zeidan
et al., 2011) as inhibition of RhoA/ROCK correspondingly blunts p38 MAPK activation as
evidenced by decreased phosphorylation and nuclear translocation (Zeidan et al., 2008; Moey et
al,. 2011).
Results from in vivo studies inhibiting RhoA activation are in concordance with the in
vitro literature such that cardiac hypertrophy and dysfunction are attenuated with RhoA inhibitor
treatment. RhoA inactivation in vivo has been mainly studied using inhibitors o f its downstream
effector molecule, ROCK. For example, in hypertensive rats receiving Y-27632, myocardial
hypertrophy was reduced and cardiac function was significantly improved (Kobayashi et al.,
2002; Satoh et al., 2003). Cross talk o f RhoA/ROCK signalling with additional pathways such as
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the oxidative stress-induced LOX-1 pathway in vivo has also been observed where cardiac
hypertrophy, remodelling and dysfunction in hypertensive salt-sensitive rats were inhibited by Y27632 (Mita et al., 2005). HF induced by isoprotemol (ISO) in rats (Wang et al., 2011) has also
been shown to be prevented with subcutaneous treatment of fasidil hydrochloride hydrate, which
is a ROCK inhibitor. ISO-induced ROCK-mediated upregulation o f ERK1/2 and JNK MAPK
were additionally reduced in the animals receiving fasidil (Wang et al., 2011). In contrast
however, there has been one report which demonstrated no effect on the regression o f cardiac
hypertrophy following haploinsufficient ROCK suppression in transgenic mice, although there
was evidence o f attenuated fibrosis (Rikitake et al., 2005). Complete deletion of ROCK resulted
in unviable litters suggesting a protective role o f RhoA for the survival of fibroblasts during the
early developmental stages o f the heart. Results from this study allowed the authors to conclude
a more contributive role o f RhoA/ROCK activation to the fibrotic response than cardiac
hypertrophy (Rikitake et al., 2005). Although multiple agonists have been shown to elicit
hypertrophic responses through the activation of RhoA/ROCK signalling, the specific
mechanism by which RhoA/ROCK is upregulated has not been fully elucidated. Consequently
more consideration has been directed towards the positive and negative regulators of small Gproteins.
1.2.3.2.1

Regulators o f Small GTPase-Proteins

Activation o f RhoA proteins are mediated by regulators that are classified as guanine
nucleotide exchange factors (GEFs), guanine nucleotide-dissociation inhibitors (GDIs) and
GTPase-activating proteins (GAPs) (reviewed in Lezoualc’h et al., 2008). RhoA proteins have a
high affinity for GDP molecules and thus GEFs promote the activation o f RhoA by facilitating
the exchange o f GDP for GTP (reviewed in Rossman et al., 2005). Negative regulators of the
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RhoA pathway include GAPs, which promote the hydrolysis of GTP while GDIs sequester
inactive RhoA-GDP in the cellular compartment distancing them from the membrane where
GDP for GTP exchange occurs (reviewed in Schmidt and Hall, 2002; Rossman et al., 2005; Bos
et al., 2007).
There are more than 70 RhoGEFs which have been identified in the human body
(reviewed in Rossman et al., 2005). GEFs specifically recognize distinct members of the five
small GTPase proteins. The Dbl (DH) and pleckstrin (PH) homology are highly conserved
among the GEF members and are known to regulate its activity (reviewed in Rossman et al.,
2005). The DH domain is responsible for binding of the RhoGEF to the RhoGTPase as well as
catalyzing the exchange o f GDP for GTP on the Rho molecule as mutations in the amino acid
sequence o f this conserved domain negatively affects nucleotide exchange activity (reviewed in
Rossman et al., 2005; Bos et al., 2007). A detailed description of the mechanism of nucleotide
exchange can be found in the review by Rossman and colleagues (Rossman et al., 2005).
Conversely, the PH domain of the RhoGEF serves as an anchor by interacting with the
phospholipids comprising the cellular membrane to bring the RhoGEF and RhoGTPase in close
proximity with the activated receptor or heterotrimeric G proteins such as Gq/n (Lutz et al., 2005)
and Cj 12/1 3 (Suzuki et al., 2003; Siehler, 2009). RTKs are another example of receptors that
associate with RhoGEFs as they have been suggested to phosphorylate tyrosine residues on
RhoGEFs to regulate its nucleotide exchange activity (reviewed in Schiller, 2006). Indeed site
mutation at Tyr738 o f p i 15RhoGEF, a RhoGEF which has been indicated in high blood pressure,
reduced its nucleotide exchange activity and subsequent RhoA activation (Guilluy et al., 2010).
Although the activation o f RhoGEFs in cardiac hypertrophy has not been extensively
studied, there have been a few reports which have demonstrated the roles o f pll5R hoG EF
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(Porchia et al., 2008; Moey et al., 2011), p63RhoGEF (Porchia et al., 2008), PDZ-RhoGEF
(Ying et al., 2009), and A-kinase anchoring protein (AKAP)-Lbc (Appert-Collin A et al., 2007)
in the hypertrophic disease process. pll5R hoG EF and p63RhoGEF expression has also been
demonstrated to be upregulated in hypertensive conditions (Guilluy et al,. 2010) while
p63RhoGEF (Souchet et al., 2002) and AKAP-Lbc (Ruehr et al., 2004) are expressed in the
human myocardium. Activation of small G proteins may be alternatively controlled by GAPs
which promote the hydrolysis of GTP thereby downregulating RhoA activation (reviewed in
Brown et al., 2005). While there has been much focus on the regulators of G-protein signalling
(RGS) such as RGS2, RGS4 and RGS5 in attenuating cardiac hypertrophy by enhancing GTPase
activity o f heterotrimeric G proteins (reviewed in Sugden, 2001), there is no study to date which
has investigated the involvement of small GTPase GAPs. There was some effort however in our
laboratory to assess the role o f an endogenous activator o f pl90RhoGAP, Rnd3 (Wennerberg
2003; Riou et al., 2010), to downregulate leptin-induced RhoA activation (C hapter 3).
1.2.3.3 Calcineurin/NFA T3 Pathway
The calcineurin/NFAT3 signalling pathway is considered one of the key processes involved
in ventricular remodelling as it results in the induction of hypertrophy (reviewed in Frey and
Olson, 2003). Calcineurin (CaN), a phosphatase enzyme which dephosphorylates NFAT3
(nuclear factor of activated T cells) allowing nuclear translocation and upregulation of the
transcriptional product MCIP-1 (modulatory calcineurin interacting protein-1), has been shown
to be activated by several humoral factors released in HF such as phenylephrine (Molkentin et al.,
1998; Taigen et al., 2000; Guo et al., 2011), Angll (Molekintin et al., 1998; Taigen et al., 2000;
Fu et al., 2001) and ET-1 (Zhu et al., 2000; Bao et al., 2008). Administration of the CaN
inhibitors cyclosporine A and FK506 in mice has been shown to prevent pressure-overload-
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induced cardiac hypertrophy (Sussman et al., 1998) and upregulation of CaN in human patients
with HF has likewise been observed (Lim et al,. 1999). Indeed there have been additional studies
demonstrating the significant role o f CaN/NFAT3 signalling in ventricular remodelling and heart
failure such that inhibition leads to improved echocardiographic and hemodynamic parameters
and, notably, increased survival (Sakata et al., 2000; Wilkins et al., 2004).
Activation o f CaN has also been shown to be intricately associated with the upregulation of
the sodium hydrogen exchanger isoform 1 (NHE-1), which is the dominant cellular membrane
regulator o f internal cardiomyocyte pH that expels protons (H+) for sodium (Na+) ions (reviewed
in Karmazyn et al., 2008b). Activation o f NHE-1 by the aj-adrenergic agonist, phenylephrine,
was proposed to upregulate CaN activation by increasing [Ca ]i secondary to the increases in
intracellular Na+ ([Na+]j) (Guo et al., 2011). Observed increases in [Ca2+]i as a result o f NHE-1induced elevation o f [Na+]i in the hypertrophic program and HF has been suggested to initiate
reverse mode activation o f the Na+Ca2+ exchanger (NCX) (reviewed in Karmazyn et al., 2008b;
Guo et al., 2011). Increased protein and gene expression of NHE-1 in phenylephrine-induced
cardiac hypertrophy was concomitantly observed with upregulation of CaN activity most likely
via increases of [Na+]j and [Ca2+]j (Guo et al., 2011). Upregulation of the CaN activation and
downstream MCIP-1 gene production in Mi-induced rats were also subsequently observed and
was inhibited by treatment with the ginseng, further indicating a pivotal role o f CaN in the
development of cardiac hypertrophy and remodelling in vitro and in vivo (Guo et al., 2011).
Although several studies have already demonstrated that inhibition o f CaN has the ability to
attenuate cardiac hypertrophy and HF, the potential for reversal o f CaN activation for the
treatment o f HF has only been recently demonstrated (Berry et al., 2011). Reversal o f cardiac
remodelling is the most challenging obstacle in the treatment of HF however, by demonstrating
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the ability to treat cardiac hypertrophy and dysfunction by the reversal of CaN proposes the
potential to target the reversal o f molecular pathways and specifically CaN upregulated in
cardiac remodelling for the management o f HF.
1.2.4

Obesity and Cardiovascular Disease

Obesity, which is defined by a body mass index (BMI) > 30 kg/m2 (Guh et al., 2009) or a
waist circumference > 88 cm (Health Canada, 2003) is a prevalent and insidious disease in
today’s society. Studies have shown a correlation between mortality and obesity (Horwhich et al.,
2001) as obesity is typically accompanied by pathological conditions such as type II diabetes,
osteoarthritis, cancer, sleep apnea and CVD (Sader et al., 2003; Patel et al., 2008; Guh et al.,
2009). While there is a well acknowledged relationship between obesity and CVD (Sowers,
2003), the particular mechanisms linking the two still remain unclear. A particular adipokine
encoded by the obesity (ob) gene, leptin, however has become the highlight of obesity-associated
CVD research (reviewed in Karmazyn et al., 2008a) as studies have suggested its contributive
role in the development o f obesity-associated CVD.
1.2.4.1

Leptin

1.2.4.1.1

Discovery and Physiological Functions o f Leptin

Although it was generally understood through studies involving lesions of the
hypothalamus that changes in body weight resulted in appropriate balancing of energy
consumption and metabolic processes initiated by signals from the brain, the connection between
both signal points had not yet been identified. Parabiotic experiments, which surgically link two
animals together to observe the physiological effects o f factors within the blood such as
hormones, between obese (ob/ob), diabetic obese (db/db) and normal mice allowed Coleman in
1973 to demonstrate that a particular, though unidentified, circulatory factor was responsible for
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regulating body weight (Coleman, 1973). This was shown by the parabiosis of ob/ob or normal
mice with db/db mice where the obese or normal mice became hypoglycemic, lost weight and
eventually died of starvation, while the db/db mice exhibited no changes and survived.
Interestingly however, when ob/ob mice were paired with normal mice, the weight loss was not
as drastic and the obese mice survived. The results from these parabiotic experiments
demonstrated that the ob/ob mice were not producing sufficient amounts of this unidentified
factor affecting satiety while the db/db mice were unresponsive to this satiety factor (Coleman,
1973). It was not until 20 years later through cloning of the ob gene where the factor responsible
for regulating satiety was identified and termed Teptin’, stemming from the Greek language,
leptos, meaning ‘thin’ (Zhang et al., 1994).
1.2.4.1.2

Production and Structure o f Leptin

Leptin is a 167 amino-acid polypeptide encoded by the ob gene on chromosome 7q31.1,
4 and 6 of humans, rat and mouse, respectively (Zhang et al., 1994). The amino acid sequence of
leptin from all three species is highly conserved (approximately 80% homologous), particularly
the disulphide bond between Cys96 and Cys146 at the C-terminal region (Kline et al., 1997; Zhang
et al., 1997). In fact, compromises to the amino acid sequence coding the disulphide bond or Cterminal region have been suggested to inhibit the biological activity o f leptin by impairing its
structural folding and receptor binding capacity (Imagawa et al., 1998). Its structural properties,
specifically the long chain helical cytokine fold, are comparable to the type I cytokine receptor
family including leukemia inhibitory factor (LIF), ciliary neutrotrophic factor (CNTF),
cardiotrophin-1 (CT-1) and also members o f the interleukin family, IL-6, -11 and -12 (reviewed
in Friihbeck, 2006). Although leptin is predominantly produced by and in proportion to white
adipose tissue, leptin has been shown to be found in several other tissues including the heart
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(Purdham et al., 2004), liver, skeletal muscle, stomach, hypothalamus, placenta and ovaries.
Leptin may be found either bound to the specific leptin receptor (Ob-R) isoform e (see section
1.2.4.2.1), but may also remain unbound and free floating. The latter is often increased in the
plasma of obese individuals.
1.2.4.13

Role o f Leptin in Obesity-associated Cardiovascular Disease

The discovery of this satiety factor especially in the perspective as a regulator of body
weight sparked great interest in studying this peptide for the treatment of obesity and potentially
against its associated co-morbidities. Early studies targeting leptin for the treatment of obesity
however were unsuccessful and were considered to be a result of the ‘leptin resistance’
phenomenon (Schwartz et al., 1996). Leptin resistance describes the syndrome where obese
individuals with chronic hyperleptinemia tend to be non-responsive to treatment with leptin as a
result of decreased leptin sensitivity at the hypothalamus. In the obese condition, other peripheral
tissues may likewise become resistant or even more sensitive (reviewed in Sweeney, 2010).
Indeed a non-resistant, but rather enhanced, response to leptin has been observed in both the
vascular system of mice where hyperleptinemia was induced by a high fat diet (Belin de
Chantemele et al., 2011). Although central leptin resistance was present, leptin-mediated
stimulation o f the heart and vasculature was still active (Belin de Chantemele et al., 2011).The
opposite has also been observed where ventricular cardiomyocytes isolated from rats on a
sucrose diet demonstrated impaired leptin signalling in addition to the development of
hyperleptinemia and insulin resistance (Hintz et al., 2003).
Leptin has been suggested as a contributory factor to the pathogenesis of obesityassociated CVD by potentiating sympathetic tone and catecholamine release (reviewed in Hall et
al., 2010; Kotsis et al., 2010; Rahmouni, 2010), though paradoxical effects of leptin, where it has
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been considered as a cardioprotective agent in the ‘obesity paradox phenomenon, has also been
observed (reviewed in Abel et al., 2008). Enhanced sympathetic activation results in increased
blood pressure, while catecholamine release would aggravate the hypertension in addition to
directly promoting abnormal biochemical and molecular changes within the cardiac tissue.
Hypertension caused by leptin-induced increase in sympathetic tone has indeed been
demonstrated (Belin de Chantemele et al., 2009; Morgan et al., 2008) and may be a considerable
target for the treatment of obesity-associated CVDs. Alternatively, leptin-induced increased
production and release o f catecholamines have been proposed to occur by direct stimulation of
the adrenal medullary cells via MAPK activation (Shibuya et al., 2002). In addition to an
increased risk o f hypertension in obese conditions, leptin may contribute to atherothrombosis
(Ciccone et al., 2001; Singh et al., 2010), endothelial dysfunction (Bouloumie et al., 1999; Korda
et al., 2008; Cirillo et al., 2010) and the formation o f atherosclerotic plaques (Park et al., 2001)
possibly by upregulating the activity of inflammatory cells (Schneiderman et al., 2008).
1.2.4.2

Leptin Sisnallins in the Cardiovascular System

Leptin administration to cultured cardiomyocytes generally elicits a prohypertrophic
effect, although there has been one study stating that leptin does not induce hypertrophy (Pineiro
et al., 2005). In human subjects, elevated plasma leptin levels o f > 30 ng/ml has been shown as
an indicator o f cardiac dysfunction independently o f obesity (Schulze et al., 2003). Direct leptininduced cardiomyocyte hypertrophy has been suggested to occur through several different
signalling mechanisms, which mainly include JAK/STAT3 (Janus kinase/signal transducer and
activator of transcription), MAPK, RhoA/ROCK (Ras homolog gene family, member A/Rhoassociated, coiled-coil containing protein kinase), PI3K/PD3B/cAMP (phosphoinositide 3kinase/phosphodiesterase 3B) and AMPK (5’-AMP-activated protein kinase) (reviewed in
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Karmazyn et al., 2008a). Although these pathways are unique in the molecular events that ensue,
it is important to note that they are very much intertwined with each other. For the purpose of
this thesis, leptin-induced activation o f MAPK and RhoA/ROCK-activation will be discussed,
however detailed information on leptin-induced activation of PI3K/PD3B/cAMP and AMPK can
be read elsewhere (reviewed in Fruhbeck, 2006; Yang and Barouch, 2007; Karmazyn et al,.
2008a). A summary o f the activated pathways discussed is illustrated in Figure 1.2.
1.2.4.2.1

Leptin Receptors: Isoforms and Expression

Leptin elicits its physiological effects by binding to its receptors (Lep-R or Ob-R) of
which there are five identified spliced variants. These include the short-intracellular domain
isoforms (Ob-Ra, Ob-Rc, Ob-Rd and Ob-Re) and its long-intracellular domain isoform (Ob-Rb),
which are encoded by the db gene (Lee et al,. 1996) located on chromosome 1, 4 and 5 in
humans, mice and rats, respectively. Although there has been less focus on the function of the
shorter leptin receptor isoforms, Ob-Re, which lack an intracellular domain, has been shown to
primarily bind to leptin in plasma for the regulation of free leptin. Ob-Ra typically
heterodimerizes with the long-domain isoform receptor, Ob-Rb (reviewed in Fruhbeck, 2006),
where the latter has also been shown to homodimerize to produce a post-receptor response
(Devos et al., 1997), which is linked to a multitude o f downstream signalling processes discussed
in subsequent sections 1.2.4.2.2 to I.2.4.2.4. It is the long intracellular domain containing the
STAT box o f Ob-Rb which predominantly results in leptin signalling via JAK2 recruitment as
Ob-Ra, c, d and e lack this essential binding region (Tartaglia et al., 1995; Tartaglia, 1997). The
extracellular domains (800 amino acids) of all five isoforms however are highly conserved,
which consists of two cytokine (four Cys residues and WSXWS) and four fibronectin III
domains (Tartaglia et al., 1995). Within cardiac tissue, all isoforms except Ob-Rc have been
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detected, though Ob-Ra and Ob-Rb are dominantly expressed (Purdham et al., 2004).
Distribution of the specific receptor isoforms has been shown to be dependent on the specific
chamber of the heart where expression o f Ob-R was greater in the atria than the ventricles and
also varied depending on gender (Purdham et al., 2004).
1.2.4.2.2

Leptin in JAK/STAT3 Signalling

Shortly after the discovery o f leptin and its role in obesity, studies into the post-receptor
signalling mechanisms subsequently followed which detailed the molecular events attributing to
the physiological effects o f leptin. It is to no surprise that the first leptin-activated signalling
pathway identified was JAK/STAT because o f the functional similarity of the dominant leptin
receptor isoform, Ob-Rb, to the type I cytokine receptor family (reviewed in Friihbeck, 2006).
Among the four JAK members, which include, JAK 1, JAK2, JAK3 and tyrosine kinase 2
(TYK2), the intracellular domain of Ob-Rb contains box motifs which bind predominantly to
JAK2 (Tartaglia et al., 1995). Upon binding o f leptin to a homodimer formation of Ob-Rb, the
activated receptor recruits JAK2 whereby JAK2 undergoes autophosphorylation. Subsequent
phosphorylation of Tyr985, Tyr1077 and Tyr1138 on Ob-Rb by JAK2 occurs (Eyckerman et al.,
2000), however it is the specific phosphorylation o f Tyr985 that promotes the recruitment of
STAT3, which dimerizes and translocates to the nucleus, activating transcription o f its respective
genes (reviewed in Myers, 2004). Phosphorylation of Tyr

and Tyr

has been shown to

recruit STAT5 and STAT1/3/5, respectively, independently of JAK2-Ob-Rb association
(Hekerman et al., 2005) (Figure 1.2).
1.2.4.2.2.1 Leptin-induced Activation o f JAK/STAT3 Signalling in Cardiac
Hypertrophy and Heart Failure
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Figure 1.2. Leptin-induced activation of signalling pathways in cardiac hypertrophy. Leptin binds to the leptin-receptor
(Ob-Rb) and may activate several signalling cascades though which namely include RhoA/ROCK, p38 and ERK 1/2 MAPK as
well as JAK/STAT3. Leptin-induced signalling is mainly due to the phosphorylation of the receptor by JAK2. Activaton of
these pathways leads to the uregulation of several transcription factors leading to hypertrophy. See text for more details.

Although many studies have demonstrated activation of the JAK/STAT3 pathway by
leptin in immune cells, cancer cells and cardiomyocytes, there are few examples which have
shown activation in leptin-induced cardiac hypertrophy. In fact, the general perspective of leptininduced activation of JAK2/STAT3 appears to be a protective mechanism in immunity (Gruen et
al., 2007), neuron health (Cui et al., 2006) and as well as in ob/ob conditions (McGaffin et al.,
2008; McGaffin et al., 2011).
Others however have argued that excess leptin contributes to eccentric hypertrophy in
vivo as chronic infusion of leptin in post-infarcted mice caused enhanced compensated cardiac
function that was associated with cardiomyocyte elongation (Abe et al., 2007). Leptin-induced
cardiac hypertrophy was associated with upregulated JAK2/STAT3 activity evidenced by
augmented phosphorylation states of JAK2 and STAT3, nuclear translocation and DNA binding
o f STAT3 in cardiomyocytes (Abe et al., 2007). Incubation with the JAK2 inhibitor, AG490,
however attenuated these responses to leptin stimulation. In the same report, chronic leptin
infusion enhanced CAL-induced MI, which was demonstrated by an increase in the LV enddiastolic diameter as well as fractional shortening. As the gene expression level of Ob-Rb was
higher than Ob-Ra in CAL-operated animals, JAK2/STAT3 activation was suggested to occur
predominantly via Ob-Rb signalling.
Conversely, in mice depleted o f leptin (ob/ob) (McGaffin et al., 2008) or of response to
leptin in Ob-Rb knockouts (McGaffin et al., 2011), mice exhibited increased LV hypertrophy,
decreased contractile function with poor survival survival outcomes. Repletion with leptin
however reversed these observed effects and improved myocardial function therefore suggesting
leptin as an anti-hypertrophic agent. It is important to note however that the ob/ob model
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includes a plethora o f metabolic abnormalities that is compensated by systemic alterations
resulting in cardiac hypertrophy and dysfunction. The ob/ob model has been regarded as a non
ideal model for studying the direct effects o f leptin as the anti-hypertrophic effects of leptin
observed after leptin infusion are considered to correct the physiological compensations in ob/ob
conditions that occurred as a result of a chronic lack o f leptin. These statements however have
been disputed by a study which demonstrated that leptin exerted a direct antihypertrophic effect
in ob/ob and db/db mice as weight loss induced by caloric restriction did not decrease wall
thickness or cardiomyocyte hypertrophy, while leptin infusion completely reversed ventricular
hypertrophy (Barouch et al., 2003). Consequently there is still much to understand about the
effects of leptin in vivo.
1.2.4.2.3

Leptin and MAPK Signall ing

Phosphorylation of Tyr985 on Ob-Rb has additionally been shown to be associated with
activation of MAPK signalling pathways that are upregulated in cardiac hypertrophy (reviewed
in Myers, 2004). Leptin-induced MAPK activation, specifically ERK1/2 and p38, has been
demonstrated to occur via JAK2-dependent or independent phosphorylation of Tyr

(Bjorbaek

et al., 2001). In JAK2 phosphorylation o f Tyr985, the src homology 2 (SH2) domain of the src
homology 2-containing tyrosine phosphatase (SHP-2) is recruited and phosphorylated by JAK2.
Activation o f SHP-2 results in the association of growth factor receptor binding-2 (Grb-2), which
leads to the subsequent activation of ERK1/2 via the Ras/Raf/MEKl/2 cascade (reviewed in
Friihbeck, 2006) (Figure 1.2). Leptin-induced MAPK activation independent of receptor
phosphorylation occurs via direct interaction of JAK2 with the SHP-2 domain (Bjorbaek et al.,
2001). Expression o f c-fos and egr-1 transcriptional factors, which contributes to cell
proliferation and differentiation, is subsequently upregulated after ERK1/2 activation.
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Although leptin-induced p38 activation has been previously demonstrated (Madani et al.,
2006; Zeidan et al., 2006; Zeidan et al., 2008), the exact mechanism of activation still remains
unidentified, however this may involve upstream activation of RhoA (Zeidan et al., 2006; Zeidan
et al., 2008). Activation o f p38 is observed by increased phosphorylation as well as translocation
o f total p38 forms into the nucleus to induce the expression o f transcriptional factors contributing
to cardiac hypertrophy. Another downstream target o f p38 implicated in leptin-induced cardiac
hypertrophy may be NF kB (nuclear factor kappa B) as it is essential in the induction of proinflammatory cytokines TNFa (tumour necrosis factor a) and IL-ip (interleukin 1-beta), which
have been shown to be increased in CVD (Napoleone et al., 2007).
1.2.4.2.3.1 Leptin-induced Activation o f MAPK Signalling in Cardiac
Hypertrophy
In cultured cardiomyocytes, leptin-induced activation of the p38 and ERK1/2 MAPK
signalling cascade has been shown to elicit a pro-hypertrophic effect (Rajapurohitam et al., 2003;
Madani et al., 2006; Zeidan et al., 2006; Zeidan et al., 2008; Schram et al., 2010; Moey et al.,
2011). Although there was significant activation o f both p38 and ERK1/2 in leptin-treated cells,
p38 upregulation in cardiac hypertrophy has been considered to be more robust than ERK1/2
activation as incubation with the ERK1/2 inhibitor PD98059 did not inhibit leptin-induced
cardiac hypertrophy measured by cell surface area, aSA and myosin light chain-2 (MLC-2) fetal
gene expression and protein synthesis (Rajapurohitam et al., 2003), while the p38 inhibitor
completely prevented leptin-induced effects. A similar observation was also demonstrated in
leptin-treated hypertrophied cardiomyocytes where only total p38 nuclear translocation was
observed (Zeidan et al., 2008; Moey et al., 2011).

34

Activation o f MAPK pathways in leptin-induced cardiac hypertrophy has also been
demonstrated in human pediatric ventricular myocytes (Madani et al., 2006) and in HL-1 murine
cardiomyocytes (Schram et al., 2010). Both studies focused on the contribution o f leptin to ECM
remodelling in the pathogenesis o f HF via JAK (Madani et al., 2006) and MAPK pathways
(Schram et al., 2010; Madani et al 2006). Increased cell surface area, protein synthesis and fetal
gene expression were observed with marked fibrosis and collagen deposition in leptin-treated
cells. Incubation with inhibitors of the JAK, p38 and ERK1/2 pathways, AG490, SB203580 and
PD96059, respectively, however significantly attenuated leptin-induced cardiac hypertrophy and
ECM remodelling (Madani et al., 2006; Schram et al., 2010), indicating a pivotal role o f MAPK
in leptin-induced cardiac remodelling. Activation o f the MAPK pathways however appears to be
dependent on the upregulation o f the classic small G-protein RhoA/ROCK signalling pathway as
inhibitors of the RhoA pathway attenuated p38 activation (Zeidan et al., 2006; Zeidan et al.,
2008).
1.2.4.2.4

Leptin and RhoA/ROCK Signalling

Leptin-induced activation o f the RhoA/ROCK pathway has been a relatively recent
finding as leptin is not a member o f the GPCR group o f classical RhoA/ROCK upregulators that
include Angll, ET-1 and phenylephrine (reviewed in Brown et al., 2006). Activation of
RhoA/ROCK by leptin may however be comparable to cytokine upregulation o f RhoA such as
by IL-6 (Campos et al., 2009). Upregulation o f RhoA by leptin has been observed in several
different tissues o f the body such as chondrocytes (Liang et al., 2011), endothelial cells (De Rosa
S et al., 2009), liver (Jiang et al., 2008), kidney (Attoub et al., 2000), vascular smooth muscle
(Zeidan et al., 2007) and cardiomyocytes (Zeidan et al., 2006; Zeidan et al. 2008; Moey et al.,
2011; Zeidan et al., 2011) and is associated with the pathogenesis of a variety of disorders.
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1 .2 .4 .2 .4 .1

L e p tin - in d u c e d A c tiv a tio n o f R h o A /R O C K S ig n a llin g in C a r d ia c

H y p e r tr o p h y a n d H e a r t F a ilu r e

Although direct administration of leptin in isolated cardiomyocytes has been shown to
induce hypertrophy via MAPK pathways, activation o f the p38 and ERK1/2 cascade appears to
be dependent on the upregulation of the RhoA/ROCK pathway (Zeidan et al., 2006; Zeidan et al.,
2008). Zeidan and colleagues showed that leptin-induced increase in cell surface area and protein
synthesis was associated with a robust activation of RhoA and its downstream components,
particularly cofilin-2 phosphorylation and a decrease in the G/F actin ratio (Zeidan et al. 2006;
Zeidan et al., 2008). Incubation with the RhoA inhibitor C3 exoenzyme, ROCK inhibitor Y27632 or actin depolymerizing agent latrunclin B attenuated leptin-induced cardiac hypertrophy,
RhoA signalling and additionally p38 and ERK1/2 MAPK activation (Zeidan et al., 2008). The
signalling events in RhoA activation was further investigated in a subsequent study by the same
authors where the importance o f caveolae, which are invaginations of the cellular membrane
(Das and Das, 2011), was identified in post-receptor Ob-Rb RhoA signalling (Zeidan et al.,
2008). Furthermore, the dependency o f p38 MAPK upregulation on caveolae formation and
RhoA activation was additionally demonstrated as p38 nuclear translocation was inhibited by the
cholesterol chelator agent methyl-beta-cyclodextrin (MpCD), C3 exoenzyme and Y-27632
compounds (Zeidan et al., 2008). Recently, further downstream events as well as association of
RhoA/ROCK

signalling

kinase/mammalian

target

with

the

PI3K/mTOR/p70(S6K)

of rapamycin/serine/threonine

p70

(phosphotidylinositol
S6 kinase)

cascade

3and

transcriptional activation by GATA4 in cardiac hypertrophy have been additionally identified
(Zeidan et al., 2011). Crosstalk between RhoA/ROCK and the PI3K/PKB (protein kinase B) axis
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has been observed in leptin-induced hypertrophy o f vascular smooth muscle cells of the rat portal
vein (Zeidan et al., 2007).
The specific mechanism of leptin-induced activation of RhoA/ROCK in cardiac
hypertrophy however at the time had not yet been fully elucidated. Recently published work
from our laboratory has suggested the role o f RhoGEFs in this signalling cascade and our
findings have been summarized in detail in C hapter 2.
1.2.5

Pharmacotherapy fo r the Prevention and Treatment o f Heart Failure

The goals o f pharmacotherapy for the prevention and treatment of HF are primarily to
improve survival outcomes, alleviate associated symptoms and reduce incidences of
hospitalization (reviewed in Tamargo and López, 2011). The difficulty however with treating HF
is to reverse the characteristic accompanying feature o f cardiac remodelling where detrimental
cellular changes have occurred. By understanding the molecular mechanisms that are involved in
the cardiac remodelling process, new efficient drugs which target specific signalling pathways
are being produced in an attempt to completely abrogate and reverse the disease.
1.2.5.1 Pharmacolosical Agents in the Treatment o f Heart Failure
The appropriate line o f treatment is determined by the HF symptoms manifested at the
time o f clinical presentation. Although a single drug may be used, these are often prescribed in
combination with additional pharmacological agents. The conventional drug regimen for the
treatment of HF may include one or more o f the following: inhibitors of the RAAS (Ma et al.,
2010) which include angiotensin converting enzyme (ACE) inhibitors, Angll type 1 receptor
blockers (ARBs) and aldosterone blockers, p-adrenergic blockers, calcium (Ca ) channel
blockers (CCBs), loop diuretics and positive ionotropic agents (reviewed in Hellawel and
Margulies, 2010; Tamargo and López, 2011).
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The RAAS is an important physiological system that regulates blood pressure by sensing
pressure changes, receiving information from the central nervous system and relaying
information to the rest o f the body to promote or inhibit the release o f factors regulating blood
pressure (Skeggs et al., 1976). ACE inhibitors prevent the conversion of angiotensin I to
angiotensin II (Erdos, 1976), o f which the latter is a robust humoral factor released during states
o f cardiac stress that contributes to the pathogenesis of cardiac hypertrophy and HF (Wollert and
Drexler, 1999; Blaufarb and Sonnenblick, 1996). ACE inhibitors are usually prescribed to reduce
afterload or an increase in systemic arterial pressure (Brown and Vaughn, 1998). Captopril,
enalapril and lisonopril are a few examples of ACE inhibitors that have been shown to elicit
antihypertrophic and antiremodelling effects (Tamura et al., 2000; Juan et al., 2003; Gagnon et
al., 2004; Brower et al., 2007) and have proven efficacious in several clinical trials (Cohn et al.,
1991; Konstam et al., 1992; Yusuf et al., 1992). Generally, ACE inhibitors produce optimal
outcomes for patients as trials have shown a reduction in all-cause mortality, reduction in
hospitalizations as well as improvement in NYHA functional class (The CONSENSUS Trial
Study Group, 1987). Appropriate dosages o f ACE inhibitors must be taken into careful
consideration as higher doses can easily result in hypotension and worsening cardiac dysfunction
(Phillips et al., 2007). Compliance may also become an issue because of the ACE inhibitorinduced cough as a result of excessive build up of bradykinin (Dicpinigaitis, 2006), a product
secondary to angiotensin II from angiotensin I. Consequently, ARBs such as losartan and
cadesartan, which act essentially via the same inhibitory pathway of ACE-I by blocking
angiotesin II binding, may be preferred over ACE-I (O’Meara et al., 2004; Young et al., 2004;
Konstam et al., 2009). While ARBs may be the preferred prescription, there is conflictive
discussion as to which o f the two RAAS inhibitors is more effective. Aldosterone blockers which
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include spirinolactone and epelemone are the third common drug prescribed in the treatment of
HF that acts in close proximity with the RAAS (Guglin et al., 2011). There are a multitude of
published articles which have shown direct inhibition of agonist-induced hypertrophy where
aldosterone antagonism attenuated cardiac hypertrophy (Yoshida et al., 2010; Veliotes et al.,
2010). In clinical trials assessing the efficiency o f aldosterone antagonism in the treatment of HF,
significant decrease in all cause mortalities and hospitalization incidences were observed in
patients receiving aldosterone blocker treatment (Pitt et al., 2003; Chan et al., 2007).
Treatment of HF may include sympathetic blockade such as p-adrenergic receptor
blockers, which include practolol, atenolol, metopolol, carvedilol, bisoprolol as well as others
(Ambrosioni et al., 2001; Foody et al., 2002). The use of P-blockers in HF almost appears
contradictory however, in HF patients taking P-blockers there was a marked improvement in
cardiac function as well as a decrease in the chamber enlargement (Waagstein et al., 1975). The
success o f P-blockers were measured based on all-cause mortality and rate of hospitalization
which were in fact significantly reduced in large randomized clinical trials (Hjalmarson et al.,
2000; Packer et al., 2002). The remaining drugs include diuretics such as furosemide, torsemide
and bumetanide (Jentzer et al., 2010) and the calcium channel receptor blockers (Opie et al.,
1995), which are used for the treatment o f HF by reducing preload and afterload, respectively.
While diuretics and calcium channel blockers have received less attention in clinical trials,
results from trials investigating the latter are less convincing for the treatment of HF (Packer et
al., 1987). Consequently there is an increased need to discover new pharmacotherapy that would
prove efficacious in the treatment of HF.
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1 .2 .5 .2 N a tu r a l P r o d u c ts f o r th e T r e a tm e n t o f H e a r t F a ilu r e

There has been a reported 15 million number of complementary and alternative medicine
(CAM) users in the United States (Eisenberg et al., 1998), which includes herbs, relaxation
techniques, chiropractic, yoga, massage, special diet, megavitamins, homeopathy and tai chi
(Eisenberg et ah, 1993). Among the list of CAM therapeutics, herbal supplements rank at the top
o f the list and are particularly common in patients with already prescribed conventional
medications and in individuals who are older in age (Eisenberg 1998; Wood et ah, 2003). The
rise in CAM use has been seen in patients suffering from CVDs, where in fact in one example,
64% of the patients from the Improving Cardiovascular Outcomes in Nova Scotia (ICONS)
group reported the use o f CAM. Fourty percent o f these patients were taking herbal supplements
and referred to their CVD as the main reason for the use of CAM as they believed CAM would
“potentially improve their condition”, that CAM had “proven beneficial” or that they were
“dissatisfied with their current treatment regimen” (Wood et ah, 2003). Among the list of herbal
supplements that has been increasing in usage is NA ginseng.
1.3

North American Ginseng (Panax quinquefolius)
1.3.1

History o f Ginseng and its First Application in Cardiovascular Disease

Ginseng, considered a prized possession in Asian communities and often prescribed in
TCM has a rich history dating more than 2000 years. The medicinal properties of ginseng,
known by the Chinese as ‘ren shen’ (meaning ‘essence o f man’, as well as other colloquial terms
such as ‘spirit of the earth’, ‘fat of the sea’ and ‘the remedy that dispenses immortality’), were
first recorded in an ancient Chinese book of agriculture and medicinal plant collections of TCM
practices between 300 B.C. and 200 A.D. This book describes ginseng as having the ability to
“repair the five visceras, harmonize energies, strengthen the soul, allay fears, remove toxic
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substances, brighten the eyes, open the heart and improve thought” such that “consistent use will
invigorate the body and prolong life.” (Chu and Zhang, 2009) This proposed all-curative
property o f ginseng, also referred to by its genus name Panax, stemming from panacea derived
from the Greek goddess of healing (Greek, Panakeia), was considered to be due to the close
resemblance o f the ginseng root, considered the most valuable portion o f the ginseng plant, to the
shape o f a human being. Traditionally, it was believed that healing of a diseased area of the body
or a specific organ could be accomplished by ingesting the portion of the root reflecting that
diseased area (Goldstein, 1975; Hu, 1976; Chu and Zhang, 2009), e.g. the middle portion would
be prescribed for cardiopulmonary diseases. Sprouting from the top o f the root are the stems,
leaves (Ligor et al., 2005; Liu et ah, 2010) and berries (Attele et ah, 2002; Dey et ah, 2003),
which have also been used for therapeutic purposes.
Ginseng belongs to the Araliaceae family and has several different species, namely
Panax ginseng, Panax japonicus, and Panax quinquefolius, among others, which differ in both
physical appearance and chemical constitution (Chan et ah, 2000). There have been several
claims of additional ginseng species such as Siberian ginseng; however,\ authentic ginseng
species are characterized by the presence o f ginsenosides, which in fact are absent in Siberian
ginseng (Mar and Bent, 1999). The two major species of ginseng that have been well
documented in history and used as therapeutic agents are P. ginseng C.A. Meyer (named after the
Russian botanist C.A. Meyer, who identified and separated the different ginseng species in
1842), which is found naturally in hardwood forests of large shady trees in dense and nutrientlimited soil in China and Korea, and P. quinquefolius, which is located in similar climates and
environments in North America, particularly southern Canada (Ontario and Quebec) and the US
(Wisconsin, Minnesota, Oklahoma and Georgia).
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The use o f ginseng in traditional Chinese medicine is based on the belief that there exists
an appropriate balance o f the yin and yang (loosely defined as the interrelationship and
interdependence o f seemingly opposite forces) o f the individual human being (Goldstein, 1975;
Hu, 1976). This was, and still is, an unfamiliar concept in the West, rendering it particularly
difficult to comprehend and practice. The popularity o f ginseng as a medicinal drug, not to
mention a high trade commodity item, after its introduction into New France in North America in
the early 1700s, however, was quite remarkable (Carlson, 1986). By late 1700 there were several
accounts as well as refuted claims of the therapeutic effects of ginseng, although these were
generally based on individual cases or the effects experienced by the researcher or physician
themselves (Appleby, 1983).
A PubMed database search o f ginseng- or ginsenoside-related research articles (Figure
1.3) shows minimal research interest as depicted by the low number o f publications in the late
1950s, with a significant upward trend nearing the end of the 1990s and a particularly sharp rise
during the past 10 years. The first accessible research publication in English demonstrating
quantitative data o f the effects o f ginseng on the cardiovascular system originated from Wood
and colleagues in 1964, who assessed the effect o f alcoholic P. ginseng extract (10-20 mg/kg) on
blood pressure, ventricular contraction, blood flow and heart rate in dogs (Wood et al., 1964).
They showed that ginseng exerts a biphasic influence on blood pressure with an initial
hypotensive effect followed by a slightly prolonged hypertensive response, which occurred in the
absence of significant cardiac responses. Although these authors suggested a lack of cardiac
influence o f ginseng in vivo, in vitro studies using guinea pig isolated left atrial myocytes
revealed a direct effect of P. ginseng as manifested by a significant reduction of both the
Bowditch effect (positive inotropic response with increasing heart rates, ‘positive staircase’) and
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Year
Figure 1.3 N um ber of ginseng publications from 1950 to 2010. The yearly number of
publications concerning ginseng-related research since 1950, when the first ginseng-related
publication was identification. Data were obtained from the PubMed database using the
keywords ‘ginseng’ or ‘ginsenoside’ in the search strategy. Note particularly the large surge in
publications since the year 2010.

Note: this figure was published in K arm azyn M, Moey M and Gan XT. Therapeutic potential of
ginseng in the management of cardiovascular diseases. Drugs 2011 ;71:1989-2008.
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Woodworth effect (‘negative staircase’), and prevention of calcium reuptake in calciumdepleted rabbit hearts (Hah et al., 1978). Thus, these early studies at the very least revealed that
ginseng has the potential to modify cardiovascular function. As such, these, as well as other
reports published principally in Chinese and Korean journals (inaccessible via PubMed), likely
advanced the cause of ginseng use as a therapeutic agent in the cardiovascular system. For
interested readers, a number of more detailed historical reviews of ginseng can be recommended
(Goldstein, 1975; Hu, 1976; Appleby, 1983; Carlson 1986; Chu and Zhang, 2009).

1.3.2

Chemical and Pharmacological Properties o f Ginseng
1.3.2.1 Ginsens Species and Ginsenosides

Ginseng exists as several different species that are based on their country o f origin which
namely includes Pancvc quinquefolius (North American ginseng), Panax notoginseng (Chinese
ginseng), Panax ginseng (Korean or Red ginseng) and Panax japonicus (Japanese ginseng). In
addition to the species’ variation in shape and size, their chemical profiles are uniquely distinct
resulting in diverse physiological responses (Chan et al., 2000). For example, as previously
mentioned, the goal of TCM is to achieve a balance between the yin and yang or the ‘cold’ and
‘hot’ Qi o f the body. TCM practitioners believe that Asian ginseng provides more yin to the body
which is manifested by decreasing blood pressure. These anti-hypertensive effects of Asian
ginseng have now been considered due to NO-mediated vasodilation (Jeon et al., 2000; Sung et
al., 2000). In comparison, North American ginseng has not been shown to elicit any effects on
blood pressure (Stavro et al., 2005; Stavro et al., 2006). Use of high pressure liquid
chromatography (HPLC) technique has allowed scientists to reveal the bioactive constituents
considered responsible for eliciting these physiological responses to ginseng known as
‘ginsenosides’, a type o f triterpene saponin (reviewed in Attele et al., 1999).
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Ginsenoside nomenclature is based on a simple formula, Rx, where ‘R ’ represents ‘root’
and ‘x ’ indicates the polarity o f the ginsenoside based on HPLC in alphabetic order (Shibata et
al., 1963). For example, Rg is more polar (hydrophyllic) than Ra which is the least polar and
therefore more hydrophobic o f all the ginsenosides. Consequently the degree o f polarity of
ginsenosides would not only discemibly elicit varied responses in different biological systems,
but would also be an important consideration in optimizing ginsenoside extraction techniques for
purification processes in the use o f basic or clinical studies as discussed below in section 1 .3.2.2.
There are currently more than 100 different identified ginsenosides (Jia and Zhao, 2009)
that have been further categorized into classes which catalogue each ginsenoside based on the
type, position and number of sugar moieties at the C-3 and C-20 positions o f the dammarane
(tetracyclic triterpine) skeleton (reviewed in Attele et ah, 1999; Jia and Zhao, 2009; Jian et ah,
2009; Lii et ah, 2009; Qi et ah, 2011). The major two groups include the 20-(S) protopanaxadiol
ginsenosides (PPD) (R bl, Rb2, Rb3, Rc, Rd, Rg3, Rh2, and R sl) and the 20-(S) protopanaxatriol
ginsenosides (PPT) (Re, Rf, R gl, Rg2, and R hl) which differ from PPDs because of an
additional carboxyl group at the C - 6 position (reviewed in Leung and Wong, 2010) (Figure 1.4)
Additional groups also consist of the ocotillol group (pseudoginsenoside FI 1, majoniside R1 and
R2) (Namba et ah, 1986) and the oleanane group (Ro or chikusetsusaponin V) (Sanada et ah,
1974). As indicated earlier, ginseng species vary in chemical constitution which is predominantly
defined by the different ginsenosides present. NA ginseng has been regarded as a higher grade
ginseng in comparison to its Asian counterparts as a higher amount o f ginsenosides, particularly
R bl, Rb3, Rc, Rd, Re and R gl, has been reported (Assinewe et ah, 2003). Ginsenoside
composition in the different ginseng species are provided in Table 1.
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Although many o f the salutary effects o f ginseng have been attributed to ginsenosides,
the ginseng phytochemical content actually contains less than

10

% ginsenoside while the

remaining 90% is composed of polysaccharides, amino acids, fatty acids and vitamins. Indeed
non-ginsenoside components such as trilinolein (Chen et al., 2005; Chen et al., 2010), a fatty acid
extract from P. ginseng extracted from P. quinquefolius have proven to elicit beneficial health
effects. Similarly, although much attention has been focused on the whole ginseng root or
individual ginsenosides, compounds extracted from other portions of the herb such as the leaves
(Ligor et al., 2005; Liu et al., 2010) and berries (Attele et al., 2002; Dey et al., 2003) have
additionally been demonstrated to exhibit promising therapeutic effects, if not more pronounced.

1.3.2.2

Biotransformation and Bioavailabilitv o f Ginsenosides

Pharmacokinetics describes the time-related absorption, distribution, metabolism and excretion
(ADME) of compounds in the body, which defines the capacity o f the drug to elicit its
pharmacological actions. The ADME process o f a certain compound can be affected by several
extraneous and non-extraneous factors such as variation in drug dosage or site of administration
and individual genetic variability, respectively. The gastrointestinal (GI) tract and liver play
significant roles in the biotransformation and bioavailability of ginsenosides after oral
consumption o f ginseng (Tawab et al., 2003; Ling et al., 2006; Lee et al., 2008; Leung and
Wong, 2010). In fact although ginsenosides have been regarded as the responsible constituents
for eliciting its pharmacological effects, several in vitro as well as in vivo studies in both animal
and human subjects have revealed that these effects are in fact due to the metabolites of
ginsenosides (Bae et al., 2004; Liu et al., 2006). After oral consumption o f ginseng, usually
prepared in the form of a tea, ginsenosides enter into the human GI tract where they are broken
down by either the acidic environment or the microflora into its respective metabolites (reviewed
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in Leung and Wong, 2010). The main intestinal bacteria that have been identified in the
metabolic breakdown o f ginsenosides include species of Bifidobacterium (Int-57, K-103, K-506,
and SJ32), Aspergillus (A. niger and A. usamii), Bacteroides JY 6 , Lactobacillus, Fusobacterium
K-60, Eubacterium A-44, Streptococcus, and Prevotella oris (reviewed in Leung and Wong,
2010) Generally, the production o f metabolites is a result of deglycosylation of ginsenosides at
the C-3 or C-20 positions by both acid and human intestinal microfloral however may also
include other alterations such as epimerization o f the C-20 sugar moiety (Ling et al., 2006).
Ginsenosides may follow a number of different metabolic pathways, which have been
determined from AMDE in vivo and in vitro animal and human studies and have been
summarized elsewhere (reviewed in Ling et al., 2006).
While the mechanisms of absorption and transportation of ginsenosides and metabolites
have yet to be detailed, studies have revealed poor absorption of ginsenosides most likely due to
its large bulky structure (Ling et al., 2006). Transportation of ginsenosides may involve energydependent mechanisms and therefore absorption of their respective metabolites is favoured.
Consequently, the bioavailability of ginsenosides is extremely low as previous studies measuring
ginsenoside content in rat plasma as well as urine were less than 5% recovery of the starting dose
(Odani et al., 1983a; Odani et al., 1983b; Tanizawa et al., 1993; Xu et al., 2003) and in some
cases undetectable. For example, in the first pharmacokinetic studies o f single ginsenosides in
the rat by Odani and colleagues, oral bioavailabilities o f Rbl and Rgl were only 0.1% and 1.9%,
respectively (Odani et al., 1983a, Odani et al., 1983b). In contrast however, the absorption of
primary ginsenoside metabolites such as C-K and Rhl is considered to be much higher than their
original structures as a greater percentage o f these metabolites were detected in both rat and
human serum and urine (Tawab et al., 2003). In addition to poor absorption of ginsenosides, the
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I

Protopanaxadiol (PPD)

Protopanaxatriol (PPT)

OH

Octolilol-type Saponin

Figure 1.4 Chemical structures of ginsenosides. Chemical structures were drawn with
eMolecules software edited appropriately using Adobe Illustrator. The two main types of
ginsenosides include the protopanaxadiols (PPDs) and the protopanaxatriols (PPTs). The main
difference between PPDs and PPTs is the presence of carboxyl groups at C-6 . Other ginsenosidelike compounds include the octolilol-type saponin and oleanic acid. The octoliol-type saponins
include pseudoginsenoside F ll and majoniside R1 that are unique based on the stereisomeric
orientation at C-24. R,: radical group 1, R 2 : radical group 2; #s: carbon numbering.
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Table 1.1. Primary differences in ginsenoside composition between North American and Asian ginseng
Ginsenosides

American ginseng {Panax quinquefolius)

Asian ginseng {Panax ginseng)

Total ginsenosides (g/kg)

4 0 -6 0

2 0 -4 0

Major ginsenosides

R bl, Re, Rd, Rb2, Re, R gl, Rb3

R bl, R g l, Re, Rb2, Rd, Re, Rf, Rb3

PPD Group

R bl, Rb2, Rb3, Re, Rd

R bl, Rb2, Rb3, Re, Rd

PPT Group

Re, R gl, Fn

Re, R gl, Rg2, R f

Pseudoginsenosides F 11

Present

Absent

PPD = protopanaxadiol; PPT = protopanaxatriol
Note: Table has been published in Karmazyn M, Moey M and Gan XT. Therapeutic potential o f ginseng in the
management o f cardiovascular disorders. Drugs 2011:71:1989-2008

half-lives of the major ginsenosides such as R gl, R bl, Rhl and Rh2 are relatively short (<24
hours) (Karikura et al., 1990; Xu et al., 2003). Studies are currently ongoing to enhance the
bioavailability of ginsenosides in order to appropriately assess the pharmacological actions of
ginseng as well as to determine the optimal clinical dosage.

1.3.2.3 Effects o f Processing on Ginsene Properties
Advances in technology have provided available and accessible means to analyze the
chemical constituents within the ginseng root (Qi et al., 2011). This capability is critical to the
eventual better understanding of both the pharmacodynamic and pharmacokinetic properties of
ginseng. Although the majority of studies have focused on the roots of different ginseng species,
it is important to mention that the leaf (Ligor et al., 2005; Liu et al., 2010) and berry (Attele et
al., 2002; Dey L et al., 2003) o f the ginseng root have also been shown to contain ginsenosides
along with additional compounds that are considered responsible for mediating therapeutic
effects.
Growth, maintenance, cultivation and harvesting o f ginseng are long and tedious
processes, such that when performed haphazardly will yield poor ginseng root quality as well as
value. Post-processing of ginseng for commercial sale by means of skin peeling and air drying
(North American and Chinese ginseng) or heating via steaming while keeping the skin intact
(Korean/red ginseng) has also been shown to affect the chemical profile, particularly with respect
to the ginsenoside species present. Recent studies have found improved and more efficient
methods for the extraction of the ginsenosides known to elicit these therapeutic effects (Kim et
al., 2007; Kim et al., 2010; Lee et al., 2011).
There have been various reports demonstrating the effects of different chemical ginseng
processing procedures, such as increasing temperature and pressure, which result in the
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appearance o f new ginsenoside species (Kim et al., 2000; Park et al., 2002; Lee et al., 2009) in
addition to chemically altered ginsenoside species (Kang et al., 2007) not originally present in
the raw root. These studies have shown that heat and steam processing, a characteristic method
in Korean/red ginseng, results in a more pronounced biological effect than raw air-dried ginseng,
potentially as a result o f the appearance o f new functionally active ginsenosides (Kim et al.,
2 0 0 0

), as previously noted, or as a result of chemical modification of ginsenosides yielding a

new stereoisomer or the addition/deletion o f a functional group (Park et al., 2002) thus eliciting
an enhanced physiological response (Tung et al., 2010). An example o f the latter can be provided
with respect to both P. ginseng and the ginsenoside Rb2, whose hydroxyl radical scavenging is
enhanced by heat processing (Kang et al., 2007).
The use o f different solvents such as alcohol and water for ginsenoside extraction has
also been shown to play a significant role in the amount of ginsenosides isolated, which may
certainly result in different biological properties (Lee et al., 1981; Gafner et al., 2004). There is
consensus that a higher ginsenoside yield is produced in the alcoholic versus the aqueous ginseng
extract.

The pharmacological effects of different solvent ginseng extractions on the

cardiovascular system were, in fact, demonstrated as early as 1981; the ether, ethanol and
aqueous P. ginseng extracts administered to anaesthetized dogs had differing effects on several
cardiac variables, including cardiac output, stroke volume, heart rate, mean arterial pressure and
total peripheral resistance (Lee et al., 1981). In other systems of the body, alcoholic and aqueous
ginseng extracts also elicit diverse responses. For example, King and colleagues showed that an
alcoholic ginseng extract exhibited a greater response on estrogen receptors in the estrogenreceptor-positive MC-7 human breast cancer cell line than the aqueous P. quinquefolius extract
(King et al., 2006). Elsewhere, the aqueous ginseng extract has been shown to induce apoptosis
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in several cancer cell lines, suggesting it may be useful in cancer therapy (Kim et al., 2003;
Peralta et al., 2009). Conversely, ginseng has been shown to promote angiogenesis in human
umbilical vein endothelial cells and may therefore be o f potential use for revascularization
therapy (Huang et al., 2005; Morisaki et al., 1995; Kim et al., 2007). The different
pharmacological profiles of aqueous versus alcoholic extracts are likely explained by the
different ginsenosides and compounds present in these extracts and their distinct effects in
different biological systems. Evidently, the preparation processes and extraction methods have a
significant effect on the physiological responses in different biological systems and should,
therefore, be taken into particular consideration when choosing the appropriate ginseng species
for pharmacological studies.

1.3.3

Ginseng in Cardiac Hypertrophy and Heart Failure

Cardiac hypertrophy, as described in detail in section 1.1.2, is a fundamental contributor
to cardiac remodeling which eventually leads to HF. One o f the major challenges in treating HF
is the difficulty in reversing already established pathological cardiac hypertrophy as it involves a
plethora of complex molecular mechanisms (reviewed in Frey and Olson, 2003). Consequently,
the focus of research in discovering new therapeutic agents for the management of HF involves
the identification of the underlying causes by targeting signalling pathways in cardiac
hypertrophy. Ginseng has recently become an increasingly popular candidate for the prevention
and treatment o f HF as several studies have demonstrated its anti-hypertrophic and anti
remodelling effects both in vitro (Liu et al., 2004; Chen et al., 2005; Yang et al., 2005; Jiang et
al., 2007; Guo et al., 2011; Moey et al., 2011) and in vivo (You et al., 2005; Jiang et al., 2007;
Deng et al., 2009; Deng et al., 2010; Guo et al., 2011).
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The whole ginseng root as well as individual ginsenosides, such as Rbl (Jiang et al., 2007)
have been shown to exert anti-hypertrophic effects in isolated cardiomyocytes subjected to
classical hypertrophic agonists which include Angll (Liu et al., 2004; Guo et al., 2011), ET-1
(Chen et al., 2005; Yang et al., 2005), phenylephrine (Guo et al., 2011) as well as leptin (Moey et
al., 2011) and PGF2a (Jiang et al., 2007). Prevention of agonist-induced cardiac hypertrophy in
vivo by whole NA ginseng alcoholic extracts (Moey et al., 2011; Guo et al., 2011) and Rbl
(Jiang et al., 2007) were evidenced by decreases in cell size and gene expression o f fetal gene
markers such as ANP, aSA and myosin heavy chain (MHC). In addition, non-ginsenoside
components such as trilinolein (a triacylglycerol extracted from P. ginseng) has been shown to
inhibit both Angll- (Liu et al., 2004) and ET-1 (Chen et al., 2005; Yang et al., 2005) induced
cardiac hypertrophy potentially through an antioxidant mechanism via MAPK inhibition.
While studies using cultured myocytes have demonstrated the potential o f ginseng as an
anti-hypertrophic agent, the more critical issue is to determine if these results are translatable to
in vivo models of HF. Indeed there have been many publications that have assessed the ability of
ginseng (You et al., 2005; Guo et al., 2011) and ginsenosides Rbl (Jiang et al:» 2007; Zhao et al.,
2010) and Rgl (Deng et al., 2009; Deng et al., 2010) in various in vivo models of cardiac
hypertrophy. For example, 30-day treatment with P. ginseng at a dose o f 150 mg/kg has been
shown to prevent adriamycin-induced HF (You et al., 2005) via an antioxidant effect.
Ginsenoside Rbl administration to rats subjected to monocrotaline-induced right ventricular
cardiac hypertrophy prevented ventricular remodeling and HF (Jiang et al., 2007), which was
considered to be a result of the inhibition of the CaN/NFAT3 pathway (see section 1.2.3.3). In a
recent study, Rbl similarly exhibited anti-hypertrophic effects in a genetically engineered mouse
model that had a missense mutation (R141W) in the strong tropomyosin-binding region o f the
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cardiac troponin T (cTnT) model, which is considered responsible for the development of
familial dilated cardiomyopathy. The proposed mechanism o f action of Rbl however was
proposed to be via attenuation o f the heparin-binding epidermal growth factor (HB-EGF)
involved in the activation o f STAT3 (Zhao et al., 2010) in cardiac hypertrophy. The postulated
anti-hypertrophic mechanisms of action by Rgl have been shown to involve the inhibition of
CaN and MAPK (p38, ERK1/2 and JNK) activation (Deng et al., 2009) as well as through NO
(nitric oxide)-related pathways (Deng et al., 2010). Most recently, using an alcoholic P.
quinquefolius extract, Guo and colleagues similarly showed the inhibition of HF and cardiac
hypertrophy both in vitro and in vivo by attenuating NHE-1 related CaN/NFAT3 activation (Guo
et al., 2011). As discussed in Chapter 3 and Chapter 4, we sought to assess the ability of
ginseng to treat HF by administration o f ginseng in drinking water after well-established cardiac
remodeling and HF. Results demonstrated the marked ability of ginseng to reverse multiple
agonist-induced cardiac hypertrophy and ventricular dysfunction by attenuation of CaN/NFAT3
activity as well as RhoA/ROCK-dependent MAPK activation. The following tables summarize
the experimental conditions, measured variables and proposed mechanisms in the studies of the
antihypertrophic effects o f ginseng, Rbl and Rgl in vitro (Table 1.2) and in vivo (Table 1.3).
1.4

Study Objectives
Heart failure is a complex syndrome that involves the upregulation of several cellular

signalling pathways. By identifying the molecular mechanisms that are key to the cardiac
remodelling process in the development o f heart failure, these particular signalling cascades can
be targeted for the management o f HF. NA ginseng has demonstrated significant potential for the
prevention of CVDs however its ability to prevent and treat cardiac hypertrophy and remodelling
in leptin-associated conditions have not been studied. Accordingly the objectives o f these studies
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were to determine the antihypertrophic and antiremodelling effects o f ginseng in agonist-induced
cardiac hypertrophy in vitro (Chapter 2 and 3) and in an HF animal model (Chapter 4).
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Table 1.2 Evidence for the antihypertrophic and antiremodelling effects of ginseng
Ginseng Preparation

T rilino le in (P. gin sen g)

Ginseng Dose

in v i t r o .

Parameters

Model of Hypertrophy

A n g io te n sin II

D ecrea se d:

(1 - 1000 nM )

3[H ] le u cin e in co rp o ra tio n
ß -M H C p ro m o te r a c tiv ity

0.1 - 10 pM
E ndothelin-1
(10 nM )

R O S g e n e ra tio n

Proposed
Mechanisms

Reference

A n tio x id a n t e ffe c t via

Liu e t al., 2004

M APK

C hen e t al., 2005

E R K 1/2, p38, JN K a ctiva tio n
D ecrea se d:

c-fo s g e n e e xpressio n
1 and 10 pM

Endothelin-1
(10 nM )

N A D P H o x id a s e a ctivity
R O S and s u p e ro xid e levels

A n tio x id a n t e ffe ct via
M APK

Y a ng et al., 2005

E R K 1 /2 and JN K a c tiva tio n
N F k B p ro m o te r a ctivity
D ecrea se d:
G in se n o s id e Rb1

50, 100, 200

P ro sta g la n d in F2a

M9

(100 nM )

C ell d ia m e te r a nd p ro tein level

C aN /N F A T 3

Jiang e t al., 2007

A n g io te n s in II (100 nM )
E ndothelin-1 (10 nM )
P h e n yle p h rin e (10 pM )

D ecrea se d:
C ell su rfa ce are a and A N P gene
[C a 2+]ia n d C aN a ctivity
N F A T 3 n u c le a r tra n slo ca tion
G A T A 4 binding
In tra c e llu la r pH
NHE-1 p ro tein and g e n e expressio n

NHE-1 related
C aN /N F A T 3

G uo et al., 2011

Leptin (3.1 n M )

D ecrea se d:
C ell su rfa c e area and 3[H ] leucine
a S A and M H C g e n e e xp ressio n
p 1 15 R h o G E F -R h o A /R O C K a ctivity
p 1 1 5 R h o G E F g ene a nd protein
c o filin -2 a ctiva tio n and F/G actin
p38 and E R K 1/2 a c tiva tio n

p115R hoG EFR h o A /R O C K d e p e n d e n t p38 M A P K

M oey e t al., 2011

A N P g e n e e xp re ssio n
[C a 2+]i Ca N/N F A T 3/G A T A 4 protein

T otal g in s e n o s id e s
(P. quinquefolius)
10 pg/m L

10 pg/m L

[Ca2+]i = in tra c e llu la r ca lciu m co n ce n tra tio n ; ANP = a tria l n a triu re tic pep tide ; c-fos = FBJ m u rin e o ste o sa rco m a vira l o n co g e n e h om olog; ERK1/2 =
e x tra c e llu la r re g u la to r k in a se 1/2; GEF = g u a n in e n u cle o tid e e x c h a n g e fa cto r; JNK = c-ju n N -te rm in al kinase; MHC = m yosin h e a vy ch ain; NADPH =
n ico tin a m id e a d e n in e d in u c le o tid e p h o sp h a te ; NHE-1 = so d iu m h ydrog en e x c h a n g e r-1 ; NFAT = n u c le a r fa c to r o f a ctiva te d T cells; NFkB = n u cle a r fa cto r
ka p p a -lig h t-c h a in -e n h a n c e r o f a ctiv a te d B ce lls; RhoA = R as h o m o lo g m e m b e r A; ROCK = R h o -a sso cia te d , co ile d-coil co n ta in in g protein kinase 1; ROS =
rea ctive o xyge n sp e cie s; aSA = a lp h a -ske le ta l actin

Table 1.3 Evidence for improved cardiac function and antihypertrophic effects o f ginseng
Ginseng Preparation

Ginseng Dose

Model of Hypertrophy

150 g/kg, g ava ge

A d ria m y c in (15 m g /kg )

(1 m o n th )

6 i.p in je ctio n s fo r 2

W is ta r R ats

P a n a x g in sen g

w eeks

in v i v o .

Parameters
D ecrea se d:

100 m g/kg , g ava ge

S p ra g u e -D a w le y R ats

(1 m o n th )

C A L o f th e L A D A
4 w e e ks

C a rd ia c d ysfun ction

Reference

A n tio x id a n t e ffe ct

M orta lity, H W :B W and a scites
P rotein, R N A and D N A expressio n
G S H P x, S O D and M D A levels
D ecrea se d:

P a n a x quinquefolius

Proposed
Mechanisms

Y ou e t al., 2 0 0 5

NHE-1 related
C a N /N F A T 3
G u o et al., 2011

H W :B W and L V :B W ratios
A N P , NHE-1 and M CIP-1 expressio n
C aN a ctivity

G in sen o sid e Rb1

D ecrea se d:
70 m g/kg , a d

libitum
(7 m o n th s)

_

-R 1 4 1 W

cTnT

m ice

FD C M

M ortality, H W :B W a nd fib ro sis
C a rd ia c d ysfu n ctio n , d e g en eratio n

J N K /S T A T 3

Z h a o et al., 201 0

and intercala ted d isk rem odeling
H B -E G F and S T A T 3 a ctivatio n

10 and 4 0 m g/kg
(2 w e e k s )

S p ra g u e -D a w le y R ats
M o n o cro ta lin e
(60 m g/kg )
2 to 4 w ee ks

D ecrea se d:
H W :B W , R V :B W and L V :B W
C a rd io m y o c y te inju rie s
A N P , C aN , N F A T 3 and G A T A 4

C a N /N F A T 3

Jian g et al., 2007

3.75, 7 .5 and 15
m g /kg /d a y, i.p
(3 w e e ks)

S p ra g u e -D a w le y R ats
A b d o m in a l aorta
c o a rcta tio n
(3 w e e k s )

D ecrea se d:
L V :B W and fib ro sis
A N P , C aN and E R K Ig e n e
e xp re ssio n
C aN and M APK-1 p ro tein e xpressio n

C a N /N F A T -3
E R K 1 -M A P K

D eng e t al., 200 9

15 m g /kg /d a y
(3 w e e k s )

S p ra g u e -D a w le y R ats
A b d o m in a l a o rta
co a rc ta tio n
(3 w e e k s )

D ecrea se d:
L V :B W and fib ro sis
C a rd ia c d ysfu n ctio n
A N P and e N O S g e n e expression

e N O S a n d NO

D eng e t al., 2010

G in sen o sid e Rg1

ANP = atrial n a triu re tic peptide; BW = bod y w e ig ht; CAL = c o ro n a ry a rte ry ligation; CaN = ca lcin e u rin ; cTnT = ca rd ia c trop on in T; DNA = d e o xyrib o n u cle ic acid;
eNOS = e n d o th e lia l n itric o xid e syn th a s e ; ERK1 = e x tra c e llu la r re g u la to r kina se-1 ; FDCM = fa m ilia l d ilated ca rd io m yo p a th y; GSHPx = g lu ta th io n e peroxid ase
a ctivity; HB-EGF = h e p a rin -b in d in g e p id e rm a l-g ro w th fa cto r; HW = h e a rt w eig ht; i. p = in tra p e rito n e a l; LADA = left a n te rio r d e sce n d in g artery; LV = left ve ntricle ;
MDA = m a lo n d ia ld e h yd e ; MCIP-1 = m o d u la to ry c a lcin e u rin in te ra ctin g p ro te in -1 ; NFAT3 = n u c le a r fa c to r o f tra n scrip tio n -3 ; NHE-1 = so dium h ydrogen e x c h a n g e r1; RNA = rib o n u c le ic acid; RV = rig h t ve n tricle ; SOD = s u p e ro x id e d ism u ta se
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CHAPTER 2

Ginseng (Panax quinquefolius) attenuates leptin-induced ventricular
cardiac hypertrophy through inhibition of the pll5RhoGEFRhoA/ROCK-dependent MAPK pathway activation

A version o f this chapter has been published elsewhere:
Moey M, Rajapurohitam V, Zeidan A and Karmazyn M. Ginseng (Panax quinquefolius)
attenuates leptin-induced ventricular cardiac hypertrophy through inhibition of the
pi 15RhoGEF-RhoA/ROCK-dependent MAPK pathway activation. J Pharm Exp Ther
2011;339:746-756
Reprinted with permission o f the American Society for Pharmacology and Experimental
Therapeutics. All rights reserved.
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2.1

Introduction
The prevalence of obesity in North America has significantly increased over the past 5 years

(Luo et al., 2007) along with the detrimental accompanying risks for the development of
cardiovascular disease (Bui et al., 2011). The underlying mechanisms for obesity-associated
cardiovascular disease are not well understood although emerging evidence implicates a
potential role of leptin, a member of the family of peptides known as adipokines which is
produced by the ob (obesity) gene (Zhang et al., 1994) and which has been reported by a number
of investigators to produce a direct hypertrophic effect on the heart (reviewed by Karmazyn et al.,
2008). The primary source of leptin is white adipose tissue and plasma levels of the peptide have
been shown to be closely correlated to the degree o f adiposity (Maffei et al., 1995). We have
previously shown that the rat heart produces leptin within the cardiomyocyte and also expresses
leptin receptors suggesting that the heart is a target for leptin’s effects, potentially in a
paracrine/autocrine manner (Purdham et al., 2004). Interestingly, plasma levels of leptin are
elevated in patients with heart failure independently of obesity (Schulze et al., 2003).
Several molecular signalling pathways upregulated by leptin in cardiac hypertrophy have
been identified namely the RhoA/ROCK and p38 and ERK1/2 pathways (Friihbeck, 2006;
Zeidan et al., 2006; Zeidan et al., 2008), all o f which can be activated by leptin. A particular
importance o f the RhoA/ROCK pathway is that its activation, and subsequent changes in actin
dynamics is critical for selective p38 MAPK translocation into nuclei thus initiating the
hypertrophic process (Zeidan et al., 2006; Zeidan et al., 2008). Although we have previously
demonstrated the potent stimulation of the RhoA/ROCK pathway by leptin, the specific
mechanism of activation however has not yet been defined. Regulators o f small G-proteins such
as RhoA include GTP-ase activating proteins, which hydrolyze GTP to GDP thereby
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deactivating RhoA, guanine nucleotide dissociation inhibitors which sequester GDP-bound small
G-proteins in the cytoplasm and guanine nucleotide exchange factors (GEFs) which catalyze the
exchange o f GDP to GTP resulting in activation o f RhoA (Schmidt and Hall, 2002; Rossman et
al., 2005; Bos et al., 2007).

RhoA GEFs (RhoGEFs), specifically pll5R hoG EF and

p63RhoGEF, have been shown to be involved in the upregulation of RhoA/ROCK in cardiac
hypertrophy in response to GPCR-linked hypertrophic agonists such as ET-1 (Porchia et al, 2008)
and Angll (Guilluy et al., 2010).
Ginseng (genus Panax) is a medicinal herb which has been used widely in Asia for more
than 2000 years (Goldstein, 1975; Lu et al., 2009).

Its principal bioactive components are

ginsenosides, which are triterpene saponins and are considered the main constituents responsible
for ginseng’s medicinal effects (Attele et al., 1999). Emerging understanding of the chemistry of
ginseng and its potential therapeutic use has resulted in increasing interest in western countries
for the use of ginseng as a pharmacological agent for the treatment of a number of diseases.
With respect to the cardiovascular system, ginsenosides have been shown to inhibit the
development of atherosclerosis (Li et al., 2011), hypertension (Jeon et al., 2000) and cardiac
hypertrophy, the latter effect being seen in a number of experimental models (Jiang et al., 2007;
Qin et al., 2008; Deng et al., 2010; Guo et al., 2011). Whether ginseng affects leptin-induced
hypertrophy has not been demonstrated. Accordingly, in this study we determined the effect of
North American ginseng (P. quinquefolius) on leptin-induced cardiomyocyte hypertrophy and
studied the potential underlying mechanisms for these effects.

Our study centered on the

possible modulatory effect of ginseng on the RhoA/ROCK pathway following leptin addition
and the role o f GEFs.

In addition, we studied the relationship between RhoA and MAPK

pathway activation.
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2.2

Materials and Methods

2.2.1

Treatment and Experimental Groups
Neonatal ventricular cardiomyocytes were isolated and cultured from one to three day old

Sprague Dawley rats as previously described (Rajapurohitam et al., 2006). Cells were grown in
fetal bovine serum (FBS) medium for up to 48 hours following 24 hour serum starvation. For
cell size and Western blotting time-course experiments, cardiomyocytes were pre-treated with
the alcoholic extract of North American ginseng (Panax quinquefolius). Extracts were prepared
by Naturex (South Hackensack, NJ) using ginseng roots supplied from 5 different farms in
Ontario, Canada (provided by Dr. Edmund Lui’s lab at the University o f Western Ontario) as
previously described (Guo et al,. 2011) and were studied at concentrations o f 0.1, 1, 10 and 100
pg/ml for up to 24 hours in the presence or absence o f 3.1 nM (50 ng/ml) leptin (Sigma-Aldrich,
Oakville, Ontario, Canada) a concentration representative of plasma levels in obese individuals
(Maffei et al., 1995). For all subsequent experiments, cells were pre-treated with a ginseng
concentration o f 10 pg/ml for 1 hour in the presence or absence o f leptin for up to 24 hours.
Treatment durations reflected the period o f peak activation of the parameter under study. The
protocols for the use o f animals were approved by the University of Western Ontario Animal
Care and Use Committee and conformed to guidelines in the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of Health and the Canadian Council
o f Animal Care (Ottawa, Ontario, Canada).
2.2.2

Cell Surface Area Measurement
Cardiomyocyte images were taken with a Leica microscope (Leica, Westzlar, Germany)

equipped with an Infinity 1 camera at 1OOx magnification. The surface area of a minimum of 50
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cells per treatment group was measured using SigmaScan Pro 5 software (Systat, Richmond, CA)
and averaged.
2.2.3

RNA Isolation, Reverse Transcription (RT) and Real-time Polymerase Chain Reaction
(PCR)
RNA was collected from cultured and treated neonatal ventricular cardiomyocytes using

Trizol Reagent (Invitrogen, Carlsbad, CA) as per the manufacturer’s instructions and reverse
transcribed to complementary DNA (cDNA) for real-time polymerase chain reaction analysis of
aSA, myosin heavy chain a, pi 15RhoGEF and p63RhoGEF. Briefly, cDNA was synthesized
from 4 pg of total RNA using random primers (Invitrogen, Carlsbad, CA) and M-MLV
(Moloney Murine

Leukemia Virus) Reverse

Transcriptase

(Invitrogen)

following the

manufacturer’s protocol. The reaction was performed with a SYBR® (Synergy Brands) Green
Master Mix (Applied Biosystems, Foster City, CA) and the gene products quantified with a DNA
Engine Opticon 2 thermal cycler (MJ Research, Waltham, MA). Primer sequences (Invitrogen)
for the genes o f interest are listed in Table 2.1. PCR cycle conditions involved 40 cycles of
denaturation at 95°C for 30s, followed by annealing at 60°C for 30s and finally by elongation at
72°C for 30s. The housekeeping gene, 18S, was measured and quantified to normalize cDNA
levels.
2.2.4

[3H] Leucine Incorporation M easurement
Leucine incorporation was performed as previously described (Zeidan et al., 2006) to

analyze protein synthesis under different experimental conditions. Cardiomyocytes were cultured
in 24-well Primaria culture plates for 48 hours in serum media following by 24 hour serum
starvation. Leptin was administered with or without ginseng pre-treatment in the presence o f 2
pCi of [3H]-leucine for 24 hours. Myocytes were washed the following day with cold PBS and
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proteins were precipitated with 5% trichloroacetic acid (TCA) for 30 minutes on ice. Protein
precipitates were dissolved with 0.5N NaOH following with two washes of cold 5% TCA. 0.5N
HC1 was used to neutralize the precipitates and the total radioactivity was measured by liquid
scintillation.
2.2.5

Isolation o f Cytosolic-Enriched and Membrane Fractions
Cytosolic-enriched and membrane fractions from treated cell lysates were prepared using

differential centrifugation as previously described (Zeidan et al., 2008). Briefly, cell lysates were
collected and homogenized in a cold buffer containing 20 mM Tris-HCl, 2 mM EDTA, 137 mM
NaCl, 1 mM sodium orthovanadate, 2 mM sodium pyrophosphate, 10% glycerol, ImM 4-(2aminorthyl)-benzenesulfonyl fluoride and 10 mg/ml leupeptin (buffer A). After clarification of
the homogenate by centrifugation at 750g for 20 minutes at 4°C, the collected lysate was further
centrifuged at 10,000 g for 20 minutes at 4°C and the cytosolic-enriched fraction (supernatant)
was obtained. The remaining pellet was resuspended in a second cold buffer B (buffer A with 2%
SDS) and kept on ice to be used as the nuclear-containing membrane fraction.
2.2.6

Western Blotting
Total cellular lysates were collected using a lysis buffer and protease cocktail inhibitor

mixture as previously described (Zeidan et al., 2006; Zeidan et al., 2008) for the measurement of
proteins o f interest. Proteins were loaded equally on either 7.5%, 10% or 15% SDS (sodium
dodecyl sulfate) gels as appropriate after protein quantification via BioRad Reagent (BioRad,
Hercules, CA) per the manufacturer’s instructions. For time course experiments, ventricular
cardiomyocytes were treated for 5, 10, 15, 30 or 60 minutes with leptin in the presence or
absence of ginseng (10 pg/ml). For the quantification of cofilin-2 phosphorylation, cells were
pre-treated with ginseng for 1 hour followed by administration of leptin for 10 minutes. For all
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additional protein measurements, cells were pre-treated with ginseng for 1 hour in the presence
or absence of leptin for 24 hours. The primary antibodies and respective dilutions used in this
study include total (1:1000 dilution, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) and
phosphorylated p38 (Thrl80/Tyrl82) forms (1:1000 dilution, Cell Signaling, Danvers, MA),
total (1:1000 dilution, Santa Cruz) and phosphorylated ERK1/2 (Thr202/Tyr204) forms (1:1000
dilution, Cell Signaling), actin (1:1000 dilution, Cytoskeleton Inc., Denver, CO), pll5RhoG EF
(1:250 dilution, Santa Cruz), p63RhoGEF (1:200 dilution, Santa Cruz) and phosphorylated
(1:1000 dilution, Santa Cruz) and total cofilin-2 (1:1000 dilution, Millipore, Billerica, MA).
Goat-anti-rabbit IgG (immunoglobulin) and goat-anti-mouse IgG HRP (horseradish peroxidase)
conjugate (BioRad) were used at 1:5000 dilution and donkey-anti-goat IgG HRP conjugate
(Santa Cruz) was used at 1:10,000 dilution as appropriate. P-actin (1:1000 dilution, Cytoskeleton)
and PCNA (proliferating cell nuclear antigen) (1:1000 dilution) were used for cytosolic and
nuclear loading controls, respectively. Spot densitometry using FluorChem (Alpha Innotech
Corporation, Santa Clara, CA) software was performed to quantify protein.

2.2.7

GST-Rho G17A Bead Preparation
GST-RhoG17A (glutathione S-transferase) beads were prepared as previously described

(Garcia-Mata et al., 2006; Kakiashvili et al., 2009). The nucleotide free RhoG17A cDNA
construct mutant was generously provided by Dr. Katalin Szaszi (St. Michael’s Hospital,
Toronto, ON, Canada) and Dr. Keith Burridge (University of North Carolina, Chapel Hill, NC).
2.2.8

Co-immunoprecipitation ofpllS R h oG E F
Active pi 15RhoGEF from cells treated with leptin in the presence or absence of leptin

were immunoprecipitated with the nucleotide-free (does not bind to GTP or GDP) GST-
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RhoG17A prepared beads, which has a high affinity for active RhoGEFs, including
pi 15RhoGEF, as previously described (Garcia-Mata et al., 2006; Kakiashvili et al., 2009).

2.2.9

Immunofluorescence

Cells were prepared for immunofluorescence on collagen coated (3 pi of collagen/1 ml of PBS A)
glass cover slips and incubated at 37°C for a minimum of 30 minutes. Cells were allowed to
attach to prepared cover slips in serum media for 24 hours followed by serum-free media
starvation for an additional 24 hours before appropriate treatment. Immunofluorescence
measurements from cells administered leptin for 3 hours were performed for total p38 and total
ERK1/2, 10 minutes for pll5R hoG EF and RhoA and 24 hours for G/F actin with or without
ginseng pre-treatment.
Total p38, total ERK1/2, p ll5R hoG E F and RhoA immunofluorescence. Cells were fixed with
2:5 acetone-methanol for 1 hour at 4°C followed by permeabilization of cells for 15 minutes with
0.2% (v/v) Triton X-100 and blocking with blocking solution (1% BSA, 0.1% Triton X-100) for
1 hour. Cells were incubated with the primary antibody of interest (1:100 dilution) in 2% BSA in
PBS A overnight at 4°C. Cells were subsequently probed with the appropriate secondary
antibody, IgG anti-mouse AlexFluor-488 (Invitrogen) or IgG anti-rabbit AlexFluor-596
(Invitrogen) (1:250 dilution) in 2% BSA in PBS A for 1 hour at room temperature under lightfree conditions. For detection of the nucleus, cells were incubated with Hoechst dye for 30
minutes prior to mounting on microscope slides (VWR, West Chester, PA) for image capture
using a Zeiss (Oberkochen, Germany) inverted fluorescence microscope at 630X magnification.
G and F actin immunofluorescence. Cells were prepared as previously described (Albinsson et
ah, 2004). Cells were fixed with 3.7% (w/v) paraformaldehyde in PBS A for 1 hour followed by
a similar protocol for permeabilization and blocking as indicated above. To detect G and F actin,
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cells were incubated with 1 pg/ml Phalloidin-FITC and 10 pg/ml deoxyribonuclease I (DNase I),
Texas Red conjugate in 2% BSA with 0.1% Triton X-100 in PBS A for 1 hour at room
temperature under light-free conditions. Similarly, Hoechst dye was used to detect the nucleus
and glass cover slips were subsequently mounted onto microscope slides (VWR) for
visualization of G/F actin. All immunofluorescence images shown in results are representative of
a minimum o f 3 independent experiments.
2.2.10 Measurement o f p i ISRhoGEF and RhoA Co-localization
Co-localization

of

pll5R hoG EF

and

RhoA

was

measured

from

merged

immunofluorescence images detecting pll5R hoG E F and RhoA under different experimental
conditions using a built-in co-localization plug-in (Li et al., 2004) o f ImageJ (National Institute
of Mental Health, Betheseda, MD), which is quantitatively represented by Pearson’s correlation
coefficient (Rr).
2.2.11 Measurement o f RhoA Activity
RhoA activity, measured by RhoA-GTP levels, was quantified using the RhoA G-LISA
Activity Biochem Assay Kit as per the manufacturer’s protocol (Cytoskeleton). Measurements
were performed using a SpectraMax M5 (Molecular Devices, Sunnyvale, CA) plate reader at an
absorbance of 490 nm.
2.2.12 p i 15RhoGEF Activity Assay
Measurement of immunoprecipitated pll5R hoG EF activity was measured as per the
manufacturer’s protocol using the RhoGEF Biochem Exchange Assay (Cytoskeleton Inc).
Fluorescence was measured using a SpectraMax M5 (Molecular Devices) plate reader at
excitation o f 360 nm and emission o f 440 nm.
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2.2.13 G/F Actin Measurement
Globular (G) and filamentous (F) actin were isolated using ultracentrifugation as
previously described (Albinsson et al., 2004). Briefly cell lysates were collected and
homogenized at 37°C in a lysis and F-actin stabilizing buffer (50mM PIPES, 50mM NaCl, 5mM
MgCl2, 5mM EGTA, ImM ATP, 5% glycerol, 0.1% Nonidet-P40, 0.1% Triton X-100, 0.1%
Tween 20, 0.1% (3-mercaptoethanol, 1:100 protease inhibitor cocktail and 0.0001% anti-foam).
Cell lysates were ultracentrifuged at 100,000g at 30°C for 1 hour and the supernatant (soluble,
G-actin) was collected and diluted 1:2 in Laemmli buffer. The remaining pellet (F-actin) was
resuspended in cold distilled water with 1 pM cytochalasin D. The resuspended pellet was kept
on ice for 45 to 60 minutes to dissociate the F-actin and was then diluted 1:4 with Laemmli
buffer. Protein concentrations were then quantified, equalized and loaded onto 12.5% bisacrylamide gels for Western blotting. Membranes were probed with anti-actin antibody
(Cytoskeleton) and quantified using spot densitometry.

2.2.14 Statistics
Data were analyzed with one-way ANOVA followed by a post-hoc Student’s /-test. P
values o f < 0.05 were considered statistically significant.
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Table 2.1. Gene-specific primer sequences of analyzed genes of interest.
Gene

Forward Primer Sequence

Reverse Primer Sequence

a - s k e le t a l a c tin

5 ’-C A C G G C A T T A T C A C C A A C T G -3 ’

5 ’-C C G G A G G C A T AG A G A G A C A G -3 ’

m y o s in h e a v y c h a in

5 ’-C A T C A C C G G A G A A T C C G G A G C -3 ’

5 ’-C T A T T G A G G C C A C A G T C G T C -3 ’

p i 15R hoG E F

5 ’-T A G A G G A C T T C C G C T C C A A A -3 ’

5 ’-C A G T G A C C AC A G C A G C A C T T -3 ’

p63R hoG E F

5 ’-T A T G T G G A C G A C T T G G G A C A -3 ’

5 ’-T G A T G A A C A G C T G A G C C A A C -3 ’

18S

5 ’-GT A A C C C G T T G A A C C C C A T T -3 ’

5 ’-CC A T C C A A T C G G T A G T A G C G -3 ’
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2.3

Results

2.3.1

Ginseng inhibits leptin-induced myocyte hypertrophy. To first determine an appropriate

concentration for studying the effects o f ginseng on leptin-induced cardiac hypertrophy,
cardiomyocytes were subjected to increasing concentrations of ginseng (0.1, 1, 10, and 100
pg/ml) for 1 hour prior to the addition o f leptin for a total incubation time o f 24 hours (Figure
2.1). As shown in Figure 2.1, leptin induced a significant increase (p<0.05) in cell size which
was attenuated by ginseng in a concentration-dependent manner. A ginseng concentration of 10
jig/ml o f ginseng was used for all subsequent experiments as this represented the lowest
concentration which completely abrogated the hypertrophic response to leptin (Figure 2.1).
An increase in cell surface area in leptin treated cells after 24 hours was additionally
associated with a significant increase (/?<0.05) in protein synthesis as indicated by increased [ H]
leucine incorporation as well as (Figure 2.1, left panel) MYHCa (Figure 2.1, middle panel) and
a-SA (2.1, right panel) gene expression, as quantified by real-time PCR. As shown in Figure 1
ginseng alone had no effect any parameter.
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Figure 2.1. Ginseng inhibits leptin-induced increase in cell surface area, [3H] leucine
incorporation and expression of the gene m arkers of cardiac hypertrophy, a-skeletal actin
and myosin heavy chain. Micrographs show representative images of neonatal ventricular
cardiomyocytes with or without pre-treatment with increasing ginseng (Gin) concentrations (0.1,
1.0, 10 and 100 pg/ml, respectively) in the absence (top row) or presence (bottom row) of leptin
(3.1 nM) pretreatment. Middle row shows surface area whereas bottom row shows [ H] leucine
incorporation (left panel), myosin heavy chain (MHC) (middle panel) and a-skeletal actin (a-SA)
(right panel) with different treatments. Data represent means ± S.E.M. N=8-10 for surface area,
N=6 for leucine incorporation and N=6-8 for molecular markers of hypertrophy. */?<0.05 vs.
control; fp <0.05 vs. leptin. Con, control; Lep, leptin; Gin, ginseng.
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2.3.2

Ginseng

inhibits

leptin-induced

RhoA

activation,

cofilin-2

phosphorylation

(inactivation) and the decrease in G/F actin ratio. RhoA activation was measured after 10
minutes of leptin administration in the presence or absence of ginseng. As demonstrated in
Figure 2.2A, ginseng significantly inhibited (p<0.05) leptin-induced RhoA activation, returning
RhoA-GTP levels to control values, while ginseng alone had no effect on its own. Activation of
the RhoA/ROCK pathway was additionally indirectly measured by quantifying phosphorylated
cofilin-2 (inactivated form) by Western blotting. Cofilin-2 is an ubiquitous enzyme responsible
for depolymerizing F to G actin thereby regulating cellular actin dynamics. A change in this ratio
favouring a higher F to G actin content as a result of RhoA activation and subsequent cofilin-2
phosphorylation (inactivation) has been previously demonstrated to represent a key mechanism
underlying the hypertrophic effects of leptin (Zeidan et al., 2006). The results, as shown in
Figure 2.2B, reveal a significant (25%) increase in p-cofilin-2 in cells administered leptin
(p<0.05), which was attenuated and returned to control levels in the presence of ginseng although
ginseng alone had no significant effect on p-cofilin-2 or RhoA-GTP levels.
To further characterize the effects of ginseng on leptin-induced RhoA/ROCK pathway
activation the G/F actin ratio was assessed by Western blotting of isolated G and F actin fractions
(Figure 2.3A) as well as visualization using immunofluorescence (Figure 2.3C) after 24 hours. In
leptin-treated cells, the G/F actin ratio was decreased as measured by quantification of G actin (S;
supernatant) and F actin (P; pellet) using Western blotting (Figure 2.3A), while pre-treatment
with ginseng restored this ratio to control values (Figure 2.3B). This was similarly observed in
the representative immunofluorescence images (Figure 2.3C, 2nd column) of leptin-treated cells
as depicted by a lighter red staining of G actin and intensified green staining of F actin, which
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was returned to control conditions by pre-treatment with ginseng (Figure 2.3C, 3rd column).
Treatment with ginseng alone had no direct effect on the G/F actin dynamics.
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Figure 2.2. Ginseng inhibits leptin-induced RhoA activation and phosphorylation
(inactivation) of cofilin-2. Panel A shows RhoA-GTP (activated RhoA) levels whereas panel B
demonstrates Western blots and densitométrie values for phosphorylated cofilin-2. Data
represent means ± S.E.M. N=6. *p<0.05 vs. control; fp <0.05 vs. leptin. Con, control; Lep,
leptin; Gin, ginseng
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Figure 2.3. Ginseng inhibits leptin-induced decrease in G/F actin. Panel A shows Western
blots for actin dynamics with respect to G actin in supernatant (S) and F actin in pellet fraction (P)
with different treatments. Densitometric values are shown in panel B. Representative
fluorescence images of cardiomyocytes are shown in panel C. For these studies cells were fixed
on collagen-coated glass cover slips and G actin (1st row) and F actin (2nd row) were visualized
with DNAse-I Texas Red Conjugate and Phalloidin-FITC, respectively. Hoechst staining was
used to detect nuclei whereas overlay depicts all three stains merged. For panel B, data represent
means ± S.E.M. N=6-9. */?<0.05 vs. control; fp <0.05 vs. leptin. Con, control; Lep, leptin; Gin,
ginseng.
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2.3.3

Ginseng inhibits leptin-induced p38 and ERK1/2 MAPK phosphorylation. Leptin

significantly induced both p38 (Figure 2.4A) and ERK1/2 (Figure 2.5A) phosphorylation as early
as 5 minutes after addition with maximum activation seen at 15 minutes followed by values
returning to control by 30 minutes. Pre-treatment with ginseng inhibited leptin-induced p38
(Figure 2.4A) and ERK1/2 activation (Figure 2.5A) at all time points although ginseng had no
direct effect on its own.
2.3.4

Ginseng inhibits leptin-inducedp38 nuclear translocation. Leptin induced a significant

increase (¿><0.05) in p38 expression in the nuclear-containing membrane fraction (Figure 2.4C),
which was complemented by a significant decrease (p<0.05) in cytosolic p38 levels, indicative of
nuclear translocation in p38 in leptin-treated cells (Figure 2.4B). Nuclear translocation of p38
was further visualized by immunofluorescence (Figure 2.4D) where total p38, indicated by red
fluorescence was much more centralized in the nuclear region of leptin-treated cells. The ability
o f leptin to induce p38 translocation was significantly inhibited by ginseng. As summarized in
Figure 5 (panels B-D), leptin had no effect on ERK1/2 nuclear translocation.
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Figure 2.4. Ginseng inhibits leptin-induced phosphorylation and p38 nuclear translocation
Panel A shows Western blots and corresponding densitométrie values for phosphorylated p38
whereas panels B and C show Western blots and corresponding densitométrie values for p38
MAPK content in cytoplasmic-enriched and nuclear-containing membrane fractions, respectively.
Panel D shows representative immunofluorescence images measuring total p38 indicated by red
staining (IgG AlexFluor-596) in the left column, Hoechst nuclear staining in the middle column
and merged staining in the right column. Data in panels A-C represent means ± S.E.M. N=5-8.
*p<0.05 vs. control; fp <0.05 vs. leptin. Con, control; Lep, leptin; Gin, ginseng. Minutes
indicate time after leptin addition.
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Figure 2.5. Ginseng inhibits leptin-induced ERK1/2 phosphorylation with no effect on
nuclear translocation. Panel A shows Western blots and corresponding densitométrie values
for phosphorylated ERK1/2 whereas panels B and C show Western blots and corresponding
densitométrie values for ERK1/2 MAPK content in cytoplasmic-enriched and nuclear-containing
membrane fractions, respectively. Panel D shows representative immunofluorescence images
measuring total ERK1/2 indicated by red staining (IgG AlexFluor-596) in the left column,
Hoechst nuclear staining in the middle column and merged staining in the right column. Data in
panels A-C represent means ± S.E.M. N=5-8. */?<0.05 vs. control; fp <0.05 vs. leptin. Con,
control; Lep, leptin; Gin, ginseng. Minutes indicate time after leptin addition.
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2.3.5

Ginseng inhibits leptin-induced increase in pllSRhoGEFprotein and gene expression.

The effects of ginseng on leptin-induced RhoGEF activation was first determined by
measurement of pll5R hoG EF and p63RhoGEF gene expression through real-time PCR and
protein expression using Western blotting (Figure 2.6). A 6-fold increase (/?<0.05) in
pll5R hoG EF gene expression after 24 hours was observed in leptin-treated cells, which was
abolished in the presence of ginseng (Figure 2.6A). Similarly, pre-treatment with ginseng
significantly inhibited leptin-induced increase in p i 15RhoGEF protein expression (Figure 2.6B),
while ginseng alone had no direct effect on either parameter. In comparison to pll5RhoG EF,
neither leptin nor ginseng exerted any effect on p63RhoGEF gene (Figure 2.6C) or protein
(Figure 2.6D) expression.
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Figure 2.6. Ginseng inhibits leptin-induced upregulation of p ll5 R h o G E F but not
p63RhoGEF protein and gene expression. Gene expression (panels A and C) and protein
levels (panels B and D) for pi 15RhoGEF and p63RhoGEF in cardiomyocytes treated with leptin
in the absence or presence of ginseng. Data represent means ± S.E.M. N=8. */?<0.05 vs.
control; fp <0.05 vs. leptin. Con, control; Lep, leptin; Gin, ginseng.
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2.3.6

Ginseng inhibits leptin-inducedpllSRhoG EF membrane translocation with RhoA co

localization and p i 15RhoGEF activity. Several studies have shown membrane translocation
with RhoA co-localization as a component of pll5R hoG EF activation (Kozasa et al., 1998;
Rossman et al., 2005; Aittaleb et al., 2009). Initial time course experiments with leptin treatment
revealed translocation and RhoA co-localization as early as 5 minutes after leptin addition (data
not shown). Previous studies from our laboratory have correspondingly indicated activation of
RhoA as early as 10 minutes (Zeidan et al,. 2006; Zeidan et al., 2008). Consequently,
cardiomyocytes were treated with ginseng prior to the administration of leptin for 10 minutes and
prepared for immunofluorescence. As depicted in Figure 2.7A (row c), pi 15RhoGEF membrane
translocation with RhoA co-localization was observed in leptin-treated cells as indicated by
evident yellow fluorescence at the cardiomyocyte border. Isolation of the co-localized pixels
(Figure 2.7A, row d) additionally revealed co-localization of pi 15RhoGEF and RhoA in leptintreated cells, which was inhibited by pre-treatment with ginseng. Treatment with ginseng alone
was without any effect (Figure 2.7A, 4th column).
Using the same treatment protocol, cell lysates were collected at 10 minutes after leptin
administration and incubated with GST-RhoG17A, a nucleotide-free RhoA mutant that has a
high affinity for active RhoGEFs (Garcia-Mata et al., 2006), to immunoprecipitate pi 15RhoGEF.
Measurement of activated pi 15RhoGEF from leptin-treated cells in the presence or absence of
ginseng to facilitate guanine nucleotide exchange activity by purified small GTP-ase RhoA was
then performed. pll5R hoG EF activation was increased 2-fold in leptin-treated cells in
comparison to control (Figure 2.7B). Particularly of interest, this observed increase in guanine
nucleotide exchange activity was significantly abolished in cells pre-treated with ginseng,
pi 15RhoGEF activity was unaffected by ginseng alone.
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Figure 2.7. Ginseng inhibits leptin-induced p ll5 R h o G E F co-localization with RhoA and
guanine nucleotide exchange activity. Panel A shows representative immunofluorescence
images o f pll5R hoG EF translocation and co-localization with RhoA after administration and
incubation with leptin for 10 minutes in the presence or absence of ginseng. Row (a) shows
pi 15RhoGEF (IgG AlexFluor-594) stained in red; row (b) represents RhoA (IgG AlexFluor-488)
stained in green, row (c) represents merged images of pi 15RhoGEF and RhoA; row (d) shows
isolated co-localized pixels of pll5R hoG EF and RhoA and row (e) represents isolated co
localized pixels o f merged images of pll5R hoG EF and RhoA. The Pearson’s correlation
coefficient (Rr) as calculated by the co-localization plugin of ImageJ software is represented at
the bottom right o f row (d). Panel B shows pi 15RhoGEF activity determined by fluorescence
assay at an excitation o f 360 nm and emission at 440 nm. Buffer group depicts results using
exchange buffer alone + RhoA.
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2.4

Discussion
Increasing evidence from a number of laboratories has demonstrated that leptin exerts a

direct hypertrophic effect on cardiomyocytes (Rajapurohitam et al., 2003; Xu et al., 2004;
Madani et al., 2006; Hou et al., 2010) as well as intact myocardium in vivo (Abe et al., 2007). In
addition, blocking leptin receptors attenuates remodeling and heart failure in the post-infarcted
rat heart (Purdham et al., 2008). Although the precise mechanism of action of leptin accounting
for its hypertrophic effect are not completely understood, we have previously suggested that
activation o f the RhoA/ROCK pathway plays a critical role in mediating leptin-induced cardiac
hypertrophy, likely through activation and subsequent nuclear translocation of p38 MAPK, the
latter effect dependent on alterations in actin dynamics (Zeidan et al., 2006; Zeidan et al., 2008).
In the present study, we assessed the effects of NA ginseng alcoholic extract (P. quinquefolius)
on leptin-induced cardiac hypertrophy based on emerging evidence that ginseng exerts
antihypertrophic effects in a varied number of experimental models (Jiang et al., 2007; Qin et al.,
2008; Deng et al., 2010) and also reduces the severity of heart failure in rats subjected to chronic
coronary artery ligation (Guo et al., 2011). We hypothesized that ginseng would attenuate leptininduced

cardiac

hypertrophy by

attenuating

RhoA/ROCK

activation

following

leptin

administration. Our study shows for the first time that ginseng is a potent inhibitor of leptininduced hypertrophy and indeed this occurs through a mechanism associated with the abrogation
o f RhoA/ROCK activation. Moreover, we identified a potential key role of pll5R hoG EF in
facilitating RhoA/ROCK-dependent p38 and ERK1/2 MAPK pathway activation in leptininduced cardiac hypertrophy and critically, the ability of ginseng to target pll5R hoG EF as a
mechanism for its ability to prevent RhoA/ROCK activation, thus preventing cardiomyocyte
hypertrophy.
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Leptin-induced hypertrophy was manifested by an increase in cell surface area, a 2-fold
increase in [3H] leucine incorporation, as well as increased expression of two molecular
hypertrophic gene markers, a-SA and MHC, all of which were significantly attenuated by
ginseng. Moreover, the hypertrophic effect of leptin was associated with an activation of the
RhoA/ROCK pathway as exhibited by an increase in RhoA-GTP levels, in support o f our
previous findings (Zeidan et al., 2006; Zeidan et ah, 2008). RhoA/ROCK activation was further
demonstrated by increased phosphorylation (inactivation) of cofilin-2, an ubiquitous enzyme
downstream o f RhoA which depolymerizes actin, resulting in a decrease in the G/F actin ratio.
We have previously reported that leptin-induced RhoA/ROCK activation was critical for p38
MAPK, but not ERK1/2 MAPK nuclear translocation and the subsequent hypertrophic response,
a response likely dependent on the changes in actin dynamics (Zeidan et ah, 2008). When taken
together, the ability of ginseng to completely prevent activation of the RhoA/ROCK pathway,
p38 translocation and the associated hypertrophic response strongly suggests that inhibition of
RhoA/ROCK represents a key mechanism for the antihypertrophic effect of ginseng as seen in
our study.
We next assessed the potential target mediating the ability of ginseng to inhibit
RhoA/ROCK activation. Our study centered primarily on the potential role of RhoGEFs which
are critical for downstream RhoA activation (Rossman et ah, 2005). However, the role of
RhoGEFs in the cardiac hypertrophic program has not been extensively studied. Although a
number of RhoGEFs have been identified, pll5R hoG EF and p63RhoGEF were considered of
particular interest since their expression have been demonstrated in cardiovascular tissues
including the heart (Souchet et ah, 2002; Porchia et ah, 2008; Wuertz et ah, 2010) and their
activation has been shown in response to various hypertrophic agonists including angiotensin II
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(Guilluy et al., 2010), and endothelin-1 (Porchia et al., 2008). Our study shows for the first time
that leptin induced a significant increase in pll5R hoG EF gene and protein expression without
affecting p63RhoGEF. We next studied whether increased expression of pll5R hoG EF is also
associated with increased GEF activity. Activation of pi 15RhoGEF involves receptor-mediated
membrane translocation and co-localization with RhoA (Kozasa et al., 1998; Rossman et al.,
2005; Aittaleb et al., 2009). Our results revealed membrane translocation o f pi 15RhoGEF with
RhoA co-localization after 10 minutes o f leptin stimulation and also demonstrate an increase
p i 15RhoGEF activity.
The ability of ginseng to inhibit pi 15RhoGEF activation suggest this as a target for the
ability of ginseng to inhibit leptin-induced cardiomyocyte hypertrophy and it reasonable to
assume that pll5R hoG EF activation by leptin and inhibition by ginseng represent the main
regulatory sites influencing subsequent p38 and ERK1/2 phosphorylation or translocation o f the
former. However, a limitation of our study is that it does not establish a direct causal relationship
between pll5R hoG EF activation by leptin and stimulation of the RhoA pathway.

Further

studies are required to confirm this particularly by determining the effect o f pll5RhoG EF
downregulation on the ability of leptin to activate RhoA.
As previously reported (Zeidan et al., 2008) leptin induces phosphorylation of both p38
and ERK1/2 although only the former is translocated into nuclei thus suggesting that
phosphorylation is not a precondition for nuclear transport. Although the precise mechanisms
for selective p38 translocation into nuclei are not known, the phenomenon is likely mediated by
changes in actin dynamics since the effect is prevented by latrunculin B which prevents actin
polymerization as a result of RhoA activation (Zeidan et ah, 2008). The selective translocation
o f p38 into nuclei following leptin addition also helps to explain our initial finding that
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pharmacological inhibition of p38, but not ERK1/2, prevents leptin-induced hypertrophy
(Rajapurohitam et al., 2003). The specific mechanism of pi 15RhoGEF-RhoA/ROCK-dependent
p38 and ERK1/2 MAPK inhibition by ginseng however still remains unclear. The chemical
structures of ginsenosides, which are triterpine saponins and which are considered the primary
active constituents contributing to the medicinal effects of ginseng (Attele et al., 1999), have
been compared to steroidal structures such as estrogen. Recently, Leung and colleagues alluded
to the competitive binding of the specific ginsenoside, Rbl (the predominant ginsenoside of
North American ginseng), selective to the estrogen receptor (ER) (3 where it was theorized to be
engulfed with the bound ginsenoside through endocytosis into the cytoplasm in which it
translocates into the nucleus to bind to transcription factors eliciting its effects as an antiangiogenic factor (Leung et ah, 2007). Indeed, we have previously shown that estrogen (as 17(3
estradiol) exerts a prohypertrophic effect on cultured ventricular myocytes at very low (1 pM)
concentrations but has antihypertrophic actions at nanomolar concentrations (Kilic et ah, 2009).
The observation of the ability of ginsenoside Rbl to bind to ERs is intriguing and raises the
question of potential gender specific effects o f ginseng.

Although it appears that ERs are

expressed in ventricular myocytes o f both male and female rats, nonetheless potential genderdependent effects of ginseng are deserving of further study. In the present study an alcoholic
ginseng extract containing a large number of ginsenosides was used and consequently the
specific ginsenoside(s) responsible for the observed inhibition of leptin-induced effects cannot be
currently identified.
Another potential mechanism for the observed inhibition of these pathways by ginseng
may occur extracellularly at the level o f Ob-Rb, considered the principle receptor mediating the
biological effects of leptin (reviewed in Villanueva and Myers, 2008), potentially as a result of
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early binding and antagonism o f Ob-Rb, consequently down-regulating further leptin signalling
(Figure 2.8). Although it was not an aim o f the current study, competitive binding studies
between leptin and ginseng at the Ob-Rb are deserving of further investigation.
In conclusion, our results show for the first time that ginseng markedly attenuates the
direct hypertrophic effect of leptin. Moreover, our results are strongly supportive of the concept
that this effect of ginseng against leptin-induced hypertrophy occurs via inhibition of
p i 15RhoGEF expression and activity, thus abrogating RhoA/ROCK activation. The latter results
in diminished p38 MAPK phosphorylation and translocation into nuclei thus attenuating
transcription and reducing the hypertrophic response. As previously noted, further work is
necessary to demonstrate a precise causal relationship between leptin-induced pll5RhoG EF
activation and subsequent activation o f downstream pathways.

Also, since ginseng exerts

numerous and diverse effects on the heart (reviewed in Karmazyn et al., 2011), the contribution
o f other pathways as targets for the antihypertrophic effects of ginseng cannot be excluded.
Moreover, it is important to point out that the present study was carried out using neonatal
ventricular myocytes and therefore extrapolation o f these results to the adult myocardium,
particularly under in vivo conditions should be done cautiously. Although the role of leptin in
cardiac pathology still remains to be fully determined, our overall results suggest that ginseng
could be an effective therapeutic approach aimed at mitigating potential deleterious
cardiovascular complications associated with hyperleptinemia, particularly those involving a
cardiac hypertrophic phenotype.
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Figure 2.8. Proposed mechanism of the attenuation of leptin-induced ventricular cardiac
hypertrophy by ginseng via inhibition of the pll5R hoG EF-R hoA /R O C K -dependent
MAPK pathw ay. Leptin binds to its receptor (Ob-Rb) resulting in activation of pi 15RhoGEF,
which subsequently facilitates the exchange of GDP for GTP on RhoA after co-localization and
translocation to the membrane. Activated RhoA (RhoA-GTP) results in the activation of ROCK
and LIMK, which consequently phosphorylates (inactivates) cofilin-2 resulting in an increase in
the F to G actin ratio. Changes in actin dynamics results in activation of p38 and ERK1/2 via
phosphorylation and nuclear translocation of the former thus leading to an increase in
transcriptional growth factors of hypertrophy. Pre-treatment with ginseng attenuates the leptininduced ventricular cardiac hypertrophy by inhibiting the pi 15RhoGEF-RhoA/ROCK-dependent
MAPK pathways potentially through down regulating leptin signalling by competitive binding at
the receptor or by additional mechanisms, currently undefined, via direct entry into the cell.
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CHAPTER 3:

Ginseng reverses leptin-induced ventricular cardiac hypertrophy via
Rnd3-mediated inhibition of RhoA/ROCK pathway
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3.1

Introduction
Pathological cardiac hypertrophy, which involves the abnormal structural and molecular

changes o f the heart, is a classical feature in myocardial remodelling leading to the development
o f HF (reviewed in Bemado et al., 2010). Once cardiac remodelling has been established
however, the success for reversal o f HF decreases drastically and becomes exceptionally
challenging to treat. As a result, current research on therapeutic options has focused on targeting
the molecular mechanisms involved in the development of cardiac hypertrophy.
The cardiac remodelling process can manifest as early as 24 hours after a cardiac insult
such as after an MI, whereby additional hypertrophic humoral factors are released further
aggravating the disease. One of these factors includes the 16kDa adipokine peptide, leptin, which
has been demonstrated to be elevated in plasma (>30 ng/ml) of HF patients independently of
obesity (Schulze et al., 2003). Indeed elevated plasma leptin levels have been shown to be
associated with an increased risk of acute MI (Soderberg et al., 1999).
In cultured ventricular cardiomyocytes, several laboratories including our own, have
demonstrated the marked ability of leptin to directly induce cardiac hypertrophy both in vitro
(Rajapurohitam et al., 2003; Madani et al., 2006; Zeidan et al., 2005; Zeidan et al., 2008; Hou et
al., 2010; Schram et al., 2010; Moey et al., 2011) and in vivo (Abe et al., 2007). In a four week
sustained infarction rat model produced by coronary artery ligation (CAL) of the left anterior
descending artery, treatment with leptin and Ob-Rb antibodies significantly inhibited cardiac
hypertrophy and improved ventricular function (Purdham et al., 2008). A key signalling
mechanism that has been shown to facilitate leptin-induced cardiac hypertrophy is the activation
o f RhoA/ROCK-dependent MAPK pathway (Zeidan et al., 2006; Zeidan et al., 2006).
RhoA/ROCK is a small G-protein signaling pathway that is essential for the management
o f the cellular actin dynamics (reviewed in Brown et al., 2006) in several different cellular
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systems including cardiomyocytes. RhoA is activated upon the exchange o f GTP for its bound
GDP molecule, which is facilitated by factors known as Rho guanine nucleotide exchange
factors (RhoGEFs) (reviewed in Schmidt and Hall, 2002; Rossman et al., 2005; Bos et al., 2007)
Recently, our laboratory demonstrated the critical role of pll5R hoG EF (also known as
ARHGEF1) in the facilitation of leptin-induced RhoA activation which leads to a decrease in the
G to F cellular actin ratio and induction o f cardiac hypertrophy (Moey et al,. 2011). In addition to
RhoGEFs, RhoA may be negatively regulated by GTPase activating proteins (GAPs) which
promotes the hydrolysis of GTP to GDP. A major GAP protein and downregulator of RhoA is
pl90RhoGAP (Wennerberg et al., 2003), which itself is regulated by other small G-protein
members belonging to the Rho family known as Rnd (Rndl/2/3) proteins (Riou et al., 2010).
Little however is known about Rnd expression in cardiomyocytes and its potential role in
preventing cardiac hypertrophy through downregulation of the RhoA/ROCK signaling pathway.
The present study was therefore carried out to determine the potential role of Rnd3 in
leptin-induced cardiomyocyte hypertrophy and its involvement in the antihypertrophic effect of
ginseng.

Specifically, we hypothesized that ginseng can reverse leptin-induced RhoA/ROCK

activation by upregulation of the pl90RhoGAP endogenous activator Rnd3 and by inhibition of
pi 15RhoGEF facilitated activation of RhoA/ROCK.
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3.2

Materials and Methods

3.2.1

Treatment and Experimental Groups

Neonatal ventricular cardiomyocytes from one to three day old Sprague Dawley rats were
isolated and cultured as previously described (Moey et al., 2011). Cells were grown in FBS
containing medium for up to 48 h following 24 h starvation. For reversal experiments,
cardiomyocytes were pre-treated with 50 ng/ml leptin (3.1 nM) for up to 24 h followed by the
addition o f NA ginseng alcoholic extract provided by Dr. Edmund Lui’s lab at the University of
Western Ontario (Gin, 10 pg/ml; a concentration originally tested to be optimal in attenuating
cardiac hypertrophy) (Moey et al., 2011) (Naturex, South Hackensack, NJ) for up to 24 h. Leptin
and ginseng were present throughout the entire treatment duration of up to 48 h. The protocol for
the use of animals were approved by the University of Western Ontario Animal Care and Use
Committee and conformed to the guidelines in the Guide for the Care and use of Laboratory
Animals published by the US National Institutes o f Health and the Canadian Council of Animal
Care (Ottawa, Ontario, Canada).
3.2.2

Cell Surface Area Measurement

A Leica microscope (Leica, Westzlar, Germany) equipped with an Infinity 1 camera at lOOx
magnification was used to take cardiomyocyte images. The surface area of a minimum of 50
cells per treatment group was measured using SigmaScan Pro 5 software (Systat, Richmond, CA)
and averaged.
3.2.3

RNA Isolation, Reverse Transcription (RT) and Real-time Polymerase Chain Reaction
(PCR)

RNA was collected from treated cardiomyocytes using Qiazol Reagent (Invitrogen, Carlsbad,
CA) as per the manufacturer’s instructions and reverse transcribed to complementary DNA
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(cDNA) for real-time PCR analysis o f aSA and Rnd3 gene expression as previously described
(Moey et al., 2011). cDNA was synthesized from 5gg o f total RNA using random primers
(Invitrogen) and M-MLV Reverse Transcriptase (Invitrogen) per the manufacturer’s protocol.
The reaction was performed with a SYBR Green Master Mix (Applied Biosystems, Foster City,
CA) and the gene products quantified with a DNA Engine Opticon 2 thermal cycler (MJ
Research, Waltham, MA). Primer sequences (Invitrogen) used the PCR analyses are summarized
in Table 3.1 PCR cycle conditions involved 40 cycles of denaturation at 95°C for 30 seconds,
followed by annealing at 50°C and 60°C for 30s for 18S and aSA, MCIP-1, p63RhoGEF and
Rnd3, respectively, ending with elongation at 72°C for 45s. The housekeeping gene, 18S, was
measured and quantified to normalize cDNA levels.
3.2.4

Western Blotting

Total cellular lysates were collected using a lysis buffer and protease cocktail inhibitor mixture
as a previously described (Moey et al., 2011) for the measurement o f proteins of interest.
Proteins were loaded equally on either 10% or 15% SDS gels as appropriate after protein
quantification via BioRad reagent (BioRad, Hercules, CA) following the manufacturer’s protocol.
Cardiomyocytes were treated with leptin and collected at either 5 or 10 minutes to measure
phosphorylated (p)-p38 (1:1000 dilution, Cell Signaling), p-ERKl/2 (1:1000 dilution, Cell
Signaling) and normalized to total p38 (1:1000 dilution, Santa Cruz) and total ERK1/2 (1:1000
dilution, Santa Cruz). Ginseng was administered after 10 minutes of leptin incubation and
collected after 5 minutes. For the measurement o f all additional proteins were, cardiomyocytes
were pre-treated with the hypertrophic agonist for 24 hours followed by the administration of
ginseng for an additional 24 hours. The primary antibodies and respective dilutions used in this
study include total and phosphorylated p38 forms (1:1000 dilution, Santa Cruz Biotechnology
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Inc., Santa Cruz, CA, USA), total and phosphorylated ERK1/2 forms (1:1000 dilution, Santa
Cruz), actin (1:1000 dilution, Cytoskeleton Inc., Denver, CO), phosphorylated and total cofilin-2
(1:1000 dilution, Upstate) and Rnd3 (1:200 dilution, Santa Cruz). Cells were treated for 24 hours
with leptin followed by treatment with ginseng for an additional 24 hours to measure Rnd3,
p63RhoGEF and ROCK protein expression. Membranes were incubated with either Rnd3 (1:250
dilution, Santa Cruz), p63RhoGEF (1:250 dilution, Santa Cruz) or ROCK (1:500 dilution, Santa
Cruz). Goat-anti-rabbit IgG and goat-anti-mouse IgG HRP conjugate (BioRad) were used at
1:5000 dilution and donkey-anti-goat IgG HRP conjugate (Santa Cruz) was used at 1:10,000
dilution as appropriate. Spot densitometry using FluorChem (Alpha Innotech Corporation, Santa
Clara, CA) software was performed to quantify protein.
3.2.5

In vivo Studies

Six to ten male Sprague-Dawley rats weighing between 215 and 250 g were randomly assigned
to the following four treatment groups: sham or CAE with drinking water or sham or CAE with
NA ginseng (0.9 g/L) ad libitum treatment 4 weeks after surgery. Coronary artery ligation was
performed as previously described (Guo et al., 2011). Buprenorphine (0.03 mg/kg) was
immediately administered to all animals after completion of surgery for pain management.
Studies were completed for a total of 8 weeks.
3.2.6

Statistical A nalysis

Data were analyzed with a one-way ANOVA test followed by a post-hoc Student’s t-test. P
values of < 0.05 were considered statistically significant.
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T a b le 3 .1 .

Gene-specific primer sequences of analyzed genes of interest.

Gene

Forward Primer Sequence

Reverse Primer Sequence

18S

5 ’-G T A A C C C G T T G A A C C C C A T T -3 ’

5 1-CC A T C C A A T C G G T A G T A G C G -3 1

a-skeletal actin

5'-C A C G G C A T T A T C A C C A A C T G -3 ’

5 ’-C C G G A G G C A T A G A G A G A C A G -3 ’

p63RhoGEF

5 ’-T A T G T G G A C G A C T T G G G A C A -3 1

5 ’-T G A T G A A C A G C T G A G C C A A C -3 ’

Rnd3

5 ’-C G G A C A G A T G T C A G C A C A C T -3 ’

5'-G T G G C C C T C T G T G A T T T G T T -3'
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3.3

Results

3.3.1

Ginseng reverses leptin-induced cardiac hypertrophy and increase in a-skeletal actin
gene expression.
Serum-starved isolated neonatal ventricular cardiomyocytes were treated with leptin for

24 h followed by administration o f ginseng for an additional 24 h. At the 48 h time point, images
of the treated cardiomyocytes were captured or RNA was collected to measure cell surface area
or aSA, a fetal gene reexpressed during cardiac hypertrophy, gene expression, respectively.
Leptin-induced increase in cell size (Figure 3 .IB) and aSA gene expression (Figure 3.1C)
observed at 48 h was reversed after administration with ginseng. Leptin induced an increase in
both measured indices of cardiac hypertrophy at 24 h (data not shown). Treatment with ginseng
alone was without effect on cell surface area and aSA gene expression.
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Figure 3.1. Ginseng reverses leptin-induced ventricular cardiac hypertrophy and increase
in a-skeletal actin gene expression. Micrographs show representative images (A) o f neonatal
ventricular cardiomyocytes in the presence or absence of leptin (3.1 nM) with or without
treatment with ginseng (10 pg/ml) at 48 h. Panel B shows cell surface area and panel C shows
expression of aSA, respectively, with different treatments. Data represent means ± S.E.M. N=8
for surface area and N=6 for a-SA gene expression. */?<0.05 vs. control; \p <0.05 vs. leptin. Con,
control; Lep, leptin; Gin, ginseng.
S
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3 .3 .2

G in s e n g r e v e r s e s le p t i n - i n d u c e d d e c r e a s e in G /F a c tin ra tio .

Cofilin-2 (unphosphorylated state) is a ubiquitous enzyme which depolymerizes F to G
actin controlling the cellular actin dynamics. Inactivation o f cofilin-2 by upstream RhoA
activation results in a decrease in the G/F actin ratio. After 24 h treatment with leptin,
cardiomyocytes were further incubated with ginseng for an additional 24 h and subsequently
lysed to collect and isolate G and F actin fractions as previously described (Moey et al., 2011).
Western blotting (Figure 3.2A) and immunofluorescence (Figure 3.2C) were used to quantify
and visually observe changes in the G/F actin ratio in leptin-induced cells with or without
ginseng treatment. Leptin-induced decrease in the G/F actin ratio was significantly reversed with
ginseng treatment while ginseng alone was without any effect (Figure 3.2A to C).
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Figure 3.2. Ginseng reverses leptin-induced decrease in G/F actin. Panel A shows Western
blots for actin dynamics with respect to G actin in supernatant (S) and F actin in pellet fraction (P)
from cells treated with leptin in the presence or absence o f ginseng. Densitometric values are
shown in panel B. Representative fluorescence images of cardiomyocytes are shown in panel C.
For these studies cells were fixed on collagen-coated glass cover slips and G actin (1st column)
and F actin (2nd column) were detected with DNAse-I Texas Red Conjugate and Phalloidin-FITC,
respectively. Hoechst staining was used to detect nuclei (3rd column) whereas the merged (4th
column) depicts all three stains combined. For panel B, data represent means ± S.E.M. N=7.
*/?<0.05 vs. control; fp <0.05 vs. leptin. Con, control; Lep, leptin; Gin, ginseng.
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3 .3 .3

G in s e n g r e v e r s e s l e p t i n - i n d u c e d R n d 3 g e n e a n d p r o t e i n e x p r e s s io n in v itr o a n d in v ivo .

Upregulation of Rnd3 protein, a small G-protein Rho family member, has been
demonstrated to inhibiting RhoA/ROCK activation by upregulating pl90RhoGAP activity
(Wennerberg et al., 2003) as well as inhibition o f ROCK (Riento et ah, 2003). Both Rnd3 gene
and protein expression were measured in cultured neonatal ventricular cardiomyocytes treated
with leptin for 24 or 48 h with or without ginseng treatment. Leptin induced a significant
decrease in both Rnd3 gene and protein expression after 24 hours however both Rnd3 gene and
protein expression were increased back to control levels after treatment with ginseng (Figure
3.3B and A, respectively). The protein expression of Rnd3 in LV tissues from sham and
sustained CAL rats with or without ginseng were further measured. Rnd3 protein expression was
decreased in LV tissues of CAL rats however in CAL rats receiving ginseng treatment the
expression of Rnd3 was markedly upregulated (Figure 3.3C).
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Figure 3.3. Ginseng reverses leptin-induced decrease in Rnd3 expression in vitro and in vivo.
Panels A and B represent Rnd3 protein and gene expression, respectively in cultured neonatal
ventricular cardiomyocytes. Panel A shows Western blots of Rnd3 and actin as control with
respective densitométrie values immediately below. In panel C, Western blots represent Rnd3
protein expression and respective densitométrie values from two different LV samples of either
sham or CAL animals as appropriately labeled with or without ginseng treatment. For panels AC, data represent means ± S.E.M. N=6. */?<0.05 vs. control or sham; fp <0.05 vs. leptin or CAL.
Con, control; Lep, leptin; Gin, ginseng; CAL, coronary artery ligation.
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3 .3 .4

G in s e n g p r e v e n t s C A L - i n d u c e d in c r e a s e in p 6 3 R h o G E F a n d R O C K p r o t e i n e x p r e s s io n .

Activation of RhoA can additionally be positively regulated by GEFs which facilitate the
exchange o f GDP for GTP on RhoA (reviewed in Lezoualc’h et al., 2008). Activation of RhoA
results in subsequent activation of ROCK leading to a change in cellular actin dynamics and the
induction o f hypertrophy in cardiomyocytes (Zeidan et ah, 2006; Zeidan et ah, 2008). In addition
to pll5R hoG EF, p63RhoGEF is another RhoGEF that has been demonstrated to be highly
expressed in human myocardium (Souchet et ah, 2002) and is upregulated in cardiac hypertrophy
(Porchia et ah, 2008). Consequently, protein expression of p63RhoGEF (Figure 3.4A) and
ROCK (Figure 3.4B) from isolated LV tissues o f sham or CAL animals with or without post
treatment o f ginseng for four weeks was assessed. Protein expression of p63 RhoGEF and ROCK
was significantly increased in LV tissues of rats with sustained CAL, however both p63RhoGEF
and ROCK protein expression were downregulated in CAL rats receiving ginseng treatment.
p63RhoGEF and ROCK expression were unaffected in sham animals receiving water or ginseng
treatment.
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Figure 3.4 Ginseng prevents CAL-induced p63RhoGEF and ROCK increased protein
expression. Western blots and respective densitométrie values in (A) and (B) represent protein
expression o f p63RhoGEF and ROCK from two different LV samples of either sham or CAL
animals as appropriately labeled. For panels A and B, data represent means ± S.E.M. N=6.
*/?<0.05 vs. sham; fp <0.05 vs. CAL. CAL, coronary artery ligation.
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3 .3 .5

G in s e n g d o e s n o t r e v e r s e l e p t i n - i n d u c e d p 3 8 a n d E R K 1 / 2 M A P K a c tiv a tio n .

In our previous study, peak activation/phosphorylation of p38 and ERK1/2 by leptin was
observed at 10 minutes, continued to remain elevated at 15 minutes and declined at 30 and 60
minutes (Moey et al., 2011). Consequently to determine the reversibility o f leptin-induced
activation of p38 and ERK1/2 by ginseng, serum-starved isolated neonatal ventricular
cardiomyocytes were treated with leptin for 10 minutes followed by administration with ginseng
for 5 minutes (end time point was 15 minutes). As previously demonstrated (Moey et al., 2011),
leptin induced significant activation of p38 and ERK1/2 at 10 and 15 minutes. Interestingly
however, administration of ginseng after 10 minutes of incubation with leptin resulted in a
marked 2- to 3-fold increase in p38 (Figure 3.5A) and ERK1/2 phosphorylation (Figure 3.5B).
Ginseng alone had no effect on p38 or ERK1/2 MAPK activation.
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Figure 3.5. Ginseng does not reverse leptin-induced increase in p38 and ERK1/2
phosphorylation/activation. Panel A shows Western blots and corresponding densitometric
values for phosphorylated p38 whereas panel B show Western blots and corresponding
densitometric values for phosphorylated ERK1/2 from cell lysates in the presence of leptin with
or without ginseng treatment. Data in panels A and B represent means ± S.E.M. N=6. */?<0.05
vs. control; fp <0.05 vs. leptin. Con, control; Lep, leptin; Gin, ginseng.
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3.4

Discussion
A major challenge in treating HF is the ability to reverse the underlying cause of well-

established cardiac remodelling, which involves the imbalance of diverse molecular and
biochemical mechanisms (Fedak et al., 2005). Leptin, the obesity-associated peptide that acts as
a satiety factor (Zhang et ah, 1994), has also been shown to directly stimulate cardiac
hypertrophy in both cultured cardiomyocytes (Rajapurohitarn et ah, 2003; Madani et ah, 2006;
Zeidan et ah, 2005; Zeidan et ah, 2008; Hou et ah, 2010; Schram et ah, 2010; Moey et ah, 2011)
and in vivo (Abe et ah, 2007). In patients with HF, leptin has been detected at elevated levels (>
30 ng/mL) independently of obesity (Schulze et ah, 2003). The induction o f cardiac hypertrophy
by leptin has been associated with the upregulation of classic pro-hypertrophic signalling
pathways which include the MAPK and RhoA/ROCK cascades (reviewed in Karmazyn et ah,
2008b). The goals for the treatment of HF in addition to improving survival and decreasing
incidences o f hospitalization now includes the objective of downregulate enhanced signalling
pathways of the hypertrophic program (reviewed in Tamargo and Lopez, 2011). In another study
(C hapter 4) assessing the ability o f ginseng to reverse HF in vivo, ginseng administered to rats
after four weeks of sustained MI successfully reversed cardiac dysfunction and hypertrophy as
demonstrated by improved echocardiographic and hemodynamic parameters as well as decreased
heart weights and expression of the fetal gene marker, aSA. Results from this study were of
particular significance as we showed for the first time, the potential for ginseng to reverse
cardiac hypertrophy and HF by inhibiting calcineurin (CaN) activation in vivo and in vitro. The
reversal of cardiac hypertrophy may not be limited to CaN activation, although it is considered to
be a key player in the remodelling process (Wilkins et al., 2004) unique to pathological cardiac
hypertrophy, as there are a multitude of pathways that may be concomitantly upregulated
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(reviewed in Frey and Olson, 2003). In the present study, the ability of ginseng to reverse leptininduced cardiac hypertrophy was demonstrated. Moreover, the mechanisms likely involve the
reversal of RhoA/ROCK activation by upregulation of Rnd3.
In cultured ventricular cardiomyocytes, significant increases in surface area as well as
aSA gene expression were observed in cardiomyocytes incubated with leptin as early as 24 h
(data not shown) and were further increased after 48 h. Ginseng treatment however returned
these increased markers of hypertrophy to control phenotype. A major signalling pathway that
has been implicated in leptin-induced cardiac hypertrophy is the activation of the RhoA/ROCK
pathway (Zeidan et al., 2006; reviewed in Karmazyn et al., 2008; Zeidan et al., 2008; Karmazyn
et al., 2008; Moey et al., 2011; Zeidan et al., 2011) which is required for the subsequent
activation of the classic pro-hypertrophic p38 and ERK1/2 MAPK pathways. Activation of the
RhoA/ROCK pathway was indirectly measured by the changes in the G to F actin ratio using
Western blotting and immunofluorescence in cells incubated with leptin at 48 h with or without
ginseng treatment. Administration of leptin for 24 and 48 h resulted in a significant increase the
F actin component and consequently decreased the G/F actin ratio. However, ginseng treatment
for 24 h after initial incubation with leptin for 24 h completely reversed these effects.
RhoA/ROCK activation has been shown to mediate upregulation of p38 and ERK1/2
MAPK (Zeidan et ah, 2008; Moey et ah, 2011) pathways, that eventually result in the expression
o f transcription factors for cell proliferation and differentiation (reviewed in Rose et ah, 2010).
Peak activation (phosphorylation) of p38 and ERK1/2 by leptin has been previously observed at
10 minutes and plateaus at 30 minutes onwards (Moey et ah, 2011). Accordingly,
phosphorylation o f p38 and ERK1/2 was measured after treatment of ginseng in cardiomyocytes
that were already exposed to 10 minutes of leptin incubation. In agreement with our previously
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published data (Moey et al., 2011), leptin induced significant activation of both p38 and ERK1/2
at 10 and 15 minutes. The inhibition of RhoA activation by ginseng however did not reverse
these responses and instead caused a marked 2-fold increase in the phosphorylation of both p38
and ERK1/2. These results are rather intriguing as RhoA and ROCK inhibitors, C3 exoenzyme
and Y-278, respectively have been shown to directly inhibit p38 phosphorylation and nuclear
translocation (Zeidan et al., 2008). The robust increase in p38 and ERK1/2 activation may
potentially be due to increased external stress factors caused by the administration of ginseng,
which therefore potentiates the hypertrophic stimuli of leptin. Indeed, stress stimulators are
known to activate MAPK (reviewed in Rose et al., 2010). In addition, it was previously reported
in the hypertrophied hearts o f renovascular hypertensive rats that p38 and ERK1/2 activation,
which was measured by mRNA expression, was maintained at an elevated level while expression
of CaN and JNK were reversed by the CaN inhibitor cyclosporin A (Liang et al., 2006). This
may implicate the more predominant role o f other pathways, such as CaN or RhoA, rather than
the MAPK cascade as targets for the reversal of cardiac hypertrophy. Alternatively, this may
provide insight into the mechanism by which ginseng inhibits RhoA/ROCK-dependent p38
MAPK activation at the extracellular level by preventing binding of leptin at the receptor.
Accordingly, the regulation o f RhoA was investigated in cultured cardiomyocytes and
LV tissues of rats treated with ginseng after four weeks o f sustained MI. In C hapter 2, leptininduced RhoA activation was demonstrated to be mediated by pi 15RhoGEF, which along with
p63RhoGEF that is expressed in the myocardium (Souchet et al., 2002), are positive regulators
of RhoA activity linked to hypertension (Guilluy et al., 2010; Wuertz et al., 2010) as well as
cardiac hypertrophy (Porchia et al., 2008). RhoA activation may also be downregulated by
pl90RhoGAP of which its GTP hydrolysis activity is promoted by binding of Rnd proteins
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(Rndl and 3) (Wennerberg et al., 2003). Research of the effect of Rnd proteins on RhoA
activation in the CV system is limited, however has been extensively studied in the area of
cancer and contraction o f the myometrium (Cario-Toumaniantz C et al., 2004; Lartey et al.,
2006). Regulation of Rnd is primarily observed by gene transcription (reviewed in Riou et al.,
2010) followed by protein expression and RhoGAP activity. Here we showed for the first time
expression of Rnd3 in cardiomyocytes, the effects of leptin and ginseng on Rnd3 gene and
protein expression as well as Rnd3 protein expression in LV tissues o f sham and CAL rats.
Leptin at 24 h in cardiomyocytes caused a significant decrease in Rnd3 gene and protein
expression which were restored by treatment with ginseng. These results are in agreement with
the previously observed leptin-induced increase in RhoA activation, which may therefore be a
result of decreased downregulation of RhoA by Rnd3. Importantly, our in vitro data
corresponded with Rnd3 protein expression measured from LV tissues of CAL-operated rats.
Rnd3 protein expression in rats with sustained MI for 4 weeks was significantly depressed
however in CAL rats that were administered ginseng protein expression values were similar to
expression in sham animals. Hyperleptinemia has been associated with HF patients (Schulze et
al., 2003) and consequently these observed decreases in Rnd3 protein expression in the LV
tissues of CAL rats may be a result o f elevated plasma leptin levels in HF rats. There may
however have been additional circulatory levels o f prohypertrophic factors such as Angll, ET-1
or inflammatory markers that are typically upregulated in HF, which may have also contributed
to the observed decrease in Rnd3 protein expression in CAL rats.
Changes in the regulation of enhancers of RhoA activation in leptin-induced cardiac
hypertrophy were additionally studied by measurement of the positive regulators, p63RhoGEF
and ROCK, in the LV tissues of sham and CAL rats. Both p63RhoGEF and ROCK protein
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expression were significantly increased in rats with sustained MI however these effects were
attenuated in LV tissues o f rats treated with ginseng. Interestingly, in our previous study, leptin
administration to cultured ventricular cardiomyocytes did not induce a significant change in
p63RhoGEF gene and protein expression whereas a 4-fold increase in the expression of
pll5R hoG EF was observed (Moey et al., 2011). This likely suggests differences between
hypertrophy in cultured myocytes versus changes occurring in the intact remodelled myocardium.
In summary, here we have shown for the first time the reversibility o f leptin-induced
cardiac hypertrophy by ginseng via an increase Rnd3-mediated downregulation of RhoA/ROCK.
Results from our study provide prospective insight into targeting the RhoA/ROCK pathway as
potential therapy for the treatment of cardiac hypertrophy and HF associated with
hyperleptinemia.

\
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CHAPTER 4:

Ginseng reverses cardiac hypertrophy in vitro and heart failure in
vivo
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4.1

Introduction
Cardiovascular disease (CVD) continues to remain the number one cause of mortality in

the world (World Health Organization, 2011). Although ischemic heart disease predominates as
the most prevalent CVD, mortality from ischemic heart disease has been on the decline whereas,
based on American Heart Association statistics (Lloyd-Jones et al., 2010), the incidence of heart
failure continues to rise. Current pharmacotherapies for the treatment of HF, including p*
adrenergic blockers, RAAS blockers such as Angll receptor blockers (ARBs), angiotensin
converting enzyme (ACE) inhibitors and aldosterone blockers (Marian 2009; Hellawel and
Margulies, 2010) have been proven to be o f substantial benefit in prolonging and improving
quality o f life for HF patients without markedly reducing mortality rates (Krum and Teerlink,
2011; Rouleau, 2011) which are currently greater than 40%, 5 years after diagnosis (Jessup and
Brozena, 2003). The high mortality rate associated with HF likely reflects the complexity of the
myocardial remodelling process which contributes to HF and the difficulty in reversing this
process with current pharmacotherapy (Marian 2009; Hellawel and Margulies, 2010).
As recently reviewed, improvement in the treatment of HF will likely result as a
consequence of better understanding o f the underlying mechanisms for this complex syndrome
which should lead to the development o f new and effective pharmacological agents (Tamargo
and Lopez, 2011). Another possible route for the identification of novel therapeutic approaches
for treating HF may lie with alternate and less conventional medications such as TCMs which
have been used for treating a variety o f disorders including CVDs for thousands o f years. Among
these TCMs, NA ginseng as well as other ginseng varieties have been gamering increasing
interest for their salutary effects in the CV system specifically as a cardioprotective agent in
ischemia and reperfusion as well as prevention of cardiac hypertrophy and HF (reviewed in
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Karmazyn et al., 2011).

Recently, we have demonstrated a robust ability o f NA ginseng to

prevent cardiomyocyte hypertrophy and heart failure through a mechanism likely involving
prevention of CaN activation (Guo et al., 2011), the latter representing a key factor for
myocardial hypertrophy and remodelling (Molkentin, 1998; Frey and Olson, 2003). A recent
intriguing study has shown that CaN-dependent cardiac hypertrophy is a reversible process
(Berry et al., 2011). Accordingly, in view o f the potential importance of CaN as a target for the
antihypertrophic effect of ginseng, we determined whether the latter can reverse already
established hypertrophy and heart failure using both in vitro and in vivo approaches.

\
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4.2

Methods

4.2.1

Cultured Cardiomyocyte Treatment and Experimental Groups

Neonatal ventricular cardiomyocytes from one to three day old Sprague Dawley rats were
isolated and cultured as previously described (Moey et al., 2011). Cells were grown in FBS
containing medium for up to 48h following 24h starvation. For reversal experiments,
cardiomyocytes were pre-treated with either Angll (100 nM),

ET-1 (10 nM) or the al

adrenoceptor agonist Phe (10 pM) (Sigma Aldrich, St. Louis, Missouri) for up to 24h followed
by the addition o f ginseng extract (Gin, 10 pg/ml) for a further 24h, in the presence of the
hypertrophic stimuli. The extract was prepared from

four-year-old NA

ginseng (Panax

quinquefolius) roots collected from 5 farms in Ontario, Canada (provided by Dr. Edmund Lui’s
lab at the University o f Western Ontario) and shipped to Naturex (South Hackensack, NJ) for
ginsenoside extraction with use of a hydroalcoholic process (Naturex, South Hackensack, NJ), as
previously described (Guo et al., 2011). The protocol for the use of animals were approved by
the University of Western Ontario Animal Care and Use Committee and conformed to the
\
guidelines in the Guide for the Care and use of Laboratory Animals published by the US
National Institutes of Health and the Canadian Council o f Animal Care (Ottawa, Ontario,
Canada).
4.2.2

Cell Surface Area Measurement

A Leica microscope (Leica, Westzlar, Germany) equipped with an Infinity 1 camera was used to
obtain cardiomyocyte images using lOOx magnification. The surface area of a minimum of 50
cells per treatment group was measured using SigmaScan Pro 5 software (Systat, Richmond, CA)
and averaged to produce one “N” value.
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4.2.3

RNA Isolation, Reverse T ranscription (RT) and Real-time Polymerase Chain
Reaction (PCR)

RNA was collected from treated cardiomyocytes using Qiazol Reagent (Invitrogen, Carlsbad,
CA) as per the manufacturer’s instructions and reverse transcribed to complementary DNA
(cDNA) for real-time PCR analysis o f aSA and modulatory calcineurin interacting protein-1
(MCIP-1) as previously described (Moey et al., 2011). cDNA was synthesized from 5 pg of total
RNA using random primers (Invitrogen) and M-MLV Reverse Transcriptase (Invitrogen) per the
manufacturer’s protocol. The reaction was performed with a SYBR Green Master Mix (Applied
Biosystems, Foster City, CA) and the gene products quantified with a DNA Engine Opticon 2
thermal cycler (MJ Research, Waltham, MA). Primer sequences (Invitrogen) included in the
PCR analyses are summarized Table 4.1. PCR cycle conditions involved 40 cycles of
denaturation at 95°C for 30 seconds, followed by annealing at 50°C and 60°C for 30s for 18S
and aSA and MCIP-1, respectively, ending with elongation at 72°C for 45s. The housekeeping
gene, 18S, was measured and quantified to normalize cDNA levels.
\

4.2.4

Calcineurin A ctivity Assay

CaN activity from cellular and tissue extracts collected with a lysis buffer and protease inhibitor
cocktail was measured following the colorimetric Calcineurin Cellular Activity Assay Kit as per
the manufacturer’s instructions (Enzo Life Sciences, Ann Arbor, MI). CaN activity was
measured by the amount of nmol phosphate (PO 4) released at 620nm using the SpectraMax 5
(Molecular Devices, Sunnyvale, CA) plate reader from tissue and cellular extracts.
4.2.5

Imm unofluorescence

Cardiomyocytes were prepared for immunofluorescence on collagen coated (3 pi of collagen/1
ml of PBS A) glass cover slips and incubated at 37°C for a minimum of 30 minutes. Cells were
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allowed to attach to prepared cover slips in serum-containing medium for 24 hours followed by
serum starvation for an additional 24h before appropriate treatments. Cardiomyocytes were pre
treated with Ang II, ET-1, or Phe for 24h without ginseng or 48h with or without treatment of
ginseng for an additional 24h. Cells were fixed with 2:5 acetone-methanol for 1 hour at 4°C
followed by permeabilization of cells for 15 minutes with 0.1% (v/v) Triton X-100 and blocking
with blocking solution (1% BSA in PBS A). Cells were incubated with NFAT3 (1:100 dilution)
in 2% BSA in PBS A overnight at 4°C. Cells were subsequently probed with the secondary
antibody IgG anti-rabbit AlexFluor-596 (Invitrogen) (1:250 dilution) in 2% BSA in PBS A for 1
hour at room temperature under light-free conditions. Cells were mounted with Vector Staining
medium that also detects the nucleus onto microscope slides (VWR, West Chester, PA) for
image capture using a Zeiss (Oberkochen, Germany) inverted fluorescence microscope at 630X
magnification. Nuclear translocation was measured using ImageJ (Noursadeghi et al., 2008).
4.2.6

In vivo Studies

Fourty male Sprague-Dawley rats weighing between 200 and 250 g were randomly assigned to
either a sham or CAL group without or with ginseng treatment (0.9 g/L in drinking water
provided a d libitum ) started four weeks after surgery and maintained for a further four weeks.
CAL was performed as previously described under sodium pentobarbital (50 mg/kg bw)
anesthesia (Guo et al., 2011). Buprenorphine (0.03 mg/kg) was immediately administered to all
animals after completion of surgery for pain management. Studies were completed for a total of
8

weeks.

4.2.8

Echocardiography

Echocardiography measurements were taken at the following three different time points:
baseline/before surgery (week 0), 4 weeks after surgery (week 4) and at the end of the study
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(week 8 ). Rats were prepared for echocardiography as previously described (Guo et al., 2011).
Briefly, rats were anesthetized with 2% isofluorane and placed supine on a heated platform.
Echocardiography measurements were performed using a Vevo 770 high-resolution in vivo
microimaging system equipped with a real-time microvisualization scan head of 17.5 MHz
(VisualSonics, Toronto, Ontario, Canada) to obtain M-Mode 2-dimensional and Doppler images.
M-Mode was obtained from the parasternal short axis to analyze left ventricular dimensions
during diastole and systole and Doppler mode was obtained from the parasternal long axis to
determine for the E/A ratio calculation. All images were analyzed using the Vevo 770 ProtocolBased Measurements software.
4.2.9

Hemodynamic Measurements

After 8 weeks of treatment (end of the study), rats were anesthetized with pentobarbital sodium
(50 mg/kg) and an anterior thoractomy was performed as previously described (Guo et al., 2011).
A 2.OF P-V Mikro-Tip catheter (Millar Instruments, Houston, Texas) was retrogradely inserted
into the LV via the right carotid artery as previously described. Hemodynamic data were
recorded and analyzed using the Notocord-Hem 4.2 Software (Notocord, Croissy-sur-Seine,
France) digitized with a sampling rate of 1000 Hz.
4.2.10 Statistical A nalysis
Data were analyzed with a one-way ANOVA test followed by a post-hoc Student’s /-test. P
values o f < 0.05 were considered statistically significant.
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T a b le 4 .1 .

Gene-specific primer sequences of analyzed genes of interest.

Gene

Forward Primer Sequence

Reverse Primer Sequence

18S

5 ’-G T A A C C C G T T G A A C C C C A T T -3 ’

5 ’-CC A T C C A A T C G G T A G T A G C G -3 ’

a-skeletal actin

5 ’-C A C G G C A T T A T C A C C A A C T G -3 ’

5 ’-C C G G A G G C A T A G A G A G A C A G -3 ’

MCIP-1

5 ’-T C T C C A A G C T G G G A C C A G G A G A G A - 3 ’

5 A T C A G A A C G C G C G T G T C G G T -3 ’
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4.3

Results

4.3.1

Ginseng reverses CAL-induced cardiac hypertrophy
We first determined whether ginseng administration four weeks after CAL reverses

indices of myocardial remodelling and heart failure after a further four week follow-up with
continued ligation. Forty animals were initially recruited into the study as described in Materials
and Methods with an average body weight of 230 ± 4.4 g. Treated animals were administered
NA ginseng (900 mg/L) dissolved in the drinking water four weeks after CAL (Figure 4.1 A).
Water consumption was monitored for the following four weeks and was found to be identical
(approx 50 mL/day/animal at week 4) in all groups studied. Sustained CAL produced no
mortality during the eight week post CAL period although 20% o f the animals died within 24 h
after CAL.

All animals exhibited identical growth patterns throughout the eight week post

surgery period (Figure 4 .IB).

CAL produced a significant increase in all indices of cardiac

hypertrophy as evidenced by increased expression of aSA(Figure 4.1C) and both total (Figure
4 .ID) as well as left ventricular (Figure 4 .IE) heart weights. As shown in Figure 1, all markers
o f hypertrophy were normalized by ginseng treatment.
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Ginseng (0.9 g/L)

i
W eek 0

W eek 4

Week 8

Echocardiography

Echocardiography

Echocardiography
Hemodynamics
LV Isolation

□

Sham

No Treatment

CAL

■

Ginseng

Sham

CAL

Figure 4.1. Ginseng reverses cardiac hypertrophy and a-skeletal gene expression in vivo
w ithout any effect on body mass changes. (A) Experimental design time as described in
methods. Ginseng was administered to animals four weeks after sham or CAL surgery. (B)
Sprague-Dawley rats averaging between 215 to 250 g were randomized to either sham or CAL
administered water or ginseng. Body mass changes over the course of the eight-week study in all
experimental groups were not significantly different from each other. CAL-induced cardiac
hypertrophy demonstrated by increases in aSA gene expression (C), HW/BW (D) and LV/HW
ratios (E) were significantly reduced with ginseng. Treatment with ginseng alone was without
effect on any o f the above measured parameters. *p<0.05 vs. sham; ^<0.05 vs. CAL. BW: body
weight; HW: heart weight; LV: left ventricle; aSA: a-skeletal actin.
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4.3.2

Evidence o f reversibility o f CAL-induced left ventricular dysfunction by serial
echocardiography
Reversibility o f cardiac dysfunction by ginseng was assessed by serial echocardiography

in which animals were analyzed before surgery (week 0), 4 weeks after surgery but before
starting ginseng treatment and finally, 8 weeks after surgery. As shown in Figure 4.2 animals
subjected to 4 weeks of CAL had significantly depressed left ventricular performance as
determined by EF (panel A), FS (panel B), CO (panel C) and SV (panel D) with values
progressively declining during the subsequent four week follow-up period.

However,

administration of ginseng four weeks after CAL resulted in a dramatic restoration in left
ventricular function resulting in restoration in all parameters to values not significantly different
from baseline but significantly greater than those observed in animals not treated with ginseng.
Figure 3.3 shows echocardiograms and corresponding quantified data for cardiac
parameters.

As illustrated in M mode images (panel A) as well as in panels B and C, left

ventricular internal diameters during systole (LVIDs) and diastole (LVIDd) were significantly
increased by four weeks in CAL rats although ginseng significantly reversed both parameters.
Furthermore, the E/A ratio determined by Doppler echocardiography analysis was increased in
CAL rats while administration with ginseng for 4 weeks restored the ratio to control values
(Figure 4.3D and E).
Echocardiographic parameters in rats subjected to sham surgery remained unchanged
throughout the 8 week follow-up period nor was there any influence of ginseng on any parameter
studied in sham-operated animals. These data are summarized in Table 4.1
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No Treatment

Ginseng

A

Figure 4.2. Ginseng reverses CAL-induced decreased ejection fraction (EF), fractional
shortening (FS), cardiac output (CO) and stroke volume (SV). Echocardiographic recordings
were measured before the surgery (week 0), four weeks after surgery (week 4) and at the end of
the study (week 8 ) to assess ejection fraction (EF) (A), fractional shortening (FS) (B), (C)
cardiac output (C) and stroke volume (SV) (D) as indicators of cardiac function. CAL (solid
black line) induced significant decreases in EF, FS, CO and SV four weeks post-surgery and
further worsened these parameters at eight weeks. Four week treatment with ginseng (dotted grey
line) however returned EF, FS, CO and SV to control values at week 0. The EF, FS, CO and SV
values for sham rats receiving water or ginseng were not significantly different from values
shown at week 0. (N=10; */?<0.05 and **p<0.01 vs. week 0; f/?<0.05 and f t p< 0.01 vs. week 4)

153

—

B

No Treatment

c

Ginseng

•a

9 4
>

2

0 -I------------------ T------------------------------------------------ !
0
4
8
W eek

E

Figure 4.3. Ginseng reverses CAL-induced increased left ventricular internal diam eters
during systole (LVIDs) and diastole (LVIDd) and E/A ratio. Echocardiographic recordings
were measured before surgery (week 0), four weeks after surgery (week 4) and at the end of the
study (week 8 ) to assess changes in left ventricular internal diameter during systole (LVIDs) and
diastole (LVIDd) as well as the early and late (atrial) ventricular filling velocity (E/A). CAL
induced (solid black line) significant increases during both systole (B) and diastole (C) at week 4
which were returned to normal however with ginseng treatment (dotted grey line) at week 8 .
Changes in LVIDs and LVIDd at week 8 were not significantly different from week 4
measurements. Ginseng treatment further reversed the significant increase in E/A ratio (E) at
week 4 and 8 to control values. The LVIDs, LVIDd and E/A ratio values of sham rats receiving
water and ginseng were consistent control values similar to week 0 throughout the duration of
the study. Representative echocardiographic M-Mode images exhibit increases in LVIDs and
LVIDd (A) in CAL rats at week 4 (2nd image panel) and 8 (3rd image panel) and the reversal of
these increases with ginseng treatment at week 8 (4lh image panel). Doppler echocardiographic
images demonstrate an increased and decreased amplitude in the E and A wave (D), respectively,
in CAL rats at week 4 (2nd image panel) and 8 (3rd image panel), however this effect was
returned to normal with ginseng treatment (4th image panel). (N=10; *p< 0.05 vs. week 0;
fjP<0.05 vs. week 4).
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Table 4.1 Echocardiographie parameters at week 4 and week 8 in sham rats receiving drinking
water (Sham) and ginseng treatment (Sham+Gin).
Sham

Sham+Gin

Week 4

Week 8

Week 4

Week 8

EF (%)

79.5+1.67

80.4+2.08

80.7+2.44

81.1+1.48

FS (%)

49.8+1.9

49.8+2.1

51.6+2.8

51.0+1.5

CO (ml/min/kg)

198.7+21.1

166.7+4.9

181.3+13.8

161.5+12.1

SV (pL)

267.5+26.9

247.9+11

251.2+17.6

248.9+13.9

LVIDd (mm)

7.2+0.31

7.6+0.34

7.4+0.35

7.8+0.25

LVIDs (mm)

3.9+0.35

4.06+0.27

3.6+0.32

4.3+0.29

E/A ratio

1.4+0.14

1.33+0.04

1.31+0.05

1.40+0.07

E chocardiographie Param eter

CO = cardiac output; E/A ratio = early/late (atrial) ratio; FS = fractional shortening; LVIDd =
left ventricular internal diameter in diastole; LVIDs = left ventricular internal diameter in systole;
SV = stroke volume
\
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4.3.3

Hemodynamic parameters in eight week postinfarcted animals

Catheter-based hemodynamic measurements were performed at the end of the study to further
assess additional left ventricular systolic and diastolic function. As shown in Figure 3.4, eight
weeks o f CAL resulted in significantly decreased systolic function with respect to all parameters
studied which was accompanied by markedly enhanced left ventricular end-diastolic pressures
and end-diastolic volumes. Figure 3.5 further illustrates CAL-induced contractile and diastolic
dysfunction as evidenced by a decreased slope in the ESPVR and an increased slope in the
EDVR. However, as shown in both Figures 3.4 and 3.5, animals treated with ginseng four weeks
after CAL demonstrated almost complete normalization o f hemodynamic parameters.
Mean baseline heart rates for all experimental groups (pooled data) were 358±16
beats/min. In rats subjected to CAL without subsequent ginseng administration heart rates were
318±24 and 328±17 beats/min four and eight weeks following CAL, respectively. Corresponding
heart rates in rats treated with ginseng four weeks after CAL were 342±13 and 358±20 beats/min.
There were no significant differences in heart rates between any treatment groups.
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Figure 4.4. Ginseng reverses CAL-induced cardiac dysfunction. Hemodynamic
measurements at the end of the study (week 8) were recorded as previously described (see
Methods) to obtain left ventricular end systolic and diastolic pressures and volumes as well as
dP/dT max and min. CAL significantly reduced LVESP (A), dP/dT max (E) and dP/dT min (F)
which were prevented with ginseng treatment. LVEDP, LVESV and LVEDV increases in CAL
rats were similarly prevented after four weeks of treatment with ginseng. All hemodynamic
parameters in sham rats receiving ginseng treatment were not significantly different from sham
rats receiving water. (N=10; *p< 0.05 and **p<0.01 vs. sham; tp<0.05 and ff/?<0.01 vs. CAL)
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Sham

CAL

Sham

CAL

Figure 4.5. Ginseng reverses CAL-induced increase in end-systolic and end-diastolic
pressure volume relationship (ESPVR and EDPVR). The end-diastolic (EDPVR) and endsystolic (ESPVR) pressure relationship slope from each experimental group was determined
through analysis of the pressure-volume (PV) loops obtained from hemodynamic analysis. CALinduced decrease and increase in ESPVR (A) and EDPVR (B), respectively, was significantly
(/?<0.05) prevented with four week ginseng treatment. EDPVR and ESPVR values of sham rats
receiving ginseng treatment were not significantly different from sham control values.
Representative PV loops from sham (C), CAL (D), sham with ginseng (E) and CAL with
ginseng (F). Slope lines of the ESPVR (top left of loop) and EDPVR (bottom right of loop) were
drawn using Adobe Photoshop CS. The slope of ESPVR was evidently decreased while EDVPR
was increased in CAL rats (D) however treatment with ginseng (F) restored these parameters to
sham control values. (N=10; **/?<0.01 vs. sham; ft/?<0.01 vs. CAL)

4.3.4

Ginseng prevents indices o f extracellular matrix remodelling/cardiac fibrosis
158

Isolated LV tissues were processed for real-time PCR analysis o f the gene markers for
ECM remodelling, collagen I, collagen III and fibronectin. LV tissues from CAL rats
demonstrated a significant 1.5 to 2.0-fold (/?<0.05) upregulation in the gene expressions of
collagen I (Figure 4.6A), collagen III (Figure 4.6B) and fibronectin (Figure 4.6C) which were
abolished in CAL animals treated with ginseng. Ginseng treatment in sham rats was without
effect on the expression of these markers of ECM remodelling.

\
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Figure 4.6. Ginseng prevents upregulation of m arkers of extracellular m atrix remodeling.
Gene expression of extracellular matrix (ECM) remodeling markers, collagen I, collagen II and
fibronectin were quantified using real-time PCR from isolated LV tissues of the different
experimental groups. CAL-induced significant increases in collagen I (A), collagen III (B) and
fibronectin (C) gene expression were significantly (¿><0.05) reduced in CAL animals receiving
ginseng treatment. Expression of these gene markers o f ECM were not affected by ginseng
treatment alone. (N=6-8; *p<0.05 vs. sham; ^ < 0 .0 5 vs. CAL)
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4.3.5

Direct reversal by ginseng o f cardiomyocyte hypertrophy in culture
To further assess the ability o f ginseng to reverse cardiomyocyte hypertrophy cultured

ventricular myocytes were exposed to one of three hypertrophic stimuli including ET-1, Ang II
or phenylephrine. Ginseng was added 24 h after addition of the hypertrophic stimuli. Figure 4.7
illustrates hypertrophic response to each o f the stimuli after either 24 or 48 h treatment. As
shown in micrographs (panel A) as well as quantified data (panel B) untreated myocytes
significantly increased in size when culture duration increased from 24 to 48 h, in the absence of
ginseng, although this was not accompanied by any changes in a-skeletal actin expression (panel
C). Each of the agonists significantly increased myocyte surface area by approximately 37%
compared to 24 h untreated myocytes whereas this was increased to approximately 55% in 48 h
treated myocytes. These changes in cell surface area were accompanied by increased a-skeletal
actin expression although gene expression upregulation was relatively similar for 24 and 48 h
treatment values.
We next determined whether ginseng administration could reverse the hypertrophic
response when added 24 h after addition o f the respective agonist. Cells were then maintained
for a further 24 h in the presence of the hypertrophic agonist under study in the absence or
presence o f ginseng.

As shown in Figure 4.7, cells treated with ginseng according to this

protocol demonstrated no evidence o f agonist-induced hypertrophy when assessed by either by
surface area (panel B) or gene expression levels of a-skeletal actin (panel C).
4.3.6

Ginseng reverses A n g ll, ET-1 and Phe-induced ventricular cardiac hypertrophy and askeletal actin gene expression in vitro.
Cultured neonatal ventricular cardiomyocytes were treated accordingly with Angll, ET-1

and phenylephrine (see Methods), which as alluded to earlier are classical humoral factors
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released in HF to assess the ability o f ginseng to reverse hypertrophy in vitro. Cardiac
hypertrophy was evident in cultured cardiomyocytes treated with the hypertrophic agonists at 24
h and was further increased after 48 h (Figure 4.7A) Treatment with ginseng however
significantly (p<0.05) abrogated these effects and returned cell size to control values at 48 h. An
increase in expression of aSA was concomitantly observed in cells subjected to Angll, ET-1 and
phenylephrine at 24 and 48 h (Figure 4.7B). Ginseng similarly reversed these observed increases
in aSA expression. Treatment with ginseng alone was without effect.

\
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Figure 4.7. Ginseng reverses cardiac hypertrophy and a-skeletal gene expression in vitro.
(A) Representative cell size images o f neonatal ventricular cardiomyocytes subjected to different
treatments as indicated. Top row represents an incubation time period of 24h while the second
and third row represent 48h incubation. The first and last column represents control conditions of
cells without and with ginseng, respectively. Second, third and fourth column represent cells
treated with Angll, ET-1 and Phe, respectively, with (3rd row) or without (1st and 2nd row)
ginseng. Isolated neonatal ventricular cardiomyocytes subjected to Angll, ET-1 and Phe
incubation for 24h demonstrated a significant increase in cell surface area (B) as well as aSA
gene expression (C) which were further augmented at 48h. Treatment with ginseng after 24h
incubation with the hypertrophic agonists reversed these observed increases at 24h and 48h in
cell surface and aSA. Ginseng alone was without effect. aSA: a-skeletal actin; Angll:
angiotensin II; ET-1: endothelin-1; Phe: phenylephrine; Gin: ginseng; +: with; -: without. (N=7;
*/?<0.05 vs. respective time controls; f/?<0.05 vs. respective hypertrophic agent).
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4.3.7

Potential Role o f Calcineurin as a Target fo r Ginseng-induced Reversal o f the
Hypertrophic Response
As demonstrated in Figure 4.8, there was a strong trend for ginseng to inhibit CAL-

induced increase in CaN activity (Figure 4.8E, /?=0.05) and the gene transcription product of
CaN signalling, MCIP-1 (Figure 4.8F, p=0.06). Ginseng treatment alone did not affect CaN
activity and MCIP-1 gene expression.
4.3.8

Ginseng reverses A n g ll, ET-1 and Phe-induced calcineurin activity in vitro.
Cultured neonatal ventricular cardiomyocytes were treated with Angll, ET-1, and

phenylephrine at the same time points as cell surface area and aSA gene expression
measurement (see Methods). Angll, ET-1 and Phe significantly (p<0.05) increased CaN activity
at 24 h, while significant activation o f CaN was only observed in ET-1 treated cells at 48h
(Figure 4.8A). Treatment with ginseng after 24 h administration of Angll, ET-1 and Phe
completely abolished (/?<0.05) the increases as observed at 24 h and 48 h. CaN activation in
Angll, ET-1 and Phe treated at 24 h were not significantly different from activation at 48 h.
Similarly, upregulation of MCIP-1 gene expression at 24 h and 48 h by Angll, ET-1 and Phe was
reversed by treatment with ginseng (Figure 4.8B). Increased MCIP-1 gene expression at 24 h
induced by Angll, ET-1 and Phe was not significant from expression at 48 h. Upstream NFAT3
nuclear translocation of MCIP-1 gene expression was visualized using immunofluorescence
(Figure 4.8C) and quantified by the nuclear:cytosolic fraction (Figure 4.8D) using ImageJ as
described previously (Noursadeghi et al., 2008). Significant NFAT3 nuclear translocation
observed in Angll, ET-1 and Phe treated cells at 24h and 48h was reversed with ginseng (Figure
4.8C and 4.8D). Ginseng alone was without effect on CaN activation, MCIP-1 gene expression
or NFAT3 nuclear translocation.
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Figure 4.8. Ginseng reverses calcineurin/NFAT3 signaling pathw ay in vitro and in vivo.
Calcineurin activity (A) and MCIP-1 (B) was significantly increased in ventricular
cardiomyocytes subjected to Angll, ET-1 and Phe incubation for 24h and 48h. Treatment with
ginseng after 24h however significantly reversed these effects. Ginseng alone was without effect.
(N=7). (C) Representative images demonstrating increased NFAT3 nuclear translocation, an
essential component of calcineurin signaling, after administration o f Angll, ET-1 and Phe at both
24h and 48h with or without ginseng. Selected images exhibit stimulation of NFAT3 nuclear
translocation at 48h. Top, middle and bottom row represents NFAT3, Hoechst and merged
images, respectively. First and last column represent control cells without and with ginseng,
respectively. (D) Nuclear translocation from three independent fluorescent sets was analyzed
using a nuclear:cytosolic fraction quantification method as previously described via ImageJ.
Angll, ET-1 and Phe-induced nuclear translocation was significantly reversed by treatment with
ginseng. (N=3) Calcineurin activity (E) (p=0.05) and MCIP-1 (F) (/>=0.09) increased gene
expression measured in LV tissues (N=6-8) from CAL rats were similarly prevented by ginseng.
Angll: angiotensin II; ET-1: endothelin-1; Phe: phenylephrine; Gin: ginseng; +: with; -: without.
(*/?<0.05 vs. control; tp<0.05 vs. respective hypertrophic agonist).
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4.4

Discussion
Although the use of ginseng as a therapeutic tool dates back to more than 2000 years

(Goldstein, 1975; Chu et al., 2009), its increasing use as well as that of other TCMs in Western
societies has resulted in resurgence into their possible therapeutic properties for the treatment of
cardiovascular diseases (Karmazyn et al., 2011). This has been primarily evident in the case of
ginseng as a cardioprotective agent for mitigating ischemic and reperfusion injury although
emerging evidence suggests that ginseng may be effective in preventing cardiomyocyte
hypertrophy and heart failure (reviewed in Karmazyn et al., 2011). Here, we show for the first
time, that ginseng can reverse cardiomyocyte hypertrophy in cultured ventricular myocytes in
response to three hypertrophic factors including ET-1, Ang II and the ai adrenoceptor agonist,
phenylephrine. More importantly, ginseng administration for 4 weeks following induction of MI,
at which time substantial LV dysfunction and hypertrophy is clearly evident, produces
substantial reversal resulting in the near-normalization of all parameters studied. It should be
noted that at the dose studied, ginseng produced no effect on blood pressure. This, coupled with
direct effects seen in cardiomyocytes, suggests a direct reversal of the hypertrophic program by
ginseng.
In vivo reversal of postinfarction ventricular remodelling and HF was demonstrated first
by serial echocardiography which revealed marked evidence of LV dysfunction after four weeks
o f CAL as demonstrated by reductions in EF, FS, SV and CO. These effects persisted for the
duration of the 8 week post CAL period but were completely reversed by ginseng administration
at the 8 week period. These results were reinforced by hemodynamic assessments. Although
serial catheter-based invasive hemodynamic determinations are difficult to perform in view of
the invasive nature o f the procedure, work from our laboratory and that of others has clearly
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demonstrated marked LV systolic and diastolic dysfunction four weeks after CAL (Guo et al.,
2011; Purdham et al., 2008). As seen in the results, animals with ginseng after four weeks of
CAL demonstrated normalized hemodynamic properties that were in some cases completely
identical to sham animals demonstrating potent reversibility properties of ginseng. An additional
unexpected benefit seen in ginseng-treated rats is the reduction in myocardial collagen gene
expression levels thus suggesting mitigation o f myocardial fibrosis which can contribute to
ventricular dysfunction in HF (Zannad et al., 2010; de Jong et al 2011; Konstam et al 2011).
Indeed, this represents a major component in the pathogenesis of cardiac dysfunction since a
disruption in the equilibrium between the tensile and elastic fibers constituting the collagen
network of the myocardial ECM, particularly collagen I and collagen III, contribute to the
myocardial remodelling process (Chapman et al., 1990; Brower et al., 2006).

Myocardial

collagen content represents a balance between synthesis and degradation although at present
(Chapman et al., 1990), the specific mechanism by which ginseng reduces collagen formation in
the postinfarcted heart is not known. Although the antifibrotic effect of ginseng in the heart has
not been previously studied, ginseng and its bioactive ginsenosides have been shown to reduce
fibrosis both in vitro and in vivo in various models (Peng et al., 2009; Ahn et al., 2011; Lo et al.,
2011; Tsai et al., 2011).

Irrespective of precise mechanisms, the possibility exists that the

antifibrotic effect o f ginseng may contribute to its salutary effect seen in the present study. This
therefore represents a potentially important area o f future research which may help to reinforce a
possible antifibrotic role of ginseng in remodelled myocardium.
We believe that a major contributing factor of ginseng to reversal o f remodelling and HF
stems from its ability to reverse cardiomyocyte hypertrophy, most likely by a direct effect
potentially mediated by reversal of CaN upregulation (discussed below). Indeed, reduction in
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cardiac hypertrophy represents an important component of the therapeutic strategy for treating
HF (Tamargo and Lôpez, 2011; Jessup and Brozena, 2003). The key role of cardiac hypertrophy
as a target for ginseng-induced reversibility is supported in our study by a direct reversal of
hypertrophy in cultured myocytes exposed to three different prohypertrophic agents. Moreover,
cardiac dysfunction in control animals subjected to CAL was accompanied by gravimetric and
gene analyses data indicating a hypertrophic phenotype. Additionally, échocardiographie
analysis demonstrated significantly increased systolic and diastolic LVID values which were
reversed by ginseng administration.
We assessed the possible underlying mechanisms for the ability of ginseng to reverse
myocardial remodelling in general and hypertrophy in specifics. Ginseng exerts a myriad of cell
signalling effects which could contribute to its antihypertrophic properties (reviewed in
Karmazyn et ah, 2011). For example, we have recently reported that ginseng can prevent leptininduced hypertrophy by inhibiting the activation of the RhoA-ROCK pathway (Moey et ah,
2011). In the present study we concentrated exclusively on the CaN pathway both in vivo as well
as in cultured myocytes where experimental conditions can be much better controlled. CaN is a
key signalling pathway in the pathogenesis of cardiac hypertrophy and HF (Molkentin et ah,
1998; Frey and Olson, 2003). This reflects calcium-calmodulin dependent upregulation of CaN
which results in dephosphorylation of NFAT3 and its subsequent translocation into the nucleus
(Molkentin et ah, 1998). A role for CaN in hypertrophy and HF is further supported by studies
showing that pharmacological inhibition of CaN prevents cardiac hypertrophy (Taigen et ah,
2000; Takeda et ah, 2002; Obata et ah, 2005) as well as improving cardiac function in vivo
(Takeda et ah, 2002; Obata et ah, 2005). We have previously shown that activation of CaN in the
four week postinfarcted myocardium as well as in hypertrophied cultured ventricular myocytes is
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prevented by ginseng (Guo et al., 2011). We have assessed CaN activation by determining
phosphatase activity as well as by expression levels of MCIP-1 which has been shown to be
related to the degree o f CaN activation (Molkentin et al., 1998). Robust CaN activation was
clearly seen in cultured myocytes 24 h after initiation of hypertrophy which persisted for a
further 24 h although in the presence of ginseng added at 24 h values returned to control levels.
A similar strong trend was observed in hearts subjected to CAL, although CaN activation was
markedly reduced at eight weeks compared to four week values. The latter likely reflects the
temporal kinetics of regression of peak CaN activation which clearly precedes the eight week
post CAL time point. Interestingly, our results bear some conceptual similarity to a recent report
demonstrating reversibility of CaN-dependent cardiac hypertrophy (Berry et al., 2011). That
study showed that CaN-dependent hypertrophy produced by overexpression of a mutant CaN
transgene precedes the development of HF, thus precluding the necessity o f sustained CaN
activation for the production o f ventricular dysfunction associated with HF. Moreover, turning
off CaN activity reversed the hypertrophic phenotype (Berry et al., 2011).
In conclusion, our study shows that NA ginseng reverses cardiomyocyte hypertrophy in
vitro as well as myocardial hypertrophy, remodelling and HF in rats subjected to sustained CAL.
Reversal o f cardiac hypertrophy remains a major therapeutic challenge but one which is critical
for the development of improved therapeutic strategies for treating HF (Marian, 2009; Hellawel
and Margulies, 2011). Our results based on findings in cultured myocytes and HF as well as
evidence in the literature (Berry et al., 2011) suggest that reversing of CaN-dependent processes
represents a viable mechanistic basis for the reversal o f hypertrophy by ginseng and therefore the
results reinforce the concept that targeting the CaN/NFAT3 pathway may represent a key
approach towards developing effective therapeutic strategies. At present, we do not know the
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constituent(s) responsible for the therapeutic properties of ginseng, a challenge rendered
particularly difficult in view of the large number of bioactive compounds, including more than
100 ginsenosides which are present in ginseng (Jiao and Zhao, 2009). While results from animal
experimental models should be treated with some degree of caution, our results suggest that
administration o f ginseng for the treatment of HF, particularly as adjunctive therapy with
established medications, may offer substantial additional benefit particularly with respect to
reversing the remodelling process.
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CHAPTER 5

General Discussion

5.1

Overall Findings
The main objective of these studies (C hapter 2 to 4) was to determine the molecular

mechanisms involved in the antihypertrophic and antiremodelling effects of ginseng in agonistinduced cardiomyocyte hypertrophy as well to determine if these effects could be observed in an
in vivo model. Results from our first (C hapter 2) and second (C hapter 3) study demonstrated

the ability of ginseng to prevent and treat leptin-induced cardiac hypertrophy, respectively, by
attenuating RhoA/ROCK-dependent MAPK activation via inhibition of the positive RhoA
regulator, pll5R hoG EF, as well as restoring expression of Rnd3 to downregulate RhoA
activation. These antihypertrophic and antiremodelling effects of ginseng were further observed
in HF rats such that animals receiving ginseng treatment demonstrated marked improvements in
echocardiographic and hemodynamic parameters (C hapter 4). Restoration of cardiac function
by ginseng was observed to involve the reversal of CaN activation. Overall, it is evident from our
studies that ginseng has a potent antihypertrophic and antiremodelling effect in HF because of its
ability to target several key signalling mechanisms which contribute to the pathogenesis of HF.
5.2

Ginseng Reverses H eart Failure and H ypertrophy: Insights into Mechanisms
As mentioned earlier, failure to treat HF is mainly due to the inability of conventional

drugs to reverse already established cardiac hypertrophy (reviewed in Marian, 2009; Hellawel
and Margulies, 2010; Tamargo and Lopez, 2011). As demonstrated in our studies however,
ginseng may be a potential therapeutic agent for the treatment of HF as ginseng was able to
reverse cardiac remodelling and HF in cultured cardiomyocytes as well as in rats with sustained
MI. Our results propose that these reversal effects of ginseng in the hypertrophic program are
due to the inhibition of the CaN/NFAT3 and RhoA/ROCK signalling pathway.
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The importance o f CaN/NFAT3 activation unique to pathological hypertrophy (Wilkins
et al., 2004) has been observed by several researchers (Kilic et al., 2010; Yang et al., 2010; Zhou
et al., 2010; Guo et al., 2011). Moreover, the reversibility of CaN activation (Berry et al., 2011)
in cardiac hypertrophy and dysfunction further indicates this mechanism as a potential target for
the treatment of HF. In our third study (C hapter 4), a similar trend was observed such that CALinduced upregulation of CaN activation, which was prevented by treatment with ginseng.
Additionally in cultured cardiomyocytes, agonist-induced CaN activation was markedly reversed
after the administration of ginseng. The tendency of ginseng to prevent CaN activation in CALrats was reflected in the improvement o f cardiac function measured by echocardiography and
hemodynamic analysis at eight weeks. Improvement in cardiac function was additionally
associated with decreases in the gravimetric measurements of the heart as well as the expression
of collagen gene expressions, which indicated a reversal of cardiac remodelling and hypertrophy
in CAL-induced HF by ginseng.
Reversal of HF and hypertrophy by ginseng may also involve Rnd3-mediated
RhoA/ROCK downregulation as reported in C hapter 3. These experiments stemmed from the
observation that RhoA/ROCK signalling is another key mechanism in the development of
pathological cardiac hypertrophy both in vivo (Phrommintikul et al., 2008; Ying et al., 2009) and
in vitro (Aikawa et al., 1999; Zeidan et al., 2006; Zeidan et al., 2008). By inhibiting the

RhoA/ROCK pathway via inhibition of RhoA (Phrommintikul et al., 2008; Ying et al., 2009),
cardiac hypertrophy was consequently attenuated. Inhibition o f RhoA/ROCK activation by
increasing the expression of downregulating factors such as Rnd3 or pl90RhoGAP (Wennerberg
et al., 2003; Riou et al., 2010) to attenuate cardiac hypertrophy however has not yet been
investigated. In our experiments, the reversal o f leptin-induced cardiac hypertrophy by ginseng
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(C hapter 3) was considered to be facilitated by the upregulation of Rnd3-mediated
RhoA/ROCK downregulation. Indeed, Rnd proteins, particularly Rndl and Rnd3 have been
shown to directly activate pl90RhoGAP, a specific GAP of RhoA, as well as inhibit the kinase
activity o f ROCK (Wennerberg et al., 2003; Riou et al., 2010). Although reversal of leptininduced RhoA activation was observed, leptin-induced activation of p38 and ERK1/2 was not
reversed by ginseng further supporting previously published data which have suggested MAPK
pathways as secondary to RhoA in the hypertrophic program (Zeidan et al., 2008). Results from
these studies suggest that ginseng exerts antihypertrophic and antiremodelling effects via
inhibition of CaN/NFAT3 activation or by downregulating RhoA/ROCK activation.
5.3

Implications

of the

Beneficial

Effects

of Ginseng

against

Leptin-induced

H ypertrophy
Ginseng may additionally have an important role in the prevention and treatment of
hypertrophy in obesity-associated conditions by inhibiting leptin-induced activation of the
prohypertrophic RhoA/ROCK pathway. The novelty of this project in comparison to our
previously published data, which had already demonstrated RhoA/ROCK-dependent activation
o f downstream p38 and ERK1/2 MAPK signalling (Zeidan et al., 2006; Zeidan et al., 2008), was
the identification of pi 15RhoGEF in mediating leptin-induced RhoA activation. Although small
G-proteins typically respond to GPCR agonists such as phenylephrine, Angll and ET-1,
activation of RhoGEFs has also been linked to phosphorylation by RTKs (Schiller, 2006). Leptin
receptors lack intrinsic kinase activity however they do recruit JAK2 molecules which may
phosphorylate and subsequently activate RhoGEFs (reviewed in Fruhbeck, 2006). In fact,
■710

Guilluy and colleagues demonstrated that JAK2 phosphorylates Tyr

.

#

on RhoGEF in rat aortic

smooth muscle that leads to increased vasoconstriction (Guilluy et al., 2010). Results from this
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study not only provided new insight into the mechanistic basis of RhoA activation by leptin, but
additionally supported previously cited work which described a dependency o f p38 MAPK
activation on RhoA activation. Importantly, pre-treatment with ginseng was able to completely
abolish leptin-induced cardiac hypertrophy along with increased RhoA/ROCK activation and its
downstream components. Taken together, our results demonstrate that ginseng is able to
attenuate leptin-induced cardiac hypertrophy by attenuating RhoA/ROCK-dependent MAPK
signalling. In concordance with the previous work summarized in C hapter 3, the data from both
studies implicate the potential for ginseng to both prevent as well reverse hypertrophy and
remodelling in obesity-associated conditions most likely via inhibition of positive upregulators
as well as by increasing expression o f downregulating factors of RhoA/ROCK signalling.

5.4

Conclusions and Future Directions
The increased interest in ginseng as a result of its claimed all cure effects and as potential

for the management o f CVDs has prompted researchers to identify and elucidate the mechanisms
by which ginseng elicits its antihypertrophic and antiremodelling effects. Results from our
studies (C hapter 2 and 3) have shown the ability of ginseng to both prevent and treat obesityassociated CVD via attenuation of leptin-induced p 115RhoGEF upregulation and decreased
Rnd3 downregulation of RhoA/ROCK-dependent MAPK signalling pathway. Ginseng may not
be exclusive to inhibition of RhoA/ROCK in obesity-associated hypertrophic conditions,
however may also act as an inhibitor of the CaN/NFAT3 signalling pathway in classic
representations of cardiac hypertrophy (C hapter 4). Based on our observations, there is a clear
indication of the pharmaceutical value of ginseng as adjunctive therapy for HF and further
studies investigating additional molecular pathways are encouraged.
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